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Abstract 
There is a great need for the identification of non-invasive biomarkers for early detection, 
prognosis and treatment efficacy of breast cancer. Peripheral white blood cells (WBCs) carrying 
the information related to the presence of cancer, represent an attractive source for novel 
biomarkers. The main aims of the study were to develop the pipeline to discover and validate 
novel biomarkers in WBCs of breast cancer patients using proteomic and genomic approaches, 
and assess these biomarkers’ utility. Using the highthroughput mass spectrometry and 2D-gel-
electrophoresis, the protein profiles of the WBCs from breast cancer patients and healthy 
individuals were generated and compared with publicly available gene expression data from the 
WBCs of breast cancer patients and the information on protein profiles of the WBCs from the 
metastatic breast cancer patients. The shortlisted 15 genes were then validated using Real-Time 
Quantitative Reverse Transcription PCR (RT-qPCR). The mRNA levels of ITGA4, LCN2, 
CPNE3 and SERPINB1 were found to be altered significantly in the WBCs of breast cancer 
patients. The levels of SERPINB1 (Serpin B1, neutrophil elastase inhibitor) and CPNE3 (Copine 
3, phospholipid binding protein) were assessed using Western blotting. These analyses 
demonstrated the association of SERPINB1 with breast cancer metastases, and suggested its 
potential utility as a biomarker of poor prognosis and treatment efficacy. Further quantitative 
validation of SERPINB1 in a larger panel of WBCs by ELISA will be required for a clinical 
phase in the biomarker development pipeline. No conclusive results were obtained for CPNE3 
and, together with ITGA4, LCN2 and other additional candidate biomarkers (to be selected from 
the initial list), they will be tested further. The data generated for this study has also given insight 
into differences in the molecular portraits of the cells of immune system associated with breast 
cancer, which will need to be validated by laboratory based functional assays.  
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Chapter 1: Introduction 
 
1.1 Breast Cancer- Incidence and statistics 
 Cancer can be defined as the uncontrollable proliferation of cells which then become 
invasive and metastasise by spreading to various regions through blood or lymphatic vessels. 
Cancer can be classified based on their type of origin as follows: carcinomas (epithelial cells), 
sarcomas (mesenchymal connective tissues), leukaemia and lymphomas (haematopoietic cells). 
Breast cancer is the most common cancer in women who have 1 in 8 lifetime risk of developing 
breast cancer (Cancer Research UK, 2013). Around 49000 women were diagnosed with breast 
cancer in 2011 and breast cancer incidence has increased by 72% since the 1970s. Worldwide, 
1.68 million women were diagnosed with breast cancer in 2012. It is estimated that ~522,000 
women died of breast cancer in 2012 (Cancer Research UK, 2013). However, breast cancer 
survival rates have been increasing with ~ 80% of women surviving primary breast cancer for 
more than 5 years. 
1.2 Mammary gland and breast cancer 
 The mammary gland is a modified sweat gland that originates from the ectoderm. The 
breast has two main parts: supporting stroma and parenchyma. The parenchyma consists of 
ducts, lobules and alveoli, and the stroma includes connective and fatty tissues. The parenchyma 
tissue has 15-20 lobes, and within each lobe there are smaller lobules which produce milk. The 
lobules are connected by thin ducts and all the ducts lead to the nipple. Epithelial cells line both 
the ducts and the lobules. The epithelial cells are surrounded by myoepithelial cells which are 
attached to the basal membrane. The lobules and ducts are surrounded by the stroma consisting 
of fibroblasts and adipocytes (Torácica and Mama, 2006). The mammary epithelium undergoes 
several cycles of remodelling, proliferation, differentiation and apoptosis at various stages of life 
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such as puberty, pregnancy, lactation and menopause. These changes of the breast are induced by 
hormones such as oestrogen, progesterone and prolactin (Russo and Hu, 2000). 
1.2.1 Types of Breast cancer  
 Breast cancer is classified morphologically in two major categories based on their 
histology: Invasive and non-invasive (or in situ) cancer. Breast cancer is also classified based on 
the cells of origin: Ductal, lobular and tubular cancers. Non-invasive cancer cells do not 
penetrate the basal layer and do not spread to others parts of the breast. Invasive cancer spreads 
to the surrounding ducts, lobules, lymph nodes and to distant organs. Medullary, mucinous and 
pappilary cancers of the nipple are few of the rarer morphological types accounting for 2-5% of 
all cancers (Fentiman and D’Arrigo, 2004). Invasive ductal carcinoma (IDC) accounts to up to 
80% of breast cancers. Invasive lobular carcinoma accounts to 5-15% of all diagnosed breast 
cancers. 
Breast cancers are clinically classified into primary breast cancer and metastatic breast 
cancer. Primary breast cancer are small to medium sized tumours (<50mm) which are localised 
to only the primary site of tumour development. Metastatic breast cancers are spread to different 
parts of the body such as bone, brain, lungs etc. 
 Breast tumours are also described based on their size, spread and differentiation. Tumour 
staging (1-4) depends on the size of the tumour and lymph node metastasis. Tumour grading (1-
3) depends on how different cancer cells look when compared to normal cells when viewed 
under the microscope. Estrogen receptors (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2) statuses in the breast tumour are also important to 
decide the treatment protocol and assess response to therapy. ER and PR status are currently 
diagnosed using Immunohistochemistry (IHC). HER2 status is identified by nucleic acid 
hybridisation (Cianfrocca and Gradishar, 2009). 
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 Over the last 15 years due to the development of highthroughput genomics and 
proteomics the molecular classification breast cancer has become clearer, although there is no 
common standard categorization of breast cancer based on this concept. For example breast 
tumours were classified by Perou et al based on gene expression of 456 genes in 65 tissue 
samples (Perou et al. 2000).  This study resulted in the elucidation of four different molecular 
types of breast cancers: luminal-like (ER-positive, PR-positive, HER2-negative), basal-like (ER 
negative, PR negative, HER2 negative), HER2-positive, and normal breast. The most recent 
work revealed novel molecular subgroups of breast cancer based on genomic and transcriptomic 
experiments (Curtis et al., 2012; Dawson et al., 2013). In these studies, copy number, single 
nucleotide polymorphisms, and gene-transcription rates in 2,000 breast cancers were analysed 
and 10 different molecular subtypes of breast cancer based on patient treatment outcomes were 
identified. Furthermore, 45 regions in the genome were discovered which are either deleted or 
amplified abnormally and might contribute to the pathophysiology of breast cancer. These 
findings however are not yet strong enough to be applied to clinical research.  
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Figure 1.1 Anatomy of Breast. Front view and side view of a normal breast showing ducts, 
lobules, adipose tissue, muscle and lymph nodes. The breast lies superficial to the pectoralis 
muscle and drains to the regional nodes (Source: 
http://musom.marshall.edu/graphicdesign/ibooks/Reproductive%20Normal.html Last Accessed 
09/07/2015). 
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1.3 Risk factors for breast cancer development 
 The exact cause of breast cancer is unknown and it can be caused by a number of risk 
factors. The risk factors include age (over 50 years), geographical variation (higher in western 
countries), first child bearing age (after 40 years), menarche age (before 11 years), menopause 
(after 54 years), family history of cancer incidence and genetic predisposition. Lifestyle factors 
such as obesity, alcohol intake, tobacco smoking, oral contraceptives and hormone replacement 
therapy increases susceptibility to breast cancer (Mcpherson et al., 2000). 
1.4 Molecular pathology of Breast Cancer 
 The mutations in the genes controlling the cell cycle lead to defects in the regulation of 
cell cycle which eventually lead to tumour formation. The genes which are involved in tumour 
formation can broadly be classified into Oncogenes and Tumour suppressor genes. Oncogenes 
are genes which are mutated are highly expressed in tumour cells and tumour suppressor genes 
prevent the cell from entering into tumour development stage. When DNA damage occurs in a 
cell an immediate cell reaction called the DNA damage response (DDR) is triggered. This 
response prevents the cell from undergoing DNA replication and separation of damaged DNA 
into daughter cells and thereby preventing the propagation of corrupt genetic information and 
finally acts with other cellular components to repair the damaged DNA. If the damaged DNA is 
repaired the cells will then undergo normal proliferation but if the DNA damage is so severe that 
it cannot be repaired easily the cells undergo apoptosis (Lord and Ashworth, 2012). However an 
additional outcome is also possible that the cells may go into cellular senescence. Cellular 
senescence can be defined as an irreversible state of cell cycle arrest with the survival of the cell 
in absence of any further cell division. It is still not clear what determines the cell to make its 
choice between apoptosis and senescence (Sulli et al., 2012). The link between senescence and 
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cancer development is still debatable as to whether senescent cells lead to formation of cancer 
(Rodier and Campisi, 2011).  
1.4.1 Genes involved in breast tumourigenesis 
Genes which exhibit in hereditary mutations leading to breast cancer are the most 
extensively studied genes. Examples include BRCA1, BRCA2, TP53, ATM, CHK2, PTEN and 
CDH-1 which are hereditary breast cancer causing genes which are mutated to cause the 
formation of tumour. BReastCAncer-1 gene (BRCA1) and BReastCAncer-2 gene (BRCA2)  are 
estimated to account for  between 5%-10%  of breast cancer. BRCA1 and BRCA2 are tumour 
suppressors with the main functions in homologous recombination. BRCA1 binds directly to the 
single stranded DNA and localises along with RAD51 and BARD1 to the site of the DNA 
damage which is already in complex with histones (Scully and Livingston, 2000). BRCA2 can 
bind with RAD51 while the binding nature of BRCA1 and RAD51 is unknown. BRCA1 is 
phosphorylated in this process by ataxia-telangiectasia mutated (ATM). Regardless of the 
presence BRCA1 the cellular localisation and the activity of RAD51 is controlled by BRCA2 
(Cousineau et al., 2005). The levels of these three proteins also increase when the cell enters S-
phase suggesting the role of these proteins in maintaining genome integrity (Narod and Foulkes, 
2004). In BRCA1 and BRCA2 knockout mice p21 (a p53 dependent cell cycle inhibitor) was 
induced to delay the cell cycle growth arrest only to leading to delayed death (Scully and 
Livingston, 2000). These findings imply that if BRCA genes are mutated the cell becomes 
abnormal and the cell survives for a prolonged period and driven towards tumourigenesis. Figure 
1.1 illustrates the functions of BRCA1 and BRCA2. The DNA breaks may lead to three possible 
outcomes: cell cycle arrest and repair, cell cycle arrest and apoptotic cell death, or the errors will 
be compromised leading to tumour development. 
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 BRCA1 mutations responsible for the protein’s malfunction are caused by the 
introduction of a stop codon or a substitution of base pair, and also insertions and deletions 
which leads to a truncated or mutated BRCA1 protein. BRCA1 and BRCA2 null mice cells were 
directed to apoptosis while the cells in which there were mutated BRCA proteins p53 and p21 
were inactivated. The breast epithelial cells are clonal due to the rapid growth rate during 
puberty. Hence if one cell carries a mutation the progeny of that cell will carry that mutation and 
be localised in one part of the breast (Narod and Foulkes, 2004; Scully and Livingston, 2000). 
Data also suggests that hypermethylation of the promoter region of BRCA1 and p53 is involved 
in breast cancers without the hereditary factor (Alkam et al., 2013; Baylin and Herman, 2000; 
Krasteva et al., 2012). Other genes which are hereditary involved with BRCA genes are ATM 
and CHK2 genes. CHK2 also codes for RAD3 which is involved in BRCA1-RAD51-BRCA2 
complex during double stranded breaks; Both CHK2 and ATM phosphorylate BRCA1 and p53 
thereby regulating their function. 
 Tumour suppressor gene TP53 responsible for the expression of the protein, p53,a 
transcription factor involved in the regulation of many functions including cell cycle and 
apoptosis, and is functionally inactivated in 70% of human tumours. On encountering DNA 
damage, a cell will either activate a DNA damage checkpoint to slow down or arrest cell division 
and allow repair of the lesions, or apoptosis will take place to remove cells with potentially lethal 
mutations. P53, which levels rapidly increase after DNA damage, plays the key role in these 
processes. There are various mechanisms employed by p53 to induce apoptosis in a stage-, 
tissue- and stress-signal-specific manner. One of them is direct regulation of apoptosis-related 
genes such as DR5, Fas, Bax, Noxa and Bcl-2. However, p53 can also promote apoptosis via 
transcription-independent mechanisms (Haupt et al., 2003; Möröy and Zörnig, 1996). 
 The presence of functional p53 is important in senescence (Herbig and Sedivy, 2006; 
Itahana et al., 2001). The p53 communications with the multitude of proteins such as  the Wnt-
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beta-catenin, IGF-1-AKT, Rb-E2F, p38 MAP kinase, cyclin-cdk, p14/19 ARF and the cyclin G-
PP2A, and p73  and others have been shown to be involved in the regulation of senescence and 
apoptosis in different cell types (Harris and Levine, 2005).  
The link between p53 and breast cancer has been well established. For example, 30% of 
breast tumours have been reported to have mutations in p53, although it is higher in whereas 
70% of colon tumours (70%) and generally in all cancers (50%) (Slee et al., 2004). However, 
other mechanisms, for example, nuclear exclusion can also lead to p53 malfunction and 
development of breast tumours(Moll et al., 1992). Overexpression of p53 protein was reported to 
be a tissue biomarker for disease recurrence and reduced survival rates in patients with breast 
cancer (Friedrichs et al., 1993).  
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Figure 1.2 BRCA1 and BRCA2 are important for DNA repair processes, in particular 
homologous recombination: BRCA1 and BRCA2 proteins act as scaffold to assemble DNA 
repair proteins (A); Loss of function of BRCA1 and BRCA2  may result in defects in repair, 
accumulation of mutation and, ultimately, cancer (B). Taken from Weinberg, 2006. Mutated 
BRCA protein function may lead to tumour development or the cell growth is arrested depending 
on the cell cycle checkpoint proteins such as CHK1 and PLK1 (C). (Taken from Scully & 
Livingston, 2000) 
 
(C) 
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1.5 Metastasis of breast cancer  
 Metastatic breast cancers (MBC) also known as advanced breast cancers (ABS) are 
invasive breast cancers of higher grade and stage which spread to distant organs such as lymph 
nodes, bones, lungs, brain, liver. Approximately 20-30% of the primary breast cancer patients 
develop metastatic disease. Metastatic breast cancer is major cause of breast cancer related 
deaths.  The median survival range after treatment of metastatic breast cancer is 24-36 months. 
Metastasis occurs in different steps (Fidler, 2003) that are illustrated in Figure 1.2. Several 
cellular processes and molecules are involved in cancer metastasis at each stage (Leber and 
Efferth, 2009).The subsequent metastatic events and the molecules involved are described 
below:  
i. Division and growth of tumour at the primary site. Receptors such as Vascular endothelial 
growth factor receptor (VEGF) and epidermal growth factor receptor (EGFR) are activated 
tumour secreted growth factors such as HER2 and epidermal growth factor (EGF). 
ii. Development of blood vessels (angiogenesis) in the tumour mass; when the tumour grows 
more than 2 cm it needs blood vessels to survive. Hypoxia induces the tumour cells to 
secrete angiogenic factors such as VEGF, platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), angiostatin, endostatin and thrombospondins in a concentration 
gradient which drives angiogenesis. 
iii. Invasion of tumour cells into the surrounding basal tissues or stroma; the tumour cells need 
various cell adhesion molecules such asintegrins, CD44, E-cadherin etc to adhere to the 
extracellular matrix. Matrix metalloproteinases, serine proteinases and cysteine proteinases 
help the tumour cells dissolve the extracellular matrix.   
iv. Dissemination and aggregation of cancer cells in the blood stream. Survival of the 
disseminated cells in the blood stream  
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v. Adherence to blood vessel wall and invasion through the vessel wall into the basement 
membrane of the metastasis target tissue. Autocrine motility factors such as hepatocyte 
growth factor (HGF), insulin-like growth factor II (IGF-II) and autotoxin (ATX) stimulate 
the cells to start extravasation through blood vessel walls. 
vi. Proliferation and angiogenesis of secondary tumour at the metastasis site. 
 
1.6 Diagnosis of Breast cancer 
 Breast cancer is usually detected on the basis of particular symptoms or through the 
National Health Service breast screening program for women between the age ranges 47-73 
(currently every three years). During 2009/2010, 15500 cases of breast cancer were diagnosed 
because the screening program (Cancer Research UK, 2012). Currently the process of breast 
cancer diagnosis involves “triple assessment”; 
a) Physical examination 
b) Radiological investigation- includes Mammography and Ultrasound 
c) Pathological investigation- involves tumour biopsy collection through fine needle 
aspiration or excision biopsy.  
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Figure 1.3 Development of cancer metastasis: Cancer invasion and metastasis takes place in 
different steps. The most important processes are formation of blood vessels in the primary 
tumour and extravasation through the blood vessel wall at the site of metastasis (taken from 
Fidler 2003). 
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1.7 Breast Cancer Biomarkers 
1.7.1 Biomarker overview  
 Breast cancer grows to a critical mass by the time of clinical diagnosis and becomes 
difficult to treat. Therefore there is a need for biomarkers to screen, predict and identify 
treatment as early as possible. Biomarker is a defined as a “cellular, biochemical, biological 
characteristics or molecular alterations that can be objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacological responses to 
a therapeutic intervention” (Naylor, 2010). 
 There are three types of biomarkers 1) Diagnostic biomarker- identification of preclinical 
stage of disease and disease state. 2) Predictive biomarker- used for forecasting the likely 
response to treatment. 3) Prognostic biomarker- used for predicting the course of the disease 
irrespective of treatment  (Buyse et al., 2010).  The sources of cancer biomarkers can be 
classified into two types; 1) Cellular Biomarkers- markers that are associated with the cancer 
tissue, 2) Humoral biomarkers- found in body fluids such as blood, urine, saliva, nipple 
discharge etc. 
 For the past two decades there have been advances in genomics, proteomics and 
molecular pathology and tremendous efforts have been taken to identify novel cancer biomarkers 
to be used in clinical practice. These are exemplified in the number of the grants (4928) and 
publications (441,510) up to 2008 relating to cancer biomarkers (Ptolemy and Rifai, 2010). 
However there is a discrepancy in the effort to discover cancer biomarkers and the number of 
biomarkers actually approved by the US Food and Drug Administration (Füzéry et al., 2013). 
Table 1.1 gives the list of approved cancer biomarkers which are currently in clinical use. It can 
be observed from the table that there only 6 biomarkers used in monitoring treatment response 
and disease progression of breast cancer. There are no approved biomarkers to be used in 
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screening and diagnosis of the disease before clinical symptoms begin to manifest. This shows 
the need for new breast cancer biomarkers that could be used for screening and diagnosis of 
breast cancer.  
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Table 1.1 US Food and Drug Administration-Approved Cancer Biomarkers 
Biomarker Clinical use Cancer type Specimen Methodology Year approved  
Pro2PSA Discriminating cancer from benign disease Prostate Serum Immunoassay 2012 
ROMA (HE4+CA-125) Prediction of malignancy Ovarian Serum Immunoassay 2011 
OVA1 (multiple proteins) Prediction of malignancy Ovarian Serum Immunoassay 2009 
HE4 Monitoring recurrence or progression of 
disease 
Ovarian Serum Immunoassay 2008 
Fibrin/ fibrinogen degradation 
product (DR-70) 
Monitoring progression of disease Colorectal Serum Immunoassay 2008 
AFP-L3 Risk assessment for development of disease Hepatocellular Serum HPLC, microfluidic 
capillary 
electrophoresis 
2005 
Circulating Tumor Cells (EpCAM, 
CD45, cytokeratins 8, 18+, 19+) 
Prediction of cancer progression and survival Breast Whole blood Immunomagnetic 
capture/ immune-
fluorescence 
2005 
p63 protein 
 
Aid in differential diagnosis Prostate FFPE tissue Immunohistochemistry 2005 
c-Kit Detection of tumors, aid in selection of Gastrointestinal FFPE tissue Immunohistochemistry 2004 
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patients stromal tumors 
CA19-9 Monitoring disease status Pancreatic Serum, 
plasma 
Immunoassay 2002 
Estrogen receptor (ER) Prognosis, response to therapy Breast FFPE tissue Immunohistochemistry 1999 
Progesterone receptor (PR) Prognosis, response to therapy Breast FFPE tissue Immunohistochemistry 1999 
HER-2/neu Assessment for therapy Breast FFPE tissue Immunohistochemistry 1998 
CA-125 Monitoring disease progression, response to 
therapy 
Ovarian Serum, 
plasma 
Immunoassay 1997 
CA15-3 Monitoring disease response to therapy Breast Serum, 
plasma 
Immunoassay 1997 
CA27.29 Monitoring disease response to therapy Breast Serum Immunoassay 1997 
Free PSA Discriminating cancer from benign disease Prostate Serum Immunoassay 1997 
Thyroglobulin Aid in monitoring Thyroid Serum, 
plasma 
Immunoassay 1997 
Nuclear Mitotic Apparatus protein 
(NuMA, NMP22) 
Diagnosis and monitoring of disease 
(professional and home use) 
Bladder Urine Lateral flow 
immunoassay 
1996 
Alpha-fetoprotein (AFP) Management of cancer Testicular Serum, Immunoassay 1992 
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plasma, 
amniotic 
fluid 
Total PSA Prostate cancer diagnosis and monitoring Prostate Serum Immunoassay 1986 
Carcino-embryonic antigen Aid in management and prognosis Not specified Serum, 
plasma 
Immunoassay 1985 
Human hemoglobin (fecal occult 
blood) 
Detection of fecal occult blood (home use) Colorectal Feces Lateral flow 
immunoassay 
1976 
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1.7.2 Blood based breast cancer biomarkers 
 Blood based biomarkers could be proteins in the serum/plasma, circulating tumour cells, 
circulating MicroRNAs (miRNAs), DNA, metabolites etc. Classical soluble breast cancer 
biomarkers include Cancer Antigen 15-3 (CA 15-3), Cancer Antigen 27-29 (CA 27-29) and 
carcinoembryonic antigen (CEA). Both CA 15-3 and CA 27-29 are members of the mucin-like 
membrane protein 1 (MUC1) family. The members of MUC1 family are large glycosylated 
molecules and their physiological functions are unclear but they have been implicated in cell 
adhesion and metastasis (Duffy, 2006). Both CA 15-3 and CA 27-29 are used for predicting 
prognosis after treatment in primary breast cancer. CA 15-3 along with alkaline phosphatase 
predicts breast cancer recurrence and metastasis (Keshaviah et al., 2007). The rise in 
concentrations of CA-15-3 occurs immediately after treatment. Decrease in the level of CA 15-3 
by 50% indicates suppression of tumour growth (Duffy, 2006). CEA is a secreted glycoprotein 
which is a tumour associated antigen and serum tumour biomarker. CEA is elevated in 50-60% 
of patients with metastatic breast cancer and hence is used to predict tumour metastasis. It is also 
used to monitor the therapy in breast cancer (Ebeling et al., 1999). 
 Other well known soluble biomarkers in the serum/plasma include cytokeratin 18, 
cytokeratin 20 (Moll, 1994), mammoglobin (Bernstein et al., 2005), MicroRNAs (miR-10b, 
miR-21, miR-125b, miR-145, miR-155 miR-191 and miR-382) (George and Mittal, 2010; Mar-
Aguilar et al., 2013) are in the development pipeline which are not yet applied in clinical 
diagnosis. 
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1.8 Microarray expression profiling and biomarker discovery 
1.8.1 Overview of Microarray Technology 
 Microarray is a technique used to genotype cells for identifying mutations or expression 
profile different types of cells. DNA microarrays are created by robotic machines that arrange 
thousands of small DNA sequences on a microscopic slide. These DNA sequences are 
complementary to the gene sequences in the cell. When DNA is extracted from the cell it is 
fragmented and labelled with a fluorescent probe. These small gene sequences are then allowed 
to hybridise on the DNA-chip. When the labelled DNA sequences bind to the chip the 
fluorescent signal can be detected and quantified. Expression microarrays use the sample 
principle but the RNA from the cells are extracted and converted to cDNA using reverse 
transcriptase enzyme. The cDNA is then allowed to bind to the DNA-chip (Forster et al., 2003). 
There are several sequence probes corresponding to every gene known and this depends on the 
manufacturer. The fluorescent signal is then detected using a high resolution camera. The image 
is processed by quantifying and normalising the signal/noise ratio. The expression values for 
each probe corresponding to a single gene are obtained. Different DNA-chips are normalised by 
using a combination of housekeeping genes that usually include genes such as GAPDH, β-Actin, 
18s rRNA, 28s rRNA etc. Expression microarrays can be used to identify changes in disease 
state and compare it with healthy or normal state. The first cDNA expression microarray was 
done by Augenlicht et al. 1987 and it started to gain popularity with the publication by  Ron 
Davis and Pat Brown labs at Stanford University (Schena et al., 1995). Microarrays has several 
limitations and drawbacks such as; reliance on the existing knowledge of the genome and 
isoforms of transcripts, high background levels on the DNA-chip due to cross hybridisation, lack 
of rigorous standards for data analysis and quality/ integrity of RNA used. 
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1.8.2 Genomics in biomarker discovery 
 Expression microarray technology and RNA sequencing technology are conventionally 
used to identify the expression profiles of cancer tissues and cancer cell lines to classify tumours 
based on their genotype and expression. This approach is also used to discover cellular 
biomarkers from the only the cancer tissue, recently from circulating tumour cells (Moll, 1994) 
and MicroRNAs (George and Mittal, 2010; Mar-Aguilar et al., 2013). There have been a number 
of studies aimed at discovering biomarkers for breast cancer from tissues. Perou et al. 2000 used 
cDNA microarrays to test tissue samples from 42 breast cancer patients for the expression of 
around 8000 genes. This was the first study which was done to classify breast tumours into 
different subtypes based on expression patterns. Sørliea et al. 2001 confirmed the findings and 
demonstrated that gene expression signatures of these subtypes of cancer can be used as a 
prognostic marker with respect to overall and relapse free- survival. Five types of breast cancer 
were identified based on the expression patterns; Luminal A, Luminal B, Basal-like, ERBB2 
positive/ER negative and normal breast-like. Various research groups have identified gene 
signatures which correlate with prognosis and outcome in breast cancer patients (Abba et al., 
2010; Glinsky et al., 2004; Van’t Veer et al., 2002; Yu et al., 2008b). Recent work done by 
Curtis et al. 2012 has revealed novel molecular subgroups of breast cancer based on genomic and 
transcriptomic experiments. The group analysed copy number, single nucleotide polymorphisms, 
and gene-transcription rates in 2,000 breast cancers and identified 10 different molecular 
subtypes of breast cancer based on patient treatment outcomes. The findings are yet to be 
implemented in clinical settings. The main disadvantage of genomic profiles to be used as 
prognostic biomarkers is the heterogeneity of cancers, expensive/time consuming method to be 
used in clinical settings, need for large randomised clinical trials, lack of specificity and 
sensitivity of individual genes and the RNA levels do not always correspond to protein levels. 
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 Recently several groups have tried to discover biomarkers by expression profiling in the 
patients WBCs of breast cancer (Aarøe et al., 2010; Komatsu et al., 2012; LaBreche et al., 2011; 
Sharma et al., 2005; Zuckerman et al., 2013), pancreatic cancer (Baine et al., 2011), Non-small 
cell lung cancer (Showe et al., 2009), colorectal cancer (Xu et al., 2013a) and acute myeloid 
leukemia (Metzeler et al., 2008). All these groups have performed expression analysis and come 
up with panels or expression patterns to predict cancer but none except one group (Xu et al., 
2013a) have performed validation by RT-qPCR. Since clinical tests for cancer use protein 
antibody based techniques such as ELISA, IHC and FISH, microarray data has to be validated so 
that it could be taken forward to the validation step. The difficulties in validation of biomarkers 
will be discussed later in Section 1.10. 
1.9 Proteomic profiling using Mass Spectrometry and biomarker discovery 
 Mass spectrometry based proteomics can be used for the discovery step of biomarkers to 
identify a huge list of potential candidates which can be shortlisted in the following steps of 
development. Proteomics complements and further enlarges the information generated by 
genomics in breast cancer. But the mRNA levels do not necessarily correlate with corresponding 
protein abundance. The most commonly used technologies are tissue protein microarrays, 2D-gel 
electrophoresis and mass spectrometry based techniques such as matrix assisted laser 
desorption/ionisation (MALDI),Surface Enhanced Laser Desorption/Ionization time-of-flight 
mass spectrometry (SELDI) and liquid chromatography (LC-MS/MS). In this study we have 
used 2D-gel electrophoresis and mass spectrometry using the LTQ Orbitrap hybrid ion trap mass 
spectrometer. 
1.9.1 Overview of 2-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) 
 2D-PAGE is a classical technique used to separate a cell lysate based on mass and 
charge, resulting in up to thousands of spots per gel. It can be used in tissue, plasma and serum 
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proteome analysis without prior enrichment or fractionation. The proteins are separated in two 
separate steps; in the first dimension proteins are solubilised in urea and are separated based on 
their isoelectric point on a pH gradient. Proteins will migrate until they have no net charge. After 
the proteins are separated based on their charge they are then loaded onto a polyacrylamide gel 
containing sodium dodecyl sulphate (SDS) under an electric field. The proteins get denatured 
and acquire a negative charge due to the presence of SDS. The proteins migrate under the 
electric field based on their molecular mass (Lopez, 1999; O’Farell, 1975). Thus proteins are 
separated in separate protein spots on an acrylamide gel with high resolution which can be 
stained. The protein spots are excised out of the gel and digested with proteases before mass 
spectrometric identification. 
1.9.2 Overview of  Mass spectrometry and LTQ Orbitrap hybrid ion trap mass 
spectrometer 
  Mass spectrometry has revolutionised the analysis of proteins and has become the 
tool of choice in biomarker discovery due to its speed, wide signal range, quantitative capability 
and the facility to interface with chromatographic methods. Time-of-flight mass spectrometry 
(ToF MS) is where the protein peptides are ionised and the ions are accelerated by an electric 
field of known strength. The mass analyser then separates ions according to their mass to charge 
ratio and by time taken for the ions to travel through the field (Boja et al., 2011). The data is then 
analysed by the application of algorithms to compare with the theoretical spectra of proteins in 
protein sequence databases. This mass analyser is usually coupled with MALDI, SELDI or liquid 
chromatography apparatus. 
 MALDI involves precipitation of proteins along with a matrix material (cyano-4-
hydroxycinnamic acid or dihydroxybenzoic acid). The precipitated protein is then fragmented 
and ionized with laser pulses which are fed into a ToF MS. SELDI involves the protein sample to 
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be loaded onto a ProteinChip arrays that selectively bind to proteins in the lysate according to the 
protein chemistries based on adsorption or affinity chromatography (Srinivas et al., 2002). The 
chip is then washed to avoid unspecific binding. LC-MS/MS combines liquid chromatography 
and mass spectrometry. After enzymatic digestion the mixture of peptides are resolved in a 
chromatographic column. The peptides are eluted at different rates due to their interaction with 
the column material. The separated peptides are then fed into a mass spectrometer (Khadir et al., 
2013). 
 The Orbitrap has an ion trap mass analyzer consisting of an outer barrel-like electrode 
and a co-axial inner spindle-like electrode that traps ions in an orbital motion around the spindle. 
The ions move inside in complex spiral patterns. The ions are then detected as an image current 
on the two halves of an electrode surrounding the orbitrap. Fourier transform is used obtain 
oscillation frequency for ions with different masses which gives the mass to charge ratio (Hu et 
al., 2005; Scigelova and Makarov, 2006). The Orbitrap mass spectrometer has very high 
resolution and high detection speeds of up to 5000 measurement per second per 5ppm. It also has 
very high sensitivity towards proteins of low concentrations in complex biological mixture. 
1.9.3 Proteomics in  breast cancer biomarker discovery 
 The advancement in new mass spectrometric techniques coupled with protein 
fractionation techniques has expanded the possibility of highthroughput protein identification 
and quantification in complex biological mixtures such as plasma, urine and cell lysates. The 
current FDA approved clinical tests are protein based antibody assays (Table 1.1). There are 
several candidate protein biomarkers such as cathepsin-D, 14-3-3 proteins, HSP60, PCNA, 
annexins, Calreticulin, matrix metalloproteinases etc that have been identified by mass 
spectrometry in breast cancer tissues (Hondermarck et al., 2001). There are no FDA approved 
biomarkers which was discovered by mass spectrometry based approaches (Drabovich et al., 
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2014). Biomarkers have been searched for in the plasma of cancer patients based on the 
hypothesis that tumour specific proteins maybe found in blood circulation and would have use in 
the early detection of cancer.CA 15-3 and CA 27-29 are FDA approved biomarkers of breast 
cancer to monitor disease progression and recurrence in the plasma. The main utility of both of 
these molecules are to monitor plasma levels in metastatic breast cancer patients undergoing 
therapy (Misek and Kim, 2011; Nolen et al., 2008). Early periodic peaks in CA 15-3 and CA 27-
29 levels have been reported during the therapy but these are not recommended for screening or 
diagnosis after primary therapy. Novel plasma biomarkers which have been discovered include 
apolipoprotein H (Chung et al., 2014) and 21-protein panel in metastatic breast cancer patients 
(Carlsson et al., 2011). There are several more plasma biomarkers which are in the development 
pipeline and have to be validated using clinical trials. The main drawbacks of protein biomarkers 
in plasma are dynamic changes in the blood, blood collection conditions, blood processing/ 
storage methods and detection of proteins of low concentrations. 
1.9.4 Biomarker Development Pipeline 
 Similar to drug discovery and biomarker discovery is a multi-step process. The aim of the 
pipeline is to assess the maximum possible candidates and exclude the ineffective ones as early 
as possible. Figure 1.3 gives the steps in the protein biomarker development pipeline describing 
the timeline and the approach usually taken for each step. The first step can also be called the 
discovery phase involves using clinical samples and currently there are two types of approaches; 
Exploratory approach where highthroughput methods are used and targeted approach where 
usually molecules overexpressed in cancers are measured by targeted proteomics. The 
exploratory approach consumes more money and time. It took nearly 8 years since the discovery 
of human epididymis protein 4 for ovarian cancer and interleukin 1 receptor-like 1 protein for 
heart failure to be approved by the FDA for clinical use (Drabovich et al., 2014). The 
qualification step involves analysing data from the first step to identify association between 
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clinical outcome and protein abundance by using criteria filtering to obtain a manageable list of 
biomarkers. The verification or validation step includes measuring the promising candidates 
using semi-quantitative methods like RT-qPCR, western blotting and Immunohistochemistry 
where false positive candidates are excluded. The pre-clinical step typically involves protein 
expression and purification of the biomarkers to develop antibodies against them. The clinical 
stage usually involves validation on clinical samples in large sample numbers (usually 1000s). It 
is in this stage reference values, clinical endpoints and surrogate endpoints are defined. Clinical 
endpoint is the defined by how the patient feels or survives and surrogate endpoint is defined as 
the substitute for clinical endpoint to include it and prediction of effects of treatment on the 
clinical endpoint (Buyse et al., 2010). A number issues such as deciding the number of samples 
to be analysed, criteria for inclusion or exclusion for sample and candidates, appropriate 
statistical analysis to use for both discovery phase and clinical phase, sample collection methods, 
effects of sample preparation, limitations of validation methods, validation using independent 
datasets/investigators, time taken for biomarker discovery process causing clinicians 
dissatisfaction and the cost of the process should be considered while developing a biomarker. 
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Figure 1.4 Integrated protein biomarker development pipeline: Both genomics and 
proteomics approach is combined and the biomarker candidates are validated using 
immunoassays. The numbers of candidates decrease and the number of samples increase along 
the pipeline (taken from Drabovich et al. 2014). 
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1.10 Cancer and the Immune system 
1.10.1 Immune Surveillance and Immunoediting  
 The immune surveillance theory explains that cancer cells constantly originate in the 
body but are eliminated by the immune system as antigens. The tumour which manifests itself 
either has to escape this or impair the immune system. This theory then evolved into the cancer 
immunoediting hypothesis which suggests that the immune system sculpts the tumour during its 
development and, paradoxically, results in the generation of cancer cells resistant to the immune 
system. Cancer immunoediting consists of three stages: elimination, equilibrium and escape 
(Dunn et al., 2002). During the first phase the immune system complements the immune 
surveillance hypothesis where the immune system eliminates the tumour cells based on their 
antigenic properties. The equilibrium phase occurs when tumour cells with reduced 
immunogenicity and increased immunosuppressive properties evolve. This is achieved when 
tumours secrete immunosuppressive factors, which downregulate antigen presenting molecules 
or inhibit of immune cell homing (Chouaib et al., 1997). Tumour escape occurs when the tumour 
secretes immunosuppressive factors such asvascular endothelial growth factor (VEGF), IL-10, 
IL-6, TGF-b, prostaglandin E2, soluble phosphatidylserine, granulocyte macrophage colony 
stimulating factor, tumour necrosis factor-α, soluble Fas and soluble Fas ligand (Kim et al., 
2007).  
1.10.2 Role of the Innate Immune system in promoting tumour development and 
angiogenesis: 
Approximately 15% of the cancers worldwide are caused by chronic infections. For 
example Hepatitis C increases the risk of liver carcinoma whereas chronic infection of 
Heliobacter pylori is a leading cause for stomach cancer (Cousens & Werb, 2002; De Visser, 
Eichten, & Coussens, 2006). There is a growing body of evidence suggesting the link between 
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inflammation and tumour development. The immune cells cause inflammation in the process of 
destroying an infection and produce cytokines which subject the surrounding cells to oxidative 
stress thereby damaging them. The damaged cells have a higher risk of developing into a 
neoplastic cell.  
Cell mediated immunity or innate immunity is the first line of defence of the body against 
tumour cells and comprise of macrophages, dendritic cells, mast cells, granulocytes, natural 
killer cells (NK cells) and cytotoxic T-cells (CTLs). Reduced NK cells activity and reduced 
number of T-lymphocytes were observed in breast cancer patients prior to surgery or adjuvant 
therapy. One of the major inflammatory cytokine secreted by macrophages TNF-α has also been 
found to be secreted by breast cancer cells in high levels. Also the activity of TNFα was 100% 
higher in breast cancer patients (Standish et al., 2008). TNF-α expression positively correlated 
with increased tumour grade and lymph node metastasis (Leek et al., 1998). The expression of 
class I MHC is reduced in tumour cells therefore the cytotoxic T-cells cannot recognise the 
tumour cells as they are dependent on MHC I expression. Tumour tissues from breast cancer and 
prostate cancer have abundant infiltrations of immune cells and immunoglobulin deposits 
compared to normal tissue (De Visser et al., 2006). The density of tumour associated 
macrophages in the tumours has been shown to be correlated with poor prognosis and lymph 
node metastasis. Also tumour associated macrophages secrete other inflammatory cytokines such 
as IL-8, IL-10, VEGF and Fibroblast growth factor to inhibit T cells response (Crowther et al., 
2001; Gabrilovich et al., 2012).  
Neutrophils comprise of a large subset of the white blood cell population (~70%) and are 
important in the innate immune response. Neutrophils are activated by compounds such as 
lipopolysaccharide, Interleukin-8, Interferon-γ, and TNF-α. Activated neutrophils secrete a 
growth promoting factor Hepatocyte Growth Factor (HGF) (McCourt et al., 2001). Interleukin-8, 
one of the stimulators of neutrophils is secreted in the cancer microenvironment and increases 
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the population of tumour infiltrating neutrophils in the tumour site (Waugh and Wilson, 2008). 
HGF was found to be produced by Tumour infiltrating neutrophils in response to granulocyte 
macrophage colony stimulating factor and TNF-α in pulmonary adenocarcinoma 
microenvironment (Wislez et al., 2003). HGF promotes metastasis and is a growth factor which 
improves angiogenesis and cell proliferation. In another study c-met gene which codes for the 
receptor for HGF is upregulated in colorectal cancer cells (Di Renzo et al., 1995). Recently it 
was proved that HGF was necessary to disrupt cell to cell interactions by uncoupling the myosin 
VI and E-cadherin function accompanied by loss of F-actin at cell surface junctions of zonula 
adherens (Mangold et al., 2011). Oncostatin M, a cytokine belonging to the IL-6 family was 
secreted by tumour infiltrating neutrophils in breast cancer cells. It improves the invasive 
capacity of the tumour and metastasis. When neutrophils were co-cultured with human breast 
cancer cell lines T47D and MDA-MB-231 oncostatin-M was secreted and macrophage colony 
stimulating factor was necessary for it (Queen et al., 2005). Thus neutrophils play a very 
important part in the immune response to cancer and may promote tumour progression and 
metastasis. It has been showed that TGF-β polarises tumour associated neutrophils to a N2 pro-
tumour phenotype. Blocking of TGF-β causes accumulation of N1 phenotype neutrophils which 
possess anti-tumour activity (Fridlender et al., 2009). The function of neutrophils in tumour 
microenvironment is still unclear as to whether they promote or suppress tumour development 
and growth. 
1.10.3 Cancer and the Chemokine/cytokine Network  
 The chemokines and cytokines secreted by tumour cells have been implicated in the 
suppression of the cells if the immune system. Two cytokines, CCL2 and CCL5, secreted by 
various tumours have been studied extensively. CCL2 otherwise known as MCP-1, is secreted by 
tumour and stromal cells into the surrounding attracting monocytes, basophils and T-cells to sites 
of inflammation. CCL2 levels correlate with lymphocyte and macrophage numbers in the 
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epithelial areas of the tumour along with poor prognosis and relapse (Balkwill, 2004). CCL5 
secreted by tumour cells, attracts T-cells, basophils and eosinophils; the CCL5 levels were high 
in advanced breast carcinomas (Ben-Baruch, 2003). Both CCL2 and CCL5 facilitate the 
production of matrix metalloproteinases such as MMP9 in macrophages which modify the 
extracellular matrix to aid tumour cell migration and invasion(Robinson et al., 2002). Another 
chemokine implicated in tumour development is CXCL12 (SDF1-α). CXCL12 is expressed by 
sites such as the bone marrow, liver, lung, brain etc which are metastasis sites for breast cancer. 
Its receptor, CXCR4, has been found to be up-regulated in many types of tumours including 
breast cancer, allowing cells to migrate to targeted distant organs containing cells that secrete its 
ligand (de Jong et al., 1998; Müller et al., 2001) 
1.11 Leukocyte Transendothelial Migration 
  It is very important for the immune cells reach the site of infection or 
inflammation through the blood vessel wall. Leukocyte transendothelial migration is the process 
by which T-cell, neutrophils and monocytes move through the endothelial layer. 
Transendothelial migration has also been implicated in tumour escape mechanisms. The whole 
process, illustrated in Figure 1.4,  happens in three stages: rolling and capture, adhesion on the 
endothelium and finally transmigration (Van Buul and Hordijk, 2004; Muller, 2009; Wagner and 
Roth, 2000). Monocytes, lymphocytes and neutrophils all migrate in a similar way into the 
endothelium but are activated by different signalling molecules. Many molecules such as TNF-α, 
IL-1, Leukotrienes, Platelet activating factor, Complement protein 5a, IL-8, SDF-1α etc mediate 
the interaction between the endothelium and the leukocytes (Wagner and Roth, 2000). 
1.11.1 Rolling and Capture 
Polymorphonuclear Leukocyte Neutrophils (PMNs) roll over the endothelium forming 
reversible interactions using molecules called selectins which are present on both PMNs and 
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endothelial cells. The PMNs, newly released from the bone marrow, express high levels of L-
selectin and as they age the L-selectin molecules are lost from the surface of PMNs (Kuhns et al., 
1995) .The ligand for L-selectin is CD34, it is highly expressed in lymph nodes and endothelial 
cells of the blood vessel (Krause et al., 1996). Two other selectins of the endothelium, P-selectin 
and E-selectin also have a role in this rolling step and are expressed when appropriate 
inflammatory signals are received. The ligand for P-selectin on the surface of leukocytes is 
PSGL1 which can bind to two P-selectin molecules at the same time (Wagner and Roth, 2000). 
The interaction with PSGL1 is longer than the L-selectin-CD34 interaction but if appropriate 
inflammatory signals are not received these selectin interactions are reversible and short-lived. 
1.11.2 Adhesion and Activation 
The next step in transendothelial migration is firm adhesion which happens due to either 
appropriate inflammatory signals or the activation of selectin interactions. Intracellular adhesion 
molecules and integrins play a very important part in the adhesion of PMNs onto the 
endothelium. Integrins are cells adhesion receptors which bind to a variety of ligands on the 
extracellular matrix such as collagen, fibronectin, fibrinogen, laminins, cadherins, vitronectins 
etc (Barczyk et al., 2010). Integrins are heterodimeric proteins found the membranes of most 
cells. There are 16 different α subunits and 8 β sub-units to form 23 different transmembrane 
Integrin receptors. Each Integrin is formed by one α and β sub-units with the cytoplasmic tail 
forming linkages with the cytoskeletal proteins and harbouring phosphorylation sites. The main 
integrins implicated in leukocyte migration are Mac-1(αMβ2), LFA-1(αLβ2) and VLA-4 
(α4β1).VLA-4 and LFA-1 are responsible for the movement for T-cells and monocytes while 
Mac-1 is predominantly responsible for neutrophil and NK cell movement. The receptors for 
Mac-1, LFA-1 and VLA-4 are C4a:C4b complement, ICAM-1 and VCAM-1 respectively. Both 
ICAM-1 and VCAM-1 interactions are essential for neutrophil invasion. PECAM-1 and CD99 is 
also essential for the neutrophil movement.PEACAM-1 is its own ligand forming a homodimer 
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on the opposing cell perhaps essential for signalling the cell to inform the degree of extravasion 
(Wagner and Roth, 2000). 
1.11.3 Transmigration 
Leukocytes possess proteolytic enzymes such as neutrophil elastase, proteinase 3 and 
cathepsin G which can cleave components of the extracellular matrix such as collagen and 
laminins. This step involves the actin cytoskeletal rearrangement of the PMN cell. The 
neutrophil proteases and peroxidases disrupt the VE-cadherin junctions of the endothelial cells to 
loosen the cell junctions for the movement of PMNs. This involves the reorganisation of the 
cytoskeletal structure of the PMN so it has a leading edge that adheres and protrudes into the 
endothelium and the retracting end. In fibroblasts the integrin binding activates Cdc42 and Rac1 
which intern activates the Arp2/3 complex. The molecules involved in the retracting end are 
CD44, CD43, ICAM-3 and PSLG-1 (Van Buul and Hordijk, 2004). 
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Figure 1.5 Overview of Leukocytes Transendothelial Migration: Three steps involved 
leukocyte migration along with the molecules involved. (Taken from Van Buul & Hordijk, 2004) 
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1.12 Aims of the project 
 The need for new biomarkers has been discussed in the previous sections. In this project 
the primary aim is to discover novel breast cancer biomarkers in the White Blood Cells (WBCs) 
fraction of blood of breast cancer patients using the exploratory biomarker discovery approach. 
The secondary aim is to use the findings to explain the effect of tumour on the immune system, 
specifically on the WBCs. To achieve this we divided the project into the following Objectives: 
1. Identification of the difference in gene expression profiles of WBCs between healthy 
donors and primary breast cancer patients, using the existing data deposited in the Gene 
Expression Omnibus (GEO). 
2. Identify the difference in protein profiles of WBCs of healthy donors and primary breast 
cancer patients by highthroughput proteomics and 2D-PAGE. 
3. Integrate the data from both genomic and proteomics approaches to shortlist the 
biomarker candidates. 
4. Validate shortlisted biomarker candidates using RT-qPCR and Western blotting. 
 
The expected outcome of this study would be identification of new breast cancer biomarkers. In 
addition, this investigation will add to our knowledge of how the immune system is altered in the 
breast cancer patients.  
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Chapter 2: Materials and Methods 
 
2.1 Isolation of White Blood Cells from whole blood 
  Ethical approval for this project was obtained from Essex Research Ethics Committee 
(Reference No: 10/H0301/60) and the Research & Development Department of Colchester 
Hospitals University NHS Foundation Trust. Blood samples of Breast cancer patients were 
obtained from Colchester general hospital in collections tubes with Ethylenediaminetetraacetic 
acid (EDTA) and were processed within 24 hours of collection. Blood was processed to separate 
White Blood Cells (WBCs) using the buoyancy density method (D’Arcy et al., 2006). 
Histopaque (Sigma) was used to separate the whole blood into a density gradient of plasma, 
white blood cells and red blood cells by spinning at 400 x g for 30 minutes. Red blood cells were 
discarded and the plasma was stored at -800C. The white blood cells layer was taken and washed 
with Hanks balance salt solution (HBSS) twice and was spun down at 250 x g for 5 minutes. The 
remaining pellet was treated with red blood cells lysis buffer (from Roche) to remove the red 
blood cells and washed with HBSS to obtain the WBC’s which was then split into different 
fractions to analyse them. 
2.2 Protein analysis methods 
2.2.1 Overview of Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western blotting 
SDS-PAGE is a method used to separate proteins in a mixture under the influence of an 
electric field in a polyacrylamide gel. Cells are lysed in a buffer containing SDS. The proteins 
are denatured and bind to SDS to obtain a negative charge. The proteins are then separated based 
on their molecular weight in a polyacrylamide gel (Chrambach& Rodbard 1971). Western 
blotting is a technique where the proteins which were resolved by SDS-PAGE are transferred to 
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a nitrocellulose membrane using an electric field. The membrane is then probed with a primary 
antibody raised specifically against an antigen followed by probing with secondary antibody 
labelled either a fluorescent tag or an enzyme which produces a luminescent signal in the 
presence of a substrate (Towbin et al., 1979). All the buffer and solution compositions used are 
given in Table 2.1 
2.2.1.1 Preparation of White Blood Cell lysates for gel electrophoresis 
The protein lysates were prepared from 2x10
6
 whole white blood cells in SDS lysis buffer 
containing 0.1M Tris/HCl pH 6.8, 7 M urea, 4% SDS, 10% mercaptoethanol and phenol red. The 
mixture was then heated at 95
0
C for 5 minutes to allow the proteins to be reduced. 
2.2.1.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
 Standard 8.1% SDS-PAGE gel was used to separate the proteins in the lysates. The 
separating gel was prepared and poured into the glass cassettes. After the separating gel was 
ready Stacking gel was prepared and poured on the separating gel with a well comb. Once the 
gels were set, protein samples were loaded onto the wells. SDS-PAGE gels were run with a 
protein standard marker with a molecular weight range of 7 - 175 kDa (New England Biolabs) 
under denaturing conditions at 125 V and 40 mA (80 mA for two gels run simultaneously) for 
just over two hours. The gel was incubated in running buffer with 1% methanol for 15 minutes 
on a gentle rocking platform. The PVDF membrane was treated with methanol (100%) for 10 
seconds and washed thoroughly with RO water. 
2.2.1.3 Western blotting analysis 
Protein blotting was done from the acrylamide gel onto polyvinylidenedifluoride (PVDF) 
membrane by electrotransfer.Transfer was performed using transfer buffer in a semi-dry electro 
blotting apparatus for two hours at100 mA / 35 V. The PVDF membrane was blocked overnight 
at 4
0
C in blocking buffer (PBS, 0.05% tween-20 and 5% milk). The membrane was then 
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incubated with primary antibody at a concentration at the recommended concentration in 
blocking buffer for two hours and then washed with washing buffer (1XPBS, 0.05%tween-20) 
three times for five minutes. The membrane was incubated with the horse radish peroxidase 
(HRP) conjugated secondary antibody for two hours in blocking buffer followed by washing 
thrice with washing buffer. The membrane was then soaked with the enhanced 
chemiluminescence (ECL) solution Luminata forte from Millipore (cat no: WBLUF0100) 
containing fluorescent peroxidase substrate and visualized. The signal was detected by exposing 
the membrane to an autoradiography film (Kodak Medical X-ray film). The film was then 
developed using GBX Developer and Fixer (Kodak, Japan).  
2.2.1.4 Image J analysis 
 The image obtained from the PVDF membrane was then scanned as an image file and 
analysed with Image J analysis software which can downloaded freely from 
http://imagej.nih.gov/ij/. This software analyses the band intensity and gives values. The target 
protein molecule was normalised between samples using the signal obtained from β-Actin 
antibody probing. Protein density values from different gels were normalised based on the value 
obtained from a common sample used. 
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Buffer 
 
Composition 
 
SDS Lysis Buffer 
0.1M Tris/HCl pH 6.8, 7M Urea, 10% 2 β-mercaptoethanol (add just 
before use), 4% SDS and a pinch of Phenol red dye 
Tissue Lysis buffer 
20mM Tris/Hepes pH 8.0, 2mM EDTA, 0.5M NaCl, 0.5% Na 
deoxycholate, 0.5% Triton X-100, 0.25 M Sucrose, add directly 
before use 50mM 2-ME, 50µM PMSF, 1µM Pepstatin 
Resolving Buffer* 2M Tris/HCl, 0.2% SDS (pH 8.9) 
Stacking Buffer** 0.1M Tris/HCl, 0.1% SDS (pH 6.8) 
Gel Running Buffer 0.025M Tris/HCl, 0.192M Glycine, 0.1% SDS 
Transfer Buffer 20mM Na2PO4, 2% Methanol, 0.05% SDS 
Phosphate Buffered 
Saline (PBS) (1x) 
2mM KH2PO4, 10mM Na2PO4, 137mM NaCl, 2.7mM KCl,  
(pH 7.4) 
Blocking buffer  0.1% Tween, 5% dried skimmed milk powder, 1x PBS 
Washing Buffer 0.1% Tween, 1x PBS 
 
 
 
 
 
 
 
 
 
 
 
 
Resolving gel composition 
8.1% gel 
(ml) 
Acrylamide/Bis-acrylamide  
Solution (30%) (Bio Rad) 
2.7 
Resolving gel buffer* 5 
10% APS (SIGMA) 0.05 
ddH20 2.23 
TEMED (SIGMA) 0.02 
Total 10 
Stacking gel composition 
4% gel 
(ml) 
Acrylamide/Bis-acrylamide  
Solution (30%) 
0.665 
Stacking gel buffer** 1.75 
10% APS  0.025 
ddH20 2.55 
TEMED  0.01 
Total 5 
B. 
A. 
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Table 2.1 Preparation of buffers and gels for Western Blotting. (A) Composition of general 
buffers used in the SDS-PAGE and Western Blotting.(B) Components of Resolving (left) and 
Stacking (Right) Gels used in SDS-PAGE 
2.2.2 Protein Profiling by Mass spectrometry 
2.2.2.1 Protein profiling of White blood cells using Orbitrap mass spectrometer 
To identify the protein expression patterns specific for cancer patients’ proteins from 
WBC cell pellets were fractionated into membrane and soluble fractions as discussed in 
Alldridge et al., 2008. The proteins from the leukocyte fractions were extracted and the soluble 
and membrane proteins were separated to generate two separate proteome fractions to maximize 
the coverage of the analysis. Both the fractions were then digested using trypsin and analysed on 
OrbitrapVelos instrument equipped with an Ultimate 3000 nano-scale HPLC (Olsen et al., 2009). 
The data generated by Orbitrap was processed by MaxQuant (a suite of algorithms and tools to 
perform automated analysis using the raw files from Orbitrap). The software has been accepted 
and adopted widely by the quantitative proteomics community (Cox and Mann, 2008).The above 
work was conducted by Dr.MetodiMetodiev in his lab. The output of the procedure was obtained 
as table with normalised label free quantitative intensity values for each protein. Only the data 
from only the membrane fraction was analysed. Mann Whitney U test was then performed to 
compare the protein profiles between the WBCs of cancer patients and healthy donors with a p 
values of <0.05. The proteins were then shortlisted based on their expression profiles manually.  
2.2.3 Protein profiling using 2D gel electrophoresis 
2.2.3.1 Protein profiling of White blood cells using 2D Gel electrophoresis 
2.2.3.1.1 Sample preparation for 2D Gel electrophoresis 
The protocol used for protein lysate preparation and focusing the samples on pH strips 
was developed in our lab by Dr. Dawn Farrar. Frozen cell pellets were dissolved in a lysis buffer 
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containing 1%SDS and 100mM Tris-HCl pH7 preheated to 95
0
C. The sample was then sonicated 
using a bioruptor and 5% 2β-mercaptoethanol was added. The samples was dissolved in 
solubilisation buffer (8M urea, 2.5M thiourea, 4% 3-[(3-cholamidopropyl) dimethylammonio]-1 
–propanesulfonate CHAPS, 50mM DTT and 24mM sperminetetrachloride. The proteins were 
solubilised for 1 hour at room temperature following the further addition of 24mM of spermine. 
The sample was centrifuged at 12000g for 30 minutes. The solubilised protein sample was 
divided into two and 1ml ice cold acetone was added and incubated overnight at 20
0
C followed 
by centrifugation at 12000 g for 30 minutes. The protein pellet was then washed with ice cold 
methanol-chloroform mixture and resuspended in isoelectric focusing (IEF) buffer (8M urea, 
2.5M thiourea and 4% 3-[(3-cholamidopropyl) dimethylammonio]-1 –propanesulfonate 
CHAPS). The sample protein concentration was quantified using CooAssay.  
2.2.3.1.2 Separation in first dimension using Isoelectric focussing (IEF) 
55µg of protein lysate was dissolved with IEF buffer containing 1µl IPG buffer and 2.4µl 
destreak reagent to a total volume of 202µl. IPG strips (pH3-10) from BioRad were rehydrated 
with the above sample mixture overnight according to manufacturer’s protocol. The IPG strip 
was then focused on IPGphor system with the following conditions: 250V-30 minutes, 500V-15 
minutes, 500V-3.25hrs, 1000V-1hr, 6000V-2hrs, 6000V-2hrs, and 200V-12hrs. The strips were 
then incubated in equilibrium buffer (6 mol/L urea, 20% w/v glycerol, 4% w/v SDS, and 
0.375M/L Tris-HCl (pH 8.8)) with 5% 2β-mercaptoethanol and then with equilibrium buffer 
with 2.5% iodoacetamide for 15 minutes each. 
2.2.3.1.3 Second dimension separation using acryl amide gel electrophoresis and silver 
staining of proteins 
 The second dimensional electrophoresis was carried out in Criterion gel system 
(BioRad). 12% criterion precast gels (cat no: 345-0121) were used to perform the 
electrophoresis. The running buffer used was. The gels were fixed overnight in 10% methanol 
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and 10% acetic acid. The gel was stained using the silver staining protocol from Shevchenko, et 
al., 1996. Each sample was prepared and run as triplicates. The 2D-gels were scanned and 
analysed using SameSpots analysis software.  
2.2.3.1.4  Protein spot analysis using Samespots Software 
Each gel was scanned using the ImageScanner scanner from GE Healthcare. The scanned 
images were then uploaded into the Samespots software. The spots on the gel were then 
identified by the software. Background subtraction and normalization of the spots were then 
performed. The gels were then grouped for differential analysis based on tumour grade or disease 
state. The spots were compared between gels based on volume of the spot. ANOVA test (p-
value< 0.05) was performed was used to identify spots that were differentially present in primary 
breast cancer patients. The spots which were differentially present were cut from the gel. The 
spots were then destained and prepared using a compatible protocol for mass spectrometry 
(Shevchenko et al., 1996). The spots were sent to Dr. Metodi Metodiev’s lab for identification by 
mass spectrometry. 
2.3 Methods for RNA extraction and analysis 
2.3.1 RNA extraction and quality control 
Total cell RNA was extracted from WBC’s for microarray analysis using trisure phenol 
chloroform extraction method. Due to difficulties experienced like low final RNA concentration 
and low purity of RNA samples when extracting RNA from blood samples the conventional 
phenol-chloroform RNA extraction protocol was modified to obtain high quality RNA without 
any degradation. This protocol has been described in figure 2.1. The DNA digestion proved to be 
essential since the contaminating DNA in the RNA sample would interfere the microarray 
process and which was seen when the residual DNA was amplified when PCR was done on the 
cDNA produced from the RNA sample. Cells were stored in RNAlater at -80
0
C until they were 
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processed. The cells were lysed with 1 ml of trisure per 10 X10
6
 cells. 200µl of chloroform was 
the added and the tubes were vortexed for 15 seconds. The samples were then centrifuged at 
12000 xg for 15 minutes and the top aqueous phase was then transferred to a new tube. The 
chloroform step was then repeated again by adding 200 µl of chloroform. RNA was precipitated 
from the aqueous phase for 10 minutes using 500µl of isopropanol per 1 ml of trisure used. The 
samples were then centrifuged at 12000 xg for 10 minutes. The supernatant was then discarded 
and pellet was washed twice with 1ml of 75% ethanol at 7500 xg for 5 minutes each. The 
resultant RNA pellet was then dissolved in sterile water by heating it at 55
0
C for 5 minutes.  
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Figure 2.1 Modified RNA extraction protocol for White Blood Cells: The conventional 
Trisure phenol chloroform protocol was modified to extract RNA form white blood cells. The 
modified protocol includes an extra chloroform step and ethanol washing step. DNA digestion 
was also done to ensure the purity of RNA obtained. 
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2.3.2 DNase treatment of RNA extracted from cells and tissues  
 The purified RNA samples were treated with DNase to remove any DNA contamination 
carried over from RNA extraction process. TURBO DNA-free™ Kit (Ambion) was used and the 
digestion was performed according to manufacturer’s instruction. Up to 10μg of RNA was 
treated with 1µl of TURBO DNase and 0.1 volume of 10X TURBO DNase buffer. Digestion 
was done at 37
0
C for 30 minutes followed by deactivation of enzyme by incubating with 0.1 
volume of DNase inactivation reagent for 5 minutes at room temperature. The DNA-free RNA 
was then obtained after centrifugation at 9000g for 2 minutes. The RNA quality and integrity 
was determined which are described in the following sections. 
2.3.3 Quantification of RNA using Nanodrop® ND-1000 UV/VIS Spectrophotometer 
 Purified RNA samples were quantified using NanoDrop® ND-1000 UV/VIS 
Spectrophotometer (LabTech International Ltd, UK) following the manufacturer’s guidelines. 
The nucleic acid concentration was determined by Beer’s law and the absorbances were 
measured at 260, 280 and 230nm. The ratios of 260nm/280nm and 260nm/230nm were obtained 
to assess the purity of RNA. Both ratios had to be above 1.8 to be considered pure. Although 
Nanodrop measurements indicate the purity of RNA it does not indicate the integrity of RNA or 
indicate presence of DNA in the RNA sample.   
2.3.4 Analysis of RNA quality using Agilent 2100 Bioanalyzer 
Quality of all RNA samples was assessed using Agilent 2100 Bioanalyzer instrument 
according to the manufacturer’s instruction. The Aglient Bioanalyzer performs capillary 
electrophoresis to analyze RNA, DNA and proteins (Sodowich et al., 2007). It is a very efficient 
method used to perform absolute RNA quality control before downstream applications such as 
gene expression analysis or microarrays. All the reagents of Aglient RNA 6000 Nano kit were 
incubated at RT for 30 minutes before the start of the procedure. The Dye was covered with foil 
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as it is light sensitive. The Gel matrix was filtered through the column provided in the kit. The 
gel-dye mix was prepared by mixing 1μl of the RNA 6000 Nano Dye with 65μl of the Agilent 
RNA 6000 Nano Gel matrix according to the manufacturer‘s instructions. The 6000 NanoChip 
was primed by placing a 9μl of this mixture into the specified well on the NanoChip. The gel was 
dispersed across the chip with a help of a plunger. The RNA samples were denatured for 
2minutes at +70
0
C and loaded into the NanoChip alongside 5μl of the RNA Nano Marker. The 
NanoChip was then vortexed for 60 seconds at 2499xg on a vortex mixer (IKA)and applied for 
analysis by the Bioanalyser. To start the experiment, Eukaryote Total RNA assay was selected 
on the program and run. After the run was complete the data was saved as a pdf file and the RNA 
quality was assessed from the electropherograms obtained. Only RNA of acceptable quality was 
used in downstream applications. 
2.3.5 cDNA Synthesis (Reverse transcription)  
RNA prepared and analyzed as described above was reverse-transcribed to from cDNA 
using VersoTM cDNA Synthesis Kit (Thermo Scientific) according to the manufacturer’s 
instructions. 500ng of total RNA was diluted in autoclaved ddH2O and heated for 2 min at 70°C 
to remove secondary structures. The cDNA reaction was prepared in sterile PCR tube by adding 
cDNA synthesis buffer, dNTPs, random hexamer RNA primers, RT enhancer, RT-polymerase as 
per the manufacture’s recommendations. The reaction mix (20μl) was run using following PCR 
cycle: 10 min 25°C, 120 min 42°C; 2 min at 95°C. In parallel, reactions with “no template” and 
“no enzyme” were performed as negative controls. Freshly synthesized cDNA was diluted 10 
times and 1μl of the diluted cDNA was used in subsequent PCR or qPCR reaction.  
To assess the quality of cDNA prepared, a PCR reaction usinga housekeeping gene β-
Actin (Beta Actin) primers was performed. These are also known as reference genes and they 
help in normalizing the expression data when comparing different samples. As negative control, 
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a PCR reaction with 1μl of ddH2O instead of the cDNA template was run. The PCR-amplified 
samples were then resolved on an agarose gel. 
2.3.6 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction or PCR method was originally developed by Kary Mullis 
(Mullis et al., 1986)who received the Nobel Prize in 1993 for this invention (Nobelprize.org., 
1993). PCR uses the DNA polymerase function to synthesise a new strand of DNA. Short 
complementary strands of DNA called primers are used in PCR. The primers bind to the DNA 
sequence and add nucleotides to the 3’-OH end. Two primers are always used for a reaction; 
forward primer and reverse primer to mark the start and end of the region to be amplified. This 
reaction is performed in a series of DNA denaturation (95
0
C), primer annealing (50-60
0
C) and 
DNA polymerase extension (72
0
C). Depending on the number of cycles the DNA is replicated to 
several thousand copies. This amplified DNA can be visualised on an agarose gel. 
cDNA was amplified using KOD Hot Start Polymerase (Novagen) using the TECHNE 
TC-312 thermal cycler. Each 25µl PCR reaction contained 5µl of KOD buffer, 1mM of 
Magnesium, 0.1µM of each forward and reverse primers, 0.2mM of dNTPs, 100ng of DNA 
template and 1µl of KOD polymerase diluted in ddH2O. A reaction where DNA template was 
substituted with ddH2O was used as a background control. 
2.3.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was used in this study to resolve DNA fragments   to assess 
the size of PCR products. The nucleic acid samples were visualised with Ethidium Bromide 
(Sigma) in a 1% agarose gel using 300nm UV illumination (Alpha Innotech). Before loading 6 
xDNA loading buffer (0.25% Bromophenol blue, 0.25% Xylene, 30% glycerol) was added to 
DNA preparations to increase density of the samples and also help track DNA migration. 
Agarose gels were run in 1xTAE running buffer (40mM Tris, 20mM acetic acid, 1mM EDTA). 
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The DNA marker, GeneRuler™ DNA Ladder Mix (Lab Aid, Fermentas), was run alongside 
samples to act as reference to establish the size of bands produced.  
2.3.8 Gene Expression Analysis using Reverse Transcriptase Real Time PCR (RT-qPCR) 
Quantitative PCR (qPCR) is a modification of the standard PCT technique where 
fluorescent dyes such as SYBR green are used. SYBR green binds to the minor grove of the 
DNA double helix. Thus the dye binds to amplified DNA fragments and the level of fluorescence 
corresponds to amount of DNA fragments present. The cycle threshold (Ct) is defined as the 
point where the signal becomes detectable (Bustin and Nolan, 2004). Melt curve analysis are 
performed to ensure that there is only one PCR product formed. When the DNA denatures the 
SYBR green dye disassociates and the signal is lost gradually which is measured. Melting 
temperature (Tm) is the point where the maximum signal SYBR green dye is lost. 
Reverse Transcriptase Real Time (RT-qPCR) is qPCR using cDNA to measure 
expression levels of specific genes. To compare gene expression amongst different cell lines or 
tissue samples, it is very important that equal amounts of cDNA are used. Since there is no 
method to evaluate the efficiency of reverse transcription reaction, number of cDNA copies 
formed for each sample cannot be calculated. Therefore the selection of appropriate 
housekeeping or reference gene becomes an essential criterion for reliable gene expression 
analysis. The levels of the gene of interest are always compared between samples by normalising 
the target gene levels with the levels of a reference gene. 
The RT-qPCR reactions were normally carried out in 96-well plates (Bio-Rad) using 2x 
SensiFAST™ SYBR No-ROX mix (Bioline) according to manufacturer’s manual. The real time 
qPCR reactions were prepared in triplicates using cDNA (≈100ng), forward primer (400nM), 
reverse primer (400nM) and 2x SensiFAST™ SYBR No-ROX mix and autoclaved ddH2O to a 
final volume of 20μl per reaction. Negative control reactions without the DNA were also run 
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alongside. The target genes were always measured alongside reference genes to normalise and 
compare expression profiles. Primer sequences and their PCR cycling conditions used for 
specific experiments are described in Table 2.2 and Table 2.3. CFX96 Real-Time Thermal 
Cycler C1000 (Bio-Rad) was used and the data obtained was analysed using Bio-Rad CFX 
System Test software. The software calculates the relative quantities of gene expression based on 
the delta-delta Ct (ΔΔCt) method which assumes efficiency of each RT-qPCR reaction to be 
100%. A modified formula based on ΔΔCt method that takes into account the actual efficiency of 
the qPCR reaction is given below 
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Reference 
Gene 
For Primer Rev Primer Real-Time PCR 
conditions (initial 
denaturation: 95°C 2 
min) 
HPRT1 GACCAGTCAACAGGGG
ACAT 
AACACTTCGTGGGGT
CCTTTTC 
Cycle(x40): 95°C 5 
sec; 58°C 10 sec; 72°C 
10 sec.  
RPL32 CATCTCCTTCTCGGCAT
CA 
AACCCTGTTGTCAAT
GCCTC 
Cycle(x40): 95°C 5 
sec; 60°C 10 sec; 72°C 
10 sec.  
B2M ACTGAATTCACCCCCA
CTGA 
CCTCCATGATGCTGCT
TACA 
Cycle(x40): 95°C 5 
sec; 59°C 10 sec; 72°C 
10 sec.  
18s rRNA CAGCCACCCGAGATTG
AGCA 
TAGTAGCGACGGGCG
GTGTG 
Cycle(x40): 95°C 5 
sec; 61°C 10 sec; 72°C 
10 sec.  
CycloB TGGCACAGGAGGAAA
GAGCATC 
AAAGGGCTTCTCCAC
ATCGAT 
Cycle(x40): 95°C 5 
sec; 60°C 10 sec; 72°C 
10 sec.  
TBP GCCCGAAACGCCGAAT
ATA 
CGTGGCTCTCTTATCC
TCATGA 
Cycle(x40): 95°C 5 
sec; 58°C 10 sec; 72°C 
10 sec.  
HuP0 GCAGCATCTACAACCC
TGAAG 
CACTGGCAACATTGC
GGAC 
Cycle(x40): 95°C 5 
sec; 58°C 10 sec; 72°C 
10 sec.  
 
Table 2.2 Gene primers used for finding suitable internal control housekeeping gene and 
cycling conditions: HuPO, human acidic ribosomal protein; CycloB, cyclophylinB; B2M, β2-
microglobulin; HPRT, hypoxanthine phosphoribosyltransferase; 18sRNA, 18S ribosomal RNA; 
RPL32, ribosomal protein 32; TBP, Tata box Binding Protein. 
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Gene Name Sequence Annealing 
temperatur
e (X
0
C) 
cDNA 
product size 
SERPINB1 Forward TGAGTGAGAACAATCCGGCT 62 128 
SERPINB1 Reverse GTTGAAATGGAAAGTCTTGGAC
AG 
RHOA Forward CCCTCTCCTACCCAGATACC 60 167 
RHOA reverse TGCTCATCATTCCGAAGATCCT 
ITGA4 Forward TCACACTTTCCAGACAGCCA 61 119 
ITGA4 Reverse CACTCCATAGCAACCACCAG 
CALR Forward CAACTTCCTCATCACCAACGA 21 60.76 62 188 
CALR Reverse TGTCCTCATCATCCTCCTTGTC 
FGL2 Forward CCAGCCAAGAACAAATACAGTC 60 115 
FGL2 Reverse GGATCAGGTGTAACTCTGTAGG 
ALOX5 Forward CTACATCTACCTCAGCCTCGT 
61 188 ALOX5Reverse GTACCAGTCGTCATTCAGCC 
ANXA1 Forward  TTCAATACCATCCTTACCACCA 
61 124 ANXA1Reverse CTCAATGTCACCTTTCAACTCC 
WDR1 Forward AGATCCAAGATGCACACCG 60 122 
WDR1 Reverse GCTCCTCAGTAGGTGATTGTC 
YWHAE Forward CGATACGACGAAATGGTGGA 60 121 
YWHAE Reverse GGCTCTTCTAGCTCCAATCAC 
OSTF1 Forward AGTGGGTGTTAATGGCTTAGAC 59 137 
OSTF1 Reverse TATCTCCCAACTTGTTCTGCTG 
LTF Forward CAAATGTGCCTTCTCCTCCC 61 153 
LTF Reverse GTAACTCATACTCGTCCCTTTCA
G 
NONO Forward AGAGCAGGAGATTCGGATGG 61 172 
NONO Reverse AAGCGTTCAGTTGTTGGTGG 
ANXA3 Forward TCTTAACTACCAGGACAAGCAG 59 111 
ANXA3 Reverse GAAGTCACCAGATGTTTCGG 
CPNE3 Forward AGAGATATTGTCCAGTTTGTGCC 60 164 
CPNE3 Reverse ACTGCTTCTGTTGTTTCGTGG 
Table 2.3 Primer sequences used to validate candidate biomarkers using RT-qPCR:  Primer 
sequences used to validate a biomarker panel by RT-qPCR.  Real time PCR conditions: {Initial 
denaturation 95°C 2 min [Cycle(x40): 95°C 5 sec; X°C 10 sec; 72°C 10 sec]}. 
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2.4 High throughput data analysis and bioinformatics methods 
2.4.1 Public microarray databases and Gene Expression Omnibus 
 Public microarray databases are repositories of raw/processed gene expression data that 
are peer reviewed and produced by adhering to industrial standards. These databases include 
often include tools for data analysis. There are two types of these repositories; peer reviewed 
public databases (eg. Gene Expression Omnibus (GEO) from NCBI and ArrayExpress from 
European bioinformatics institute) and specialised repository which might be associated with 
research groups, labs, disease types, cell types etc. In this study we used GEO to mine for 
microarray datasets.  GEO provides a flexible and open design that facilitates submission, 
storage and retrieval of heterogeneous data sets from high-throughput gene expression and 
genomic hybridization experiments (Edgar et al., 2002). Both raw data and processed data for 
microarray datasets can be downloaded from GEO and data analysis can be independently 
performed. 
2.4.2 Statistical analysis methods used in the study 
 The statistical hypothesis tests used in this study were Student’s T-test and one- way 
Analysis of Variance (ANOVA). Both T-test and ANOVA assume the data is normally 
distributed. The T-test looks at the t-statistic, t-distribution and degrees of freedom to determine 
a p value (probability) that can be used to determine whether the population means differ. To 
compare three or more variables ANOVA is used. Other tests used in this study were Mann-
Whitney U-test and Kruskal-Wallis test. Both are non-parametric tests and is used when the data 
is not normally distributed, if the variances for the two conditions are markedly different or if the 
data are measurements on an ordinal scale. 
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2.4.3 Tools for Molecular and Functional analysis of highthroughput data 
2.4.3.1 Multi Experiment Viewer (MeV) 
 Multi Experiment Viewer is freely available software which can be used to analyse 
microarray data. It incorporates algorithms for normalisation, clustering, visualisation statistical 
analysis and annotation based meta-analysis. MeV is one of the components of the TM4 
microarray suite and can be freely downloaded from www.tm4.org. 
2.4.3.2 Gene Ontology (GO) 
 Understanding the biological meaning of the results obtained through microarray or 
RNA-Seq can be difficult. The conventional way to achieve this is to classify the genes based on 
their function and their cellular location. Gene ontology is used to annotate genes with respect to 
their function. The gene ontology project is an initiative which evolved out of the need to 
consolidate the descriptions of each gene and its products across different species for consistence 
to enable functional interpretation of experimental data; the ontology database is maintained by 
the gene ontology consortium (http://geneontology.org/). The Gene Ontology analysis was 
performed using a tool called Gene Ontology for Functional Analysis (GOFFA) developed by 
the USA Food and Drug Administration (FDA) Department which is available as a standalone 
tool at http://www.fda.gov/ScienceResearch/BioinformaticsTools/ucm233315.htm.  
2.4.3.3 Pathway enrichment analysis 
Pathway analysis is another approach to interpret the biological meaning of a microarray 
dataset. This approach can be used to observe subtle and consistent changes in the pathways 
using functional annotations. Pathway analysis was done using the KEGG database (Kyoto 
Encyclopedia of Genes and Genomes) (Weblink: http://www.genome.jp/kegg) and the software 
used to view to apply and view the data was GenMapp (Weblink: http://www.genmapp.org ). 
KEGG pathway database is a collection of manually drawn pathway maps representing molecular 
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interactions and networks for metabolism, genetic information processing, environmental 
information processing, cellular processes, organismal systems, human diseases and drug 
development (Kanehisa et al., 2012). 
2.4.3.4 Protein Protein Interaction analysis 
 Protein-Protein interactions are crucial for all biological processes. With the rapid 
development of genomics and proteomics technologies the knowledge about cellular processes 
has increased. In practice information about molecular interactions is dispersed in the scientific 
literature and difficult to retrieve in a structured format. Therefore organised, user-friendly and 
consolidated databases about molecular interactions are needed to interpret complex biological 
data. Currently several of these databases exist; Biomolecular Interaction Network Database 
(BIND), Biological General Repository for Interaction Datasets (BIOGRID), IntAct molecular 
interaction database, Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), 
Molecular INTeraction database (MINT) etc. These databases use information from yeast hybrid 
experiments, immunoprecipitation, user submitted information etc.  Osprey is a tool for graphical 
visualisation of complex biological interaction networks using the gene ontology annotated 
dataset maintained by BIOGRID. Osprey was used in this study and it can freely downloaded 
from http://www.cs.duke.edu/donaldlab/osprey.php.  
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Chapter 3: Analysis of Protein profiles of White blood cells in breast cancer 
patients using Proteomic Approaches 
 
3.1 Introduction 
  Early detection of breast cancer allows the possibility to determine the best 
treatment options which may be surgical resection, hormone therapy, chemotherapy, 
radiotherapy or combination of those. Our understanding of the molecular pathology of breast 
cancer has recently advanced with the help of new proteome- and genome-wide technologies. 
The conventional classification based on traits such as invasiveness, tissue of origin, 
histopathology, degree of cellular differentiation etc has now been complemented by novel 
molecular stratification which derived from integrated analyses of gene expression and copy 
number (Curtis et al., 2012; Dawson et al., 2013). These studies also created an opportunity for 
discovering biomarkers to predict the prognosis of the disease thereby deciding the course of 
treatment.  
Proteomics approaches have been used in a number of studies to discover biomarkers in 
the blood plasma. Examples include biomarkers for invasive breast cancer in a mouse model 
(Pitteri et al., 2008, 2011), diagnostic and prognostic markers for gastric cancer (Qiu et al.,2009), 
non-small cell lung cancer (Izbicka et al., 2012) and breast cancer (Nolen et al., 2008) in 
patients’ plasma. Circulating biomarkers such as CA 125, CA 19-9 and carcinoembryonic 
antigen in ovarian, pancreatic and colon cancer, respectively, have been used to monitor response 
to therapy and recurrence (Ludwig and Weinstein, 2005).  There are a number FDA approved 
biomarkers (Ludwig and Weinstein, 2005) for breast cancer including CA15-3, CA27-29, 
Oestrogen receptor, progesterone receptor, HER2/NEU for prognosis and monitoring but none of 
them can be used for diagnosis. Therefore, there is a continuing quest to discover new 
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biomarkers from various sources, in particular from biological fluids (blood, urine, nipple 
aspirates) because of the less invasive procedures are involved to obtain those specimens. 
Proteomics technologies have now been widely used to study proteomes of the cells.  The 
term “proteome” refers to the entire set of proteins synthesised by the cell or tissue and the large 
scale study of it is proteomics.  This approach has advantages because (i) proteomics provide 
more  physiologically accurate information about processes in the cell; (ii) changes in protein 
activities associated with the disease can be identified and (iii) proteomics platforms are more 
applicable from therapeutics point of view. A range of methods including 2D-PAGE (Gharbi, 
2001; Somiari et al., 2003), protein arrays (Sreekumar et al., 2001) coupled with mass 
spectrometric techniques, for example, SELDI-ToF, MALDI-ToF, etc have been used to identify 
biomarkers for cancer using tissue, cancer cell lines and blood plasma.  
The evolution of mass spectrometry in the last decade has made it more sensitive, 
although it is not yet possible to resolve accurately all the proteins found in complex biological 
mixtures such as serum, cell lysates etc. Nevertheless, this approach has many advantages since 
protein biomarkers are more desirable in clinical settings. These methods will be used in this 
study to identify breast cancer biomarkers in the white blood cells (WBCs), a relatively 
unexplored source for biomarker discovery. 
3.2 Aim of the Chapter 
The main aim of this chapter is to investigate protein profiles specific for the WBCs of breast 
cancer patients and identify new breast cancer biomarkers. To achieve this, two approaches will 
be applied: the high throughput mass spectrometry using the Velos Orbitrap instrument and 2D-
PAGE.  
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 High throughput proteomics was used to identify the differences in protein profiles of 
white blood cells (WBCs) of breast cancer patients and healthy donors. For these analyses, 
samples from three participant groups will be processed: the healthy donors (Group C, n=5) and 
breast cancer patients (Group 1) stratified into two distinct groups:  Group 1A with more 
favourable prognosis   (Grade 1, Stage 1, n=5) and Group 1B with less favourable prognosis 
(Grade 3, Stage 3, n=5). We reasoned that using the groups with opposing characteristics will 
facilitate the analysis and simplify the identification of the candidates showing significant 
differences in protein profiles. Clinical information linked to the specimens used for these 
analyses is given in the Table 3.1.  
The 2D-PAGE method was employed to independently identify proteins differentially 
present in the WBCs of breast cancer patients and to compare the data with high throughput 
proteomics analysis. Clinical information linked to the specimens used in this investigation is 
presented in Table 3.2. 
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Table 3.1 Sample Patient data for the High-throughput Proteomics study: Breast cancer patient WBC samples used for high throughput 
analysis by OrbitrapVelos instrument. T size- Tumour size, T Grade- Tumour grade, T stage- Tumour stage, ER- Estrogen Receptor, PR-
Progestrone Receptor, DCIS- Ductal Carcinoma in situ, IDC- Invasive Ductal Carcinoma, ITC- Invasive tubular carcinoma and ILC- Invasive 
Lobular Carcinoma. 
 
Patient 
No 
AGE 
T 
SIZE 
NODE 
STATUS 
T 
STAGE 
T GRADE 
ER PR HER2 
DIAGNOSIS 
1462 65 11 NEG I 1 8 ND -ve ITC+DCIS 
1466 56 10 NEG I 1 8 ND 
-ve 
IDC+ILC 
1477 46 8 NEG I 1 8 ND 
-ve 
IDC,DCIS(LOW GRADE) 
1483 52 17 NEG I 1 8 ND 
-ve 
IDC+ILC 
1565 51 11 NEG I 1 8 NA 
-ve 
Tubular+DCIS 
453 26 50 POS III 3 3 0 
-ve 
IDC 
1261 44 80 POS III 3 4 NA 
-ve 
IDC+DCIS 
1503 75 20 POS III 3 8 NA 
-ve 
IDC+DCIS 
1516 46 14 NEG III 3 3 NA 
-ve 
IDC+DCIS 
1540 48 28 POS III 3 8 NA 
-ve 
IDC+Chondrosarcoma 
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Table 3.2 Sample Patient data for the 2D-PAGE: Breast cancer patient WBC samples used for 2D-PAGE. T size- Tumour size, T Grade- 
Tumour grade, T stage- Tumour stage, ER- Estrogen Receptor, PR-Progestrone Receptor, DCIS- Ductal Carcinoma in situ, IDC- Invasive Ductal 
Carcinoma, ITC- Invasive tubular carcinoma and ILC- Invasive Lobular Carcinoma.  
 
Patient 
No 
AGE T SIZE NODES T 
STAGE 
T 
GRADE 
ER PR HER2 DIAGNOSIS 
1310 69 8 NEG I 1 8   ND -ve ILC 
1455 49 18 NEG I 1 8 ND -ve ILC+LCIS 
1462 65 11 NEG I 1 8 ND -ve ITC+DCIS 
1499 67 15 NEG I 1 8 NA +ve IDC+DCIS+Tubulo-lobular 
1565 51 11 NEG I 1 8 NA -ve Tubular+DCIS 
1261 44 80 POS III 3 4 NA -ve IDC+DCIS 
1436 60 20 NEG II 3 8 ND -ve IDC+DCIS 
1528 84 20 NEG II 3 8 NA -ve IDC+DCIS 
1560 82 20 NEG II 3 0 NA -ve IDC 
1540 48 28 POS III 3 8 NA -ve IDC+Chondrosarcoma 
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3.3 Results 
3.3.1 High throughput proteomic profiling of WBCs using the Velos Orbitrap mass 
spectrometer. 
3.3.1.1 High throughput proteomic profiling and comparative analysis of WBCs from the 
Healthy donors and all Breast cancer patients groups. 
 High throughput proteomics was used to identify the differences in protein profiles of 
white blood cells (WBCs) of breast cancer patients and healthy donors. The WBCs were 
fractionated into membrane and soluble fractions  as described in Alldridge et al., 2008. Both 
fractions were digested and analysed using the OrbitrapVelos instrument (see section 2.2.2.1) 
equipped with an Ultimate 3000 nano-scale HPLC (Olsen et al., 2009). Dr Metodi Metodiev 
(University of Essex) had kindly performed the mass spectrometric analysis using this 
instrument. Only the data for the membrane fraction was analysed for this study. In total, 2577 
proteins were identified in the membrane fraction of the WBCs.  Since the data were not 
normally distributed, the Mann Whitney U-Test was performed with a P-value cutoff of <0.05 to 
compare the protein profiles between healthy donor and breast cancer patients. The test yielded 
136 proteins which were significantly different between the healthy donor and the breast cancer 
group. Out of the significant 136 proteins, 83 proteins were overexpressed and 53 proteins were 
under expressed in the breast cancer patient category. Hierarchical clustering was performed 
with the normalised Label free quantification (LFQ) intensity values of significant 136 proteins 
which are given in Figure 3.1. For this analyses the Multiexperiment viewer (see section 2.4.3.1) 
from the TM4 microarray software suite available at http://www.tm4.org/ was used.  
The hierarchical clustering revealed that the data had a high degree of variation especially 
among the breast cancer patient cohort. This can be due to the fact that WBCs are a mixture of 
different types of cells and the dynamic nature of the immune system. 
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Figure 3.1 Hierarchical Clustering of significant proteins between the WBCs of Healthy 
Donors and Breast Cancer Patients: Differentially present proteins from the membrane 
fraction were identified using the Mann Whitney test between breast cancer patients and healthy 
donors. Hierarchical clustering was performed using the Multiexperiment viewer. In the breast 
cancer patient category 83 proteins were overexpressed and 53 proteins were underexpressed. 
Red indicates that the protein is relatively overexpressed and green the vice versa in breast 
cancer patient samples. 
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3.3.1.2 Comparison between the samples with different Tumour grades: Healthy Donors 
vs Low grade Breast Cancer patients and Healthy Donors vs High grade Breast 
Cancer Patients. 
 To identify the differences the between different grades and stages samples were chosen 
in patients with either Grade1-Stage1 tumours (favourable prognosis) or Grade3-Stage3 tumours 
(less favourable prognosis). We reasoned that by choosing samples with these characteristics the 
differences in proteomes of breast cancer will be more apparent. The WBCs protein profiles 
obtained using the high throughput mass spectrometry was compared as follows: Healthy Donors 
vs Low grade Breast Cancer patients and Healthy Donors vs High grade Breast Cancer Patients. 
Kruskal-Wallis teast (dunn’s correction, p value<0.05) was used as described in section 2.4.3.1 
to compare between the groups; this resulted in 44 proteins as significantly different between the 
categories.  
 Hierarchical clustering was performed with the normalised Label free quantification 
(LFQ) intensity values (section 2.4.3.1) of significant 44 proteins (Figure 3.2).  The 
Multiexperiment viewer from the TM4 microarray software was used for this analysis. There 
were three major groups of proteins observed from clustering: Proteins which were 
overexpressed in healthy donors (n=10), proteins overexpressed in both breast cancer cohorts 
(n=14) and proteins overexpressed in Low grade patients (n=20). The protein profiles which 
follow the trend of the first two groups were chosen and the mean for each group was taken to 
plot graphs with standard deviation (Figure 3.3). 
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Figure 3.2 Hierarchical clustering of significant proteins between the WBCs of Healthy 
Donors, Grade1-Stage1 and Grade3-Stage3 Breast Cancer Patients: Mann-Whitney test was 
performed to obtain the significantly expressed proteins between the WBCs of healthy donors, 
low grade breast cancer patients and high grade breast cancer patients. Hierarchical Clustering 
was done using the proteins which had significant differences using Multiexperiment viewer. 
Red indicates that the protein is relatively overexpressed and green the vice versa in breast 
cancer patient samples. 
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Figure 3.3 Protein expression profiles of significant proteins obtained by comparison 
between the WBCs of Healthy Donor, Grade1-Stage1 and Grade3-Stage3 Breast cancer 
Patients: Kruskal-Wallis was used to compare membrane fraction protein profiles of WBCs 
between healthy donors, low grade-low stage and high grade-high stage breast cancer patients. 
The profiles of proteins which showed significant changes in healthy donors and breast cancer 
patients (both low grade and high grade) were chosen and their mean was taken to plot graphs. 
 
64 
 
3.3.1.3 Molecular and Functional analysis of proteins obtained from the high throughput 
proteomics analysis 
It is important to biologically interpret the data obtained from the high throughput 
analyses and there are various approaches to achieve this. Commonly used approaches include: 
gene ontology, pathway enrichment and protein- protein interaction network analyses (see 
section 2.4.3). The ontology analysis was done based on three categories immune response, cell 
death and cell migration. The proteins which were differentially expressed in the WBCs of breast 
cancer patients obtained by both tests mentioned in sections 3.3.1.1 and 3.3.1.2 were analysed for 
functional significance. 
3.3.1.3.1 The Gene Ontology analysis: classification of Biological Processes 
 The differentially present proteins in the breast cancer patient cohort were obtained by 
comparing the WBC membrane fraction profiles of breast cancer patients and healthy donors. 
These proteins were subjected to ontology analysis to identify enriched biological processes. 
Gene ontology is used to functionally interpret data obtained from high throughput techniques 
such as microarray, proteomics etc (Ashburner et al., 2000). The gene ontology database is 
maintained by the Gene Ontology Consortium and can be accessed freely at 
www.geneontology.org. 
Gene ontology analysis based on classification of Biological Processes was performed 
using GOFFA (Gene Ontology for Functional Analysis) as described in Section 2.4.3.2.The 
results for the classification are given in Figure 3.4.The categories which had the most number of 
proteins were cellular processes (n=73), metabolic processes (n=59), response to stimulus and 
reproduction (n=53). It was observed that 41 proteins were involved in localisation and 
establishment of localisation. This shows that around 25% of proteins which changed were 
involved in cellular localisation.  
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Figure 3.4 Gene Ontology of significantly different proteins between the WBCs of Healthy 
donors and Breast cancer Patients obtained through high throughput Proteomics: Proteins 
differentially present in the WBCs of breast cancer patient and healthy donors by high 
throughput proteomics were statistically significant by the Mann Whitney U test. Gene Ontology 
was performed using GOFFA and based on biological processes. The total number of proteins 
involved was 136. 
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3.3.1.3.2 Ontology analysis of proteins involved in immune system processes 
 There were 34 proteins involved in the immune system processes; the gene ontology 
classification of these processes and proteins involved in each subcategory are given in Table 
3.4. Among those, 21 proteins were involved in regulation of the immune system processes, with 
14 activators. In the latter category, 8 proteins were overexpressed and 6 proteins were 
underexpressed in the breast cancer cohort. The number of genes involved in negative regulation 
of immune system was 5 and all the proteins except ADA (Adenosine deaminase) were 
overexpressed. These data provided inconclusive results as to how the immune response was 
affected by breast cancer. Therefore, the proteins involved in leukocyte and lymphocyte 
activation were analysed. The proteins involved in both categories were the same except for BPI 
(Bactericidal/Permeability-Increasing Protein) and YWHAZ (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein, zeta). The proteins involved in 
positive regulation of leukocyte and lymphocyte activity (ADA, CD3D, DPP4 and TRBC1) were 
underexpressed. The proteins which negatively regulated leukocyte and lymphocyte activity, BPI 
and GIMAP5, were overexpressed. It can be concluded from the data that activation of 
leukocytes and lymphocytes are negatively affected by the breast tumour. 
The proteins involved in the inflammatory response (n=10) are shown in Table 3.4; 
except for ADA and PRDX2, all the proteins were overexpressed. ADA negatively regulates the 
inflammatory response (GO:0050728). Peroxiredoxin-2 (PRDX2) is an enzyme which has 
antioxidant activity reducing hydrogen peroxide alkyl hydroperoxides in the cell and hence has 
an anti-inflammatory effect. This shows that inflammatory response is increased in the WBCs of 
breast cancer patients. 
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Table 3.3 List of Proteins involved in the immune response: Proteins identified by high-
throughput proteomics to be differentially present between healthy donors and breast cancer 
patients by comparing the membrane fraction of the WBCs. Gene ontology was to choose 
proteins related to immune response. Proteins in red are overexpressed and green are 
underexpressed in breast cancer patient WBCs. 
Gene 
Symbol 
Gene name 
Fold 
change 
ADA Adenosine deaminase  
CD79B CD79b molecule, immunoglobulin-associated beta  
DPP4 Dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2)  
S1PR4 Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 6  
CD3D CD3d molecule, delta (CD3-TCR complex)  
S100A7 S100 calcium binding protein A7  
ITGA4 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)  
CLEC4D C-type lectin domain family 4, member D  
TRBC1 T cell receptor beta constant 1  
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide  
SOD2 Superoxide dismutase 2, mitochondrial  
UNC93B1 Unc-93 homolog B1 (C. elegans)  
TMEM173 Transmembrane protein 173  
PRDX2 Peroxiredoxin 2  
PTAFR Platelet-Activating Factor Receptor  
GIMAP5 GTPase, IMAP family member 5  
CD97 CD97 molecule  
PTPRJ Protein tyrosine phosphatase, receptor type, J  
YWHAZ 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
zeta polypeptide 
 
ANXA1 Annexin A1  
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S100A9 S100 calcium binding protein A7;Calgranulin B  
FKBP1A FK506 binding protein 1A, 12kDa  
IGF1R Insulin-like growth factor 1 receptor  
RPS27A Ribosomal protein S27a  
CD46 CD46 molecule, complement regulatory protein  
BPI Bactericidal/permeability-increasing protein  
MICA MHC Class I Polypeptide-Related Sequence A  
TAP2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)  
UNC13D Unc-13 homolog D (C. elegans)  
ILF2 Interleukin enhancer binding factor 2, 45kDa  
AP1B1 Adaptor-related protein complex 1, beta 1 subunit  
NCF2 Neutrophil cytosolic factor 2   
NCF4 Neutrophil cytosolic factor 4, 40kDa  
AP1M1 Adaptor-related protein complex 1, mu 1 subunit  
CD200R1 CD200 receptor 1  
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Table 3.4 Gene ontology of the Proteins involved in immune system processes: Immune 
system proteins identified to be differentially present in the WBCs of breast cancer patient and 
healthy donors by high throughput proteomics were obtained by Mann Whitney U test. Gene 
Ontology was performed using GOFFA and based on Immune system process. The total genes 
involved in immune system processes were 34. 
Gene Ontology 
Term 
Gene 
Ontology ID 
Genes involved 
P value 
Regulation of 
Immune system 
process 
GO:0002682 
ADA,AP1B1,AP1M1,BPI,CD200R1,CD3D, 
CD46,DPP4,FKBP1A,GIMAP5,ITGA4,MICA, 
PRDX2,PTPRJ,RPS27A,S100A7,TAP2,TMEM173, 
TRBC1,UNC13D,UNC93B1 
0.0002 
Positive 
regulation of the 
immune system 
GO:002684 
ADA,CD3D,CD46,DPP4,GIMAP5,MICA, 
PTPRJ,RPS27A,S100A7,TAP2,TMEM173,TRBC1, 
UNC13D,UNC93B1 
0.0009 
Negative 
regulation of the 
immune system 
GO:002683 ADA,BPI,GIMAP5,PRDX2,PTPRJ 
0.03 
Adaptive 
Immune 
Response 
GO:0002250 ADA,CD46,DPP4,GIMAP5,TAP2,UNC13D 
0.02 
Innate Immune 
Response 
GO:0045087 
CD46,CLEC4D,GIMAP5,MICA,NCF2,PTAFR,RPS27A, 
S100A7,TMEM173,UNC13D,UNC93B1 
0.002 
Positive 
regulation of 
Innate immune 
response 
GO:0045089 GIMAP5,MICA,RPS27A,TMEM173,UNC93B1 
0.041 
Leukocyte 
Activation 
GO:0045321 
ADA,ANXA1,BPI,CD3D,DPP4, 
FKBP1A,GIMAP5,ITGA4,MICA,PRDX2,TRBC1, 
UNC13D,YWHAZ 
0.0001 
Positive 
Regulation of 
Leukocyte 
activation 
GO:0002696 ADA,CD3D,DPP4,TRBC1 
0.004 
Negative 
Regulation of 
Leukocyte 
activation 
GO:0002695 BPI,GIMAP5,PRDX2 
0.05 
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Lymphocyte 
activation 
GO:0046649 
ADA,ANXA1,CD3D,DPP4,FKBP1A,GIMAP5,ITGA4, 
MICA,PRDX2,TRBC1,UNC13D 
0.002 
Positive 
Regulation of 
Lymphocyte 
activation 
GO:0051251 ADA,CD3D,DPP4,TRBC1 
0.003 
Negative 
Regulation of 
Lymphocyte 
activation 
GO:0051250 GIMAP5,PRDX2 
0.046 
Inflammatory 
response 
GO:0006954 
ADA,ALOX5,ANXA1,CD97,MGST2,PRDX2, 
PSMA6,PTAFR,UNC13D,YWHAZ 
0.0002 
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3.3.1.3.3 Ontology analysis of proteins involved in Cell death and Cell migration 
 The number of proteins in involved in the cell death in the 136 significant proteins 
obtained by gene ontology analysis by GOFFA was23 (17%). The genes involved in cell death 
(GO:0008219) are given in Table 3.5. Of the proteins involved in negative regulation of cell 
death (n=13) except for ADA, PPT1, SOD2 and PRDX2 were overexpressed in the breast cancer 
cohort. The proteins involved in the positive regulation of cell death (n=8) were also 
overexpressed. The analysis for cell proliferation also gave similar inconclusive results. The 
effect of breast cancer on WBC survival is ambiguous taking this data into consideration. 
 Ontology analysis was done for proteins involved in cell migration. It was found that 10 
proteins involved in cell migration were differentially present in the WBCs of breast cancer 
patients. The genes involved in the positive regulation of cell migration are S100A7, S100A9, 
IGF1R, ITGB3 and SYNE2. Only S100 calcium binding protein A7 (S100A7) is 
underexpressed. The S100 family of proteins are involved in several cellular processes like 
proliferation, differentiation, migration etc. S100A7 has been implicated to aid in breast cancer 
progression and invasion (Emberley et al., 2004). S100A9 (Calgranulin B) is implicated in 
promoting leukocyte recruitment to sites of inflammation and abnormal differentiation of 
myeloid cell in the stroma of cancer (Cheng et al., 2008; Hiratsuka et al., 2006). The proteins 
which were involved in cell adhesion were CD97, FLOT2, ITGA4, NME2 and SIGLEC7 are 
shown in Table 3.5. Only ITGA4 and SIGLEC7 were underexpressed in the breast cancer cohort. 
ITGA4 (Integrin alpha 4) binds to cell surface adhesion molecules on endothelial cells enabling 
WBCs to transmigrate. SIGLEC7 is also known as adhesion inhibitory receptor molecule 1 is 
expressed on different tumour cells and inhibits leukocyte adhesion to endothelial cells (Jandus 
et al., 2014). The cell migration and cell adhesion ontology analysis show that the WBCs of 
breast cancer patients have increased cell adhesion and migratory functions.
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Table 3.5 Gene ontology of the Proteins involved in Cell migration and Cell death: 
Ontology was done with the differentially expressed proteins, obtained by comparison between 
healthy donors and breast cancer cohorts using GOFFA. The proteins involved in Cell migration 
processes and Cell proliferation processes were obtained along with their gene ontology IDs. 
 
Gene 
Ontology 
Term 
Gene 
Ontology 
ID 
Genes Involved P 
value 
Cell Migration GO:001647
7 
ADA,ATP1B3,DPP4,IGF1R,ITGA4,PTPRJ, 
RAP2C,RHOA,S100A7,S100A9,SYNE2 
0.017 
Positive 
regulation of 
cell migration 
GO:003033
5 
S100A7,S100A9,IGF1R,ITGB3,SYNE2 0.03 
Negative 
regulation of 
cell migration 
GO:003033
6 
ADA,PTPRJ,RAP2C 0.06 
Cell Adhesion GO:000715
5 
CD97,FLOT2,ITGA4,NME2,SIGLEC7 0.018 
Cell 
proliferation 
GO:000838
3 
ADA,ANXA1,DPP4,GNB1,GPC4,IGF1R, 
NME2,PRDX2,PTPRJ,RAP1B,SOD2,TXN 
0.04 
Negative 
regulation of 
cell 
proliferation 
GO:000828
5 
PTPRJ,SOD2 0.009 
Positive 
regulation of 
cell 
GO:000828
4 
ADA,DPP4,IGF1R,ITGB3,NME2 0.017 
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proliferation 
Cell death GO:000821
9 
CFL1,CYCS,GIMAP5,H1F0,IGF1R,KCNMA1, 
KPNB1,MICA,NME2,PARP4,PIGT,PPT1, 
PRDX2,PSMA6,RHOA,RPS27A,SET, 
SOD2,SPTAN1,TAP2,TMEM13 UNC13D,YWHAB 
0.003 
Negative 
regulation of 
Cell death 
GO:006054
8 
ADA,ANXA1,GIMAP5,IGF1R,NME2, 
PPT1,PRDX2,PTPRJ,RHOA,RPS27A,SET,SOD2,YWHAZ 
0.000
1 
Positive 
regulation of 
Cell death 
GO:001094
2 
CYCS,GIMAP5,KCNMA1,NCF2,RPS27A, 
TAP2,UNC13D,YWHAB 
0.011 
 
74 
 
3.3.1.3.4 Pathway enrichment analysis 
 The pathway enrichment analysis is another approach to interpret the biological meaning 
of high throughput data. This approach can be used to observe subtle and consistent changes in 
the pathways using functional annotations. Pathway analysis was performed on the significant 
genes obtained by comparing the protein profiles between the WBCs of breast cancer patients 
and healthy donors using GenMAPP software as described in section 2.4.3.3. The pathway 
database used was KEGG (Kyoto Encyclopedia of Genes and Genomes). The top 10 list of 
pathways with the proteins involved are given in Table 3.6. The majority of the pathways are 
related to metabolism. The only pathways related to immune function was leukocyte 
transendothelial migration (Figure 3.5) and PI3K-AKT signalling pathway (Figure 3.6). All the 
proteins (RHOA, NCF2, NCF4, GNAI3 and RAP1B) in the leukocyte transendothelial migration 
pathway except ITGA4 were overexpressed in the breast cancer cohort. It can be observed from 
Figure 3.5 that the leukocyte transendothelial pathway is promoted in the WBCs of breast cancer 
patients. It was previously reported that metastasis in melanoma patients was enhanced in the 
presence of neutrophils within the alveolar capillaries. Melanoma cells release interleukin 8 
inducing neutrophils to overexpress β2 integrins and adhere to the vascular endothelium. The 
ICAM-1 on melanoma cells and the β2 integrins on neutrophils then used for these cells to bind 
and melanoma cells transverse and emigrate into lung tissue (Gregory and Houghton, 2011). It 
should be noted that the PI3K-AKT pathway is involved in the leukocyte transendothelial 
signalling (Figure3.5). The altered proteins involved in PI3K-AKT pathway were ITGA4, 
GNG5, GYS1, YWHAB, YWHAZ and IGF1R.GNG5, GYS1, YWHAZ and YWHAB were 
overexpressed in the WBCs of breast cancer patients. The PI3K-AKT pathway is a combination 
of insulin, MAPK and VEGF signaling pathways leading to cell growth progression, immune 
cell activation and increased cell migration (Koyasu, 2003). 
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Table 3.6 Top 10 Pathways obtained by comparison of Protein profiles of healthy donors 
and breast cancer patients:   List of pathways and proteins involved in immune response to 
tumour obtained by high throughput proteomics by comparison of WBCs from healthy donor 
and breast cancer patients. 
KEGG pathway Proteins involved Adj P value 
Salivary secretion 
ATP1B3, ATP1A1, CAMP, PRH1, ATP2B4, 
KCNMA1 
1.33e-06 
Fatty acid metabolism ACADM, CPT1A, ECI1, ECHS1, ALDH9A1 1.33e-06 
PI3K-AKTsignaling pathway  
ITGA4, GNG5, GYS1, YWHAB, 
YWHAZIGF1R 
1.89e-06 
Valine, leucine and isoleucine 
degradation 
ACADM, OXCT1, ECHS1, ALDH9A1 3.72e-05 
Leukocyte transendothelial 
migration 
RHOA, NCF4, GNAI3, ITGA4, RAP1B,NCF2 6.62e-05 
Metabolic pathways 
ALDH4A1, LSS, PGM1, PIGT, PPT1, ECHS1, 
NME2, MDH1, AHCY, ACADM, NDUFA10, 
ALDH9A1 
6.94e-05 
beta-Alanine metabolism ACADM, ECHS1, ALDH9A1 0.0001 
Proximal tubule bicarbonate 
reclamation 
MDH1,ATP1B3, ATP1A1 0.0001 
Propanoate metabolism ALDH9A1, ECHS1, ACADM 0.0003 
Pyruvate metabolism MDH1, ME2, ALDH9A1 0.0005 
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Figure 3.5 Regulation of the Leukocyte Transendothelial Migration Pathway in the WBCs 
of Breast Cancer Patients: Differentially expressed genes were obtained from the comparison 
between protein profiles of breast cancer patients and healthy donors. Pathway analysis was 
performed using the KEGG database. Red indicated overexpression and green underexpression 
in the breast cancer patients. 
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Figure 3.6 Regulation of the PI3K-Akt Signalling Pathway in the WBCs of Breast Cancer 
Patients: Differentially expressed genes were obtained from the comparison between protein 
profiles of breast cancer patients and healthy donors. Pathway analysis was performed using 
GENMAPP and the KEGG database. Red indicated overexpression and green underexpression in 
the breast cancer patients. 
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3.3.1.3.5 Protein-Protein interaction (PPI) analysis 
 Interactions between proteins are very important in many biological processes and the 
information about interacting protein partners can provide clues about potential protein 
functions. We therefore performed the protein-protein interaction (PPI) analysis of the identified 
proteins with the help of the Osprey tool used for visualization and manipulation of complex 
interaction networks (see section 2.4.3.4). The Osprey tool builds data-rich graphical 
representations from Gene Ontology (GO) annotated interaction data maintained by the 
BioGRID (available from http://thebiogrid.org/). The protein-protein interaction network was 
generated and the single nodes (proteins) which did not have any interaction were deleted 
(Figure 3.7).The hub genes were identified using this approach. The hub genes are those genes 
which are highly connected to other genes and when altered lead to drastic phenotypic changes 
in the cell which could determine the fate of the cell.  
 It was observed that 14-3-3 protein beta/alpha (YWHAB), insulin-like growth factor 1 
receptor (IGF1R) and the Ras homolog gene family member A (RHOA) had the most number of 
interactions. These three proteins were overexpressed in the WBCs of breast cancer patients. 
 Other minor hub genes identified were Heterogeneous nuclear ribonucleoprotein A1 
(HNRNPA1), AP-1 complex subunit beta-1 (AP1B1), SET Nuclear Oncogene (SET) and 
SEC13 Homolog (SEC13). YWHAB belongs to the 14-3-3 family of proteins involved in a wide 
range of cellular functions such as metabolism, protein trafficking, signal transduction, apoptosis 
and cell cycle regulation. YWHAB binds to RAF1 and CDC25 phosphatases suggesting it might 
play a role in cell proliferation (Conklin, 1995; Yuryev and Wennogle, 2003). IGF1R activates 
the PI3K-AKT signalling, JAK/STAT pathway and the Ras-MAPK pathway leading to cell 
growth/survival (Wilker et al., 2005). RHOA is a small GTPase protein which is involved in 
regulation of actin cytoskeleton rearrangement to form stress fibres during cell migration. RHOA 
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is also implicated in regulating the cell transformation and cell cycle progression (Klimov et al., 
2013). The overexpression of all these proteins suggests that the WBCs of breast cancer patients 
are been driven towards cell proliferation and cell survival. 
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Figure 3.7 Identification Hub gene nodes changed in the WBCs of breast cancer patient 
cohort using high throughput protein data: Differentially expressed proteins in the WBCs of 
breast cancer patients were used to construct gene regulatory networks. Network was constructed 
using Osprey (http://biodata.mshri.on.ca/osprey/servlet/Index). The lines between gene nodes 
represent interactions and the genes with most interactions (hub genes) are independently with 
their own network. 
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3.3.2 Qualitative protein profiling using Two Dimensional (2D) Protein gel 
Electrophoresis 
In this study an alternative method, the 2D-PAGE, was also used. To be resolved by 2D 
gels, the whole cell protein lysates from the WBCs of 10 breast cancer patients and 5 healthy 
donors were prepared according to procedure in Section 2.2.3.3. The sample details are given in 
Table 3.2. The protein lysates were then separated in the first dimension by the isoelectric point 
and in the second dimension by the molecular weight. All the samples were run in triplicates and 
the gels scanned after staining. The images were then analysed using the Samespots software 
(see section 2.2.3.2.4). Two types of analysis were performed on the 2D-gels based on the 
grouping of samples: (1) the disease state (Healthy donor vs Breast Cancer) and (2) tumour grade 
(Healthy donor, Low Grade and High Grade). The Samespot analysis based on disease state gave 
18 spots which were significant and the analysis based on tumour grade gave 25 spots. The gel 
images showing the significant spots for both the analyses are presented in Figure 3.8. Between 
both analyses there was an overlap of 14 spots. The spots were excised out of the gels and given 
for mass spectrometric identification in Dr M. Metodiev’s laboratory.  
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A 
 
B 
Figure 3.8 2D-PAGE gel separation of proteins identified with silver staining from WBCs 
of cancer patients and healthy donors. The proteins are separated by their isoelectric point in 
the first dimension and by molecular weight (MW) in the second dimension. Gels were run in 
triplicates and analysed with the Samespots software. The spots which were differentially present 
were obtained by comparing different conditions. The circled spots show proteins significantly 
different in the Disease State analysis A and Tumour Grade analysis B. 
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3.3.2.1 Protein Spot Identification and Functional analysis 
 The total numbers of unique protein identifications were14 out of 26 spots obtained from 
the Samespot analysis. There was more than one protein identification for certain spots. This can 
be attributed to post-translational modifications, the protein fragmentation during the sample 
preparation step or simply an error during mass spectrometric procedures. The protein ID which 
had the most number of peptide hits was taken as the spot identification. Some of the spots could 
not be identified due to low protein content in the spot. The results for the tumour grade analysis 
and diseased state analysis are given in Table 3.7 and Table 3.8 respectively. All the proteins 
picked up in the disease state analysis were present in the tumour grade analysis with the 
exception of 6-phosphogluconate dehydrogenase (PGD). In the tumour grade analysis only the 
following proteins showed a consistent trend with both low grade and high tumours (either 
increase or decrease); JUP, TKT, SERPINB1, CAPZA1, CORO1A and ARPC2 (Figure 3.9). 
The proteins which were overexpressed in low grade breast and underexpressed in high grade 
breast cancer cohort were ANXA1, PRH1, ITGAM and VCL. On the other hand the proteins 
which were underexpressed in the low grade breast cancer and overexpressed in high grade 
breast cancer cohort were CASP14 and CTNNG. The proteins which were common between 
both the types of analysis were TKT, SERPINB1, CAPZA1, CORO1A and ARPC2. 
 When gene ontology was performed as described in section2.4.3.2majority of the proteins 
identified are cytoskeletal proteins involved in actin rearrangement (Gene Ontology id:0005856 
); CASP14, ACTN1, CORO1A,ARPC2, VCL, ANXA1 and CAPZA1 (Table 3.9). The other 
categories obtained by gene ontology analysis were cell adhesion and cell migration. CAPZA 
and CORO1A are involved in the innate immune response (GO:0045087). ANXA1 and 
CORO1A are involved in leukocyte activation (GO:0045321). SERPINB1 is stored in the 
granules of neutrophils and it inhibits neutrophil elastase which has anti-microbial activity, 
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dissolves cellular junctions, increases cell migration etc (Chou et al., 2012). Except for ACTN1, 
VCL and CAPZA1 all the proteins which are involved in cell migration/adhesion were 
overexpressed in the WBCs of breast cancer patients. SERPINB1 and JUP affect cell migration 
in a negative manner (Chou et al., 2012; Lam et al., 2012).All the other proteins (CORO1A, 
ITGAM, VCL and ACTN1) involved in cell migration/adhesion enhance the process. Protein-
Protein interaction network was constructed using the significant genes identified through 2D-
PAGE analysis as described in Section 2.4.3.4. It was observed that Plakoglobin (JUP) had the 
most number of interactions. Plakoglobin is a tumour growth and metastasis suppressor (Aktary 
and Pasdar, 2012; Lam et al., 2012). From the data obtained in this analysis a conclusion could 
be drawn on the effect of tumour on WBC migration in cancer patients. 
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Table 3.7 Mass spectrometric Identification of 2D-PAGE spots from Tumour Grade 
analysis: List of Protein spots and their Protein Ids differentially present in the WBCs of breast 
cancer patients as identified through mass spectrometry obtained by comparing healthy donors, 
Low grade breast cancer and high grade breast cancer patients. The spot numbers correspond to 
the numbers in the spotpickingimageFigure3.8 B. FC-Fold Change in comparison with healthy 
donors. Red- FC>1.2, Pink-0<FC<1.2, Green FC<-1.2, Light green -1.2<FC<0. 
Grade 
Analysi
s Spot 
number 
Protein Identification Protein 
Name 
Average Normalised 
Spot Volumes 
FC 
Low 
Grade 
 
FC 
High 
Grade 
Health
y 
Donor 
Low 
Grad
e 
High 
Grade 
17 Junction Plakoglobin JUP 2.136 2.83 3.398 +1.3 +1.6 
19 Immunoglobulin J chain  14.64 16.57 21.6 +1.1 +1.3 
21 Caspase 14 CASP14 1.836 1.349 2.142 -1.4 +1.2 
23 Integrin Alpha M ITGAM 1.723 2.503 1.641 +1.4 -1.04 
30 Transketolase TKT 9.738 14.3 14.42 +1.5 +1.5 
31 Glycogen phosphorylase PYGL 3.176 2.329 2.003 -1.4 -1.16 
35 Vinculin VCL 7.864 8.853 6.143 +1.12 -1.3 
37 Gamma-catenin CTNNG 2.595 1.851 2.655 -1.4 +1.02 
38 Annexin A1 ANXA1 22.9 29.05 20.41 +1.3 -1.12 
41 Neutrophil Elastase 
Inhibitor 
SERPINB
1 
8.138 10.52 11.26 
+1.3 +1.4 
42 Parotid acidic protein PRH1 26.81 32.2 23.39 +1.2 -1.15 
43 F-actin-capping protein 
subunit alpha-1 
CAPZA1 3.439 2.903 2.513 
-1.4 -1.4 
44 Annexin A1 ANXA1 2.222 2.836 2.083 +1.3 -1.06 
45 Coronin 1A CORO1A 5.813 6.18 7.797 +1.06 +1.3 
46 Actin-related protein 2/3 
complex subunit 2 
ARPC2 18.22 15.69 13.62 
-1.16 -1.3 
49 Actinin alpha 1 ACTN1 25.38 25.32 19.87 1 -1.3 
97 Immunoglobulin J chain  10.54 8.362 7.899 -1.3 -1.3 
122 Phosphoglyceratemutase 
1 
PGAM1 9.551 9.258 7.534 
1 -1.3 
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Table 3.8 Mass spectrometric Identification of 2D-PAGE spots from Disease state analysis; 
List of Protein spots and their Protein Ids differentially present in the WBCs of breast cancer 
patients as identified through mass spectrometry obtained by comparing healthy donors and 
breast cancer patients. The spot numbers correspond to the numbers in the spotpicking image 
Figure 3.8 A. FC-Fold Change in comparison with healthy donors. Red- FC>1.2, Green FC< -
1.2. 
 
 
 
 
Disease State 
Analysis Spot 
number 
Protein 
Identification 
Protein 
Name 
Average Normalised 
Spot Volumes 
Fold Change 
in Cancer 
Healthy 
Donor 
Cancer 
14 Immunoglobuli
n J chain 
 3.17 2.16 -1.5 
29 F-actin-capping 
protein subunit 
alpha-1 
CAPZA1 3.53 4.52 -1.4 
30 Actin-related 
protein 2/3 
complex subunit 
2 
ARPC2 18.2 14.63 -1.2 
10 Transketolase TKT 9.72 14.34 +1.5 
32 Coronin 1A CORO1
A 
5.80 6.98 +1.2 
22 Glycogen 
phosphorylase 
PYGL 8.13 10.7 +1.3 
24 Neutrophil 
Elastase 
Inhibitor 
SERPIN
B1 
14.6 19.05 +1.3 
26 6-
phosphoglucona
te 
dehydrogenase 
PGD 1.33 1.71 +1.3 
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Figure 3.9 Protein Spots common between disease state and tumour grade analysis 
identified by 2D-PAGE: WBC sample lysates were run in triplicates to perform 2D-gel 
electrophoresis. Scanned protein gels were analysed using Samespots software. Two types of 
analysis was done; Disease state (Healthy donor vs Breast cancer) and Tumour grade (Healthy 
donor vs Low grade breast cancer vs High grade breast cancer). Proteins spots represented above 
were common between both analyses and also showed consistent trends in different samples 
between different grades in breast cancer patient and healthy donor cohorts.  
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Table 3.9 Gene ontology of the significant proteins identified through 2D-PAGE: White 
blood cell lysates were subjected to 2D-PAGE. Samples were run in triplicates and the scanned 
gels were analysed by Samespots software. Protein spots were identified using the Orbitrap mass 
spectrometer. Proteins identified to be differentially present in the WBCs of breast cancer patient 
and healthy donors were subjected to gene ontology analysis. Gene Ontology was performed 
using GOFFA and based on Biological process. 
 
Gene ontology Term 
Gene 
ontology ID 
Proteins involved 
Immune system 
Process 
GO:0002376 ANXA1,CAPZA1,CORO1A,ITGAM 
Cell death GO:0016265 ACTN1,ANXA1,CASP14 
Cell proliferation GO:0008383 ANXA1,CORO1A 
Actin cytoskeleton GO:0015629 ACTN1,ANXA1,ARPC2,CAPZA1,CORO1A,JUP,VCL 
Cell Adhesion GO:0007155 ACTN1,CORO1A,ITGAM,JUP,VCL 
Cell migration GO:0016477 CORO1A,ITGAM,JUP,VCL 
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Figure 3.10 Identification Hub gene nodes changed in the WBCs of breast cancer patient 
cohort using 2D-PAGE: Differentially expressed proteins in the WBCs of breast cancer patients 
obtained by 2D-PAGE method were used to construct gene regulatory networks. Networks were 
constructed using the Osprey tool (http://biodata.mshri.on.ca/osprey/servlet/Index). The lines 
between gene nodes represent interactions and the genes with most interactions (hub genes) are 
independently with their own network. 
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3.4 Discussion 
  This study utilised proteomics approaches to identify differences in protein profiles of 
WBCs between breast cancer patients and healthy donors. Two types of technologies were used 
to identify differences in WBCs protein profiles: high throughput analysis using the Orbitrap 
mass spectrometer and the 2D-PAGE. These proteomic approaches are becoming very popular in 
finding novel cancer biomarkers in tissue and blood and give advantage over gene expression 
studies since protein biomarkers are preferred in clinical settings. They are also easier to detect 
due to well-developed antibody assays such as western blotting, enzyme-linked immunosorbent 
assay, antibody arrays etc. It should be noted that both methods have limitations, for example, 
the 2D-PAGE has reduced sensitivity and resolution, low throughput, requirement of the large 
amounts of starting material, more inter-gel variations and increased chances of experimental 
errors (Verrills, 2006). Compared with 2D-PAGE the high throughput proteomics has a better 
sensitivity and can be automated, however, the data mining, analysis and validation represents a 
challenge. The high throughput studies which were performed using the Orbitrap Velos 
instrument were very sensitive and even identified very specific changes. Around 2500 proteins 
were detected only in the membrane fraction of WBCs. For example ITGA4 (also known as 
CD49d) is present predominantly in the mononuclear cell fraction of the WBCs was found to be 
underexpressed in the breast cancer patient cohort. In our experiments, this analysis also showed 
variation in individual protein levels within the same cohort. This may be due to the 
heterogeneous composition of the WBCs and also the dynamic nature of the immune system.  
This can be solved by increasing the sample numbers which would provide more statistically 
significant proteins in cancer patients. Furthermore, the number of significant proteins identified 
through high throughput proteomics was much higher than 2D-PAGE analysis. However, these 
data will still need to be validated using other techniques such as western blotting, 
immunohistochemistry and others. 
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  One of the reasons the two techniques were used independently in our studies was to 
identify common proteins. Three candidates, SERPINB1, JUP and ANXA1, appeared in both 
analyses with SERPINB1 and ANXA1 overexpressed in the breast cancer cohort. All the three 
proteins are involved in cell adhesion and cell migration in immune cells. SERPINB1, also 
known as neutrophil elastase inhibitor, is a serine protease inhibitor which inhibits the neutrophil-
derived proteinases neutrophil elastase, cathepsin G, and proteinase-3 whereby protecting tissues 
from damage at inflammatory sites. In this study SERPINB1 levels were found to be increased in 
the WBCs of breast cancer patients using both approaches (2D-PAGE and high throughput 
proteomics).The link between SERPINB1 and cancer has been reported previously. For example, 
decreased expression of SERPINB1 in hepatocellular carcinoma positively correlates with poor 
prognosis (Cui et al., 2014). SERPINB1 was also found to positively correlated with cell 
invasiveness in oral cancer cell lines (Tseng et al., 2009). 
ANXA1 (Annexin A1) is a protein with the phospholipase A2 inhibitory activity. 
Phospholipase A2 is required for the biosynthesis of important mediators of inflammation such 
as prostaglandins and leukotrienes, hence, ANXA1 may have potential anti-inflammatory activity 
(Perretti and D’Acquisto, 2009). ANXA1 was also found to aberrantly overexpressed in highly 
invasive basal like and HER2 positive breast tumours (Yousef et al., 2013). Other proteins 
related to leukotriene synthesis which changed in the breast cancer patient cohort were ALOX5 
(Arachidonate 5-lipoxygenase) and LTA4H (Leukotriene A4 hydrolase); were overexpressed in 
the breast cancer patient cohort especially in the high grade category. CORO1A (Coronin-1A) is 
essential for T-cell mediated immunity and was present in higher levels in the breast cancer 
patient cohort in the 2D-PAGE analysis. It was found that CORO1A plasma levels increase in 
mice with tumour which corresponds to experiments done in white blood cells using 2D-PAGE 
(Pitteri et al., 2008). 
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  The high throughput proteomics has provided a list of statistically significant 136 
proteins differentially present between the WBCs of breast cancer patients and healthy donors. It 
is very important to note that these data only include the membrane proteins; the data from the 
soluble fraction were not analysed.  One of the reasons for this was the presence of abundant 
proteins which masked the signals from other proteins of low abundance in this fraction. The 
Gene ontology analysis of the identified proteins revealed that 34 of those were involved 
immune response and 41 in cellular localisation; generally, this analysis showed that 
inflammatory response was enhanced in the WBCs of breast cancer patients. This finding 
supports the theory that  inflammation contributes to generation of tumour-related mutations and 
promotes tumour progression (Grivennikov et al., 2010; Jackson et al., 1997; Nowarski et al., 
2013). The Gene ontology analysis on the high throughput data also demonstrated that around 11 
proteins were involved in the cell adhesion and migration. The ability of the immune cells to 
probe tissues for infection monitoring is very important. This is achieved by the immune cells by 
movement into tissues called transendothelial migration (Luster et al., 2005). If this movement of 
cells is affected the immune function can be compromised. 
                The Pathway analysis using KEGG database revealed leukocyte transendothelial 
migration was positively regulated in the breast cancer cohort.  The Leukocyte Transendothelial 
migration is the process by which WBCs invade tissue through the endothelial layer to routinely 
search for any inflammatory signals or infections (Van Buul and Hordijk, 2004). This analysis 
also revealed that the PI3K pathway which is associated with the transendothelial migration 
pathway was activated through the overexpression of chemokine receptors. Breast cancer cells 
overexpress SDF-1α which chemotactically attracts lymphocytes and macrophages to sites of 
tumour enhancing the tumour metastasis (Müller et al., 2001). Leukocytes and macrophages 
have been implicated in enhancing tumour angiogenesis/metastasis through their recruitment 
through tumour secreted chemokines such as IL6, granulocyte macrophage colony stimulating 
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factor, SDF-1α etc (Gabrilovich et al., 2012). The 2D-PAGE analysis also complemented the 
high throughput study where 9 out of 18 proteins identified were involved in actin cytoskeletal 
rearrangement (ACTN1, ITGAM, CORO1A, ARPC2, JUP, ANXA1 CAPZA1 and VCL) and 4 
proteins (ACTN1, ITGAM, SERPINB1and VCL) were involved in leukocyte transendothelial 
migration. The effect of the tumour tissue on the movement of leukocytes into the endothelium is 
implicated in cancer. Leukocyte adherence inhibition (89%) was observed when leukocytes from 
cancer patients were treated with tumour extracts (Halliday et al., 1980). Also tumour cells 
mimic immune cells by expressing surface molecules found on WBCs when they invade the 
extracellular matrix to metastasise (Jöhrer et al., 2004; Onrust et al., 1996).  
 This proteomics analysis will yield better results if it can be repeated using the datasets as 
the training dataset with the increased sample size. Gene expression data will give the changes in 
all the gene mRNA levels which will include secreted, membrane bound and soluble proteins and 
the proteomics data has to be linked up with the gene expression data to map out the immune 
response to tumour. This will also help in short listing the markers for validation at both RNA 
levels and protein levels.  
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Chapter 4:   Comparative analysis of gene expression profiles of white blood 
cells in breast cancer patients and healthy donor 
 
4.1 Introduction 
The use of gene expression microarray and RNA-Seq technologies in the effort to identify 
biomarkers has been employed for various types of cancers (See Section 1.8.2 and references 
therein).  In these studies, tissue samples were often used to identify genes differentially 
expressed in cancers and, ultimately, discover novel tissue cancer biomarkers. However, tissue 
biomarkers have limitations which include the costs and invasiveness of the biopsy procedures; 
in addition tumour tissue is only guaranteed at diagnosis, when the tumour is biopsied or 
resected. 
Blood can used as an alternative source for biomarkers, as blood collection is less 
invasive and cheap. However, current serum markers for breast cancer such as CA27.29 and 
CA15-3 lack sensitivity for early diagnosis of breast cancer. Despite of that the search for novel 
blood plasma cancer biomarkers continues, for example for breast cancer (Pitteri et al., 2008, 
2011) and Non-small cell lung cancer (Izbicka et al., 2012). As an alternative to serum or 
plasma, white blood cells (WBC) can be used to identify new biomarkers for cancer. A number 
of studies have been undertaken to screen for biomarkers for the purpose of both diagnosis and 
prognosis for cancer using genomic approaches in the WBCs for breast cancer (Aarøe et al., 
2010; Komatsu et al., 2012; LaBreche et al., 2011; Sharma et al., 2005; Zuckerman et al., 2013), 
pancreatic cancer (Baine et al., 2011), Non-small cell lung cancer (Showe et al., 2009) and acute 
myeloid leukemia (Metzeler et al., 2008). There also have been efforts to prove DNA 
methylation patterns in WBCs may be useful in detecting cancer (Brennan et al., 2012). 
 In the study reported by Aarøe et al., 2010 blood samples from 67 female patients with 
invasive breast cancer, 54 healthy donors and 9 other control samples (pregnant women and 
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benign breast cancer) were collected. The whole WBC fraction was isolated and RNA was 
extracted. Gene expression analysis was done using the single channel Applied Biosystems 
Human Genome Survey microarray V.2 chips. The group used partial least squares regression 
modelling and suggested 208 core regulated probes which discriminate breast cancer patients 
from healthy controls. The functional analysis done by the group was limited and showed very 
few functionally enriched categories. Furthermore the aim of their analysis was  only to identify 
gene expression patterns in the WBCs of breast cancer patients without validation of the data. 
These gene expression data will be analysed in this chapter to identify a list of potential 
biomarkers and to perform a independent functional analysis on the data.  
4.2 Aims  
The main aim of this Chapter is to analyse the gene expression patterns of WBCs from 
breast cancer patients from the previously published study (Aarøe et al. 2010 ). The gene 
expression data were deposited in the Gene expression omnibus (GEO) database (the GEO 
identity number is GSE16443). These data will be used to analyse for difference in global gene 
expression between helathy donors and breast cancer patients. This list of genes differentially 
expressed in the breast cancer patient cohort will be used for further functional analysis to 
identify possible biological pathways involved in the response of WBCs to the breast cancer. The 
latter included gene ontology, pathway and protein-protein interaction analyses. The Gene 
ontology  and pathway analyses will be primarily focussed on immune response processes. The 
differentially expressed genes will also be considered as potential biomarker candidates for 
further validation. The results from this analysis will also be combined with the results obtained 
in Chapter 3 for biomarker identification and maping out the changes in immune response in 
breast cancer patients. 
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4.3 Results 
4.3.1 Comparison of gene expression profiles between peripheral Blood cells of breast 
cancer patients and healthy donors.  
The gene expression data were obtained from the GEO using the GEO id GSE16443 in 
the form of log2 normalised gene expression value for each sample and gene in matrix. The 
numbers of breast cancer patient samples were 67 and healthy donors were 54. Students’ paired 
T-test was done using Multiexperiment viewer (see Section 2.4.3.1) between the two groups to 
obtain significant probes with fold change greater than ±1.2 and p-value less than 0.05. Genes 
which had more than one probe were filtered and the most significant fold change taken for 
further analysis. The test yielded 506 genes being significant with 214 genes under expressed 
and 292 genes overexpressed in the breast cancer patient cohort. Figure 4.1 is the volcano plot 
showing significant probes in blue which are being overexpressed in breast cancer patients with 
the fold change greater than ±1.2 and pvalue>0.05. Table4.1 gives the list of all the genes along 
with their fold change that were changed in the WBCs of breast cancer patients and are arranged 
in alphabetical order of their gene symbols. Hierarchical clustering for the 506 significant probes 
(Figure 4.2) was done using Multiexperiment viewer as discussed in Section2.4.3.1. It was 
observed that intensity values had a high degree of variance. This can be explained due to the 
fact that the molecular pathology of breast cancer is different to each tumour and also the 
immune system is very dynamic. 
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 Figure 4.1 Volcano plot of the probes in GSE16443 dataset: Student’s T test was performed 
to obtain probes which are significantly different between breast cancer patients and healthy 
donors. Individual probes are represented as dots. Blue dots represent probes which have p value 
<0.05 and fold change of ±1.2 which is relative to the breast cancer patient cohort. 
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Figure 4.2 Hierarchical Clustering of significant genes differentially expressed in the WBCs 
of Breast Cancer Patients: Hierarchical Clustering was done using the 506 genes which had 
significant differences between Healthy donors and Breast cancer Patients as identified by T test. 
Mutiexperiment viewer was used to perform clustering. Red indicates that the gene is relatively 
overexpressed and green the vice versa in the breast cancer cohort. 
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Table 4.1 List of genes changed significantly in the WBCs of breast cancer patients: 
Students T-test was done on the GSE16443 dataset comparing between the expression profiles of 
WBCs of breast cancer patients and healthy donors. The p value cutoff for the test was 0.05 and 
fold change ±1.2. The test gave 506 genes being significantly different in breast cancer cohort. 
Gene symbol Gene name FC 
AANAT arylalkylamine N-acetyltransferase 1.34 
ABP1 amiloride binding protein 1 (amine oxidase (copper-containing)) 1.21 
ACAD8 "acyl-Coenzyme A dehydrogenase family, member 8" -1.20 
ACATE2 
"likely ortholog of mouse acyl-Coenzyme A thioesterase 2, 
mitochondrial" -1.21 
ACBD6 acyl-Coenzyme A binding domain containing 6 -1.31 
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 1.25 
ACPT "acid phosphatase, testicular" 1.26 
ADCK2 aarF domain containing kinase 2 -1.21 
ADRA2B "adrenergic, alpha-2B-, receptor" 1.33 
ADRA2C "adrenergic, alpha-2C-, receptor" 1.34 
ADRB1 "adrenergic, beta-1-, receptor" 1.38 
ADSS adenylosuccinate synthase -1.28 
AF1Q ALL1-fused gene from chromosome 1q -1.20 
AFG3L1 AFG3 ATPase family gene 3-like 1 (yeast) -1.25 
AGPAT5 
"1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid 
acyltransferase, epsilon)" -1.23 
AGR2 anterior gradient 2 homolog (Xenopuslaevis) 1.40 
AGRP agouti related protein homolog (mouse) 1.32 
AIM1L absent in melanoma 1-like 1.25 
AIP1 atrophin-1 interacting protein 1 1.29 
AK2 adenylate kinase 2 -1.23 
ALDH18A1 "aldehyde dehydrogenase 18 family, member A1" -1.23 
ALPL "alkaline phosphatase, liver/bone/kidney" 1.54 
ALS2CR3 
"amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 
3" -1.20 
AMELX "amelogenin (amelogenesisimperfecta 1, X-linked)" 1.31 
AMELY "amelogenin, Y-linked" 1.25 
AMY2B "amylase, alpha 2B; pancreatic" -1.24 
ANKRD10 ankyrin repeat domain 10 -1.26 
ANXA3 annexin A3 1.97 
AP1M2 "adaptor-related protein complex 1, mu 2 subunit" 1.32 
AP3M2 "adaptor-related protein complex 3, mu 2 subunit" 1.26 
APOC2 apolipoprotein C-II 1.35 
APOC4 apolipoprotein C-IV 1.22 
APOE apolipoprotein E 1.36 
APOL3 "apolipoprotein L, 3" -1.22 
ARFGEF2 
ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin 
A-inhibited) 1.27 
ARHGAP17 Rho GTPase activating protein 17 -1.21 
ARHGDIG "protein disulfide isomerase, pancreatic,Rho GDP dissociation inhibitor 1.29 
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(GDI) gamma" 
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 -1.20 
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 -1.21 
ARL11 ADP-ribosylation factor-like 11 1.29 
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 -1.21 
ASIP "agouti signaling protein, nonagouti homolog (mouse)" 1.29 
B3GAT3 "beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)" 1.31 
BASP1 "brain abundant, membrane attached signal protein 1" 1.23 
BAZ2A "bromodomain adjacent to zinc finger domain, 2A" -1.21 
BCL7A B-cell CLL/lymphoma 7A 1.25 
BCNP1 B-cell novel protein 1 1.30 
BM88 BM88 antigen 1.28 
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 1.29 
BOMB BH3-only member B protein 1.28 
BRSK2 BR serine/threonine kinase 2 1.29 
BTBD2 BTB (POZ) domain containing 2 1.27 
BTC betacellulin 1.20 
C10orf33 chromosome 10 open reading frame 33 -1.28 
C10orf47 chromosome 10 open reading frame 47 -1.22 
C11orf16 chromosome 11 open reading frame 16 1.33 
C19orf25 chromosome 19 open reading frame 25 1.39 
C1orf19 chromosome 1 open reading frame 19 -1.27 
C2 complement component 2 1.30 
C20orf175 chromosome 20 open reading frame 175 1.22 
C21orf106 chromosome 21 open reading frame 106 1.32 
C21orf88 chromosome 21 open reading frame 88 1.30 
C22orf3 chromosome 22 open reading frame 3 -1.22 
C2orf22 chromosome 2 open reading frame 22 -1.29 
C5orf13 chromosome 5 open reading frame 13 -1.21 
C5orf15 chromosome 5 open reading frame 15 -1.31 
C5orf18 chromosome 5 open reading frame 18 -1.22 
C6orf110 chromosome 6 open reading frame 110 1.40 
C6orf209 chromosome 6 open reading frame 209 -1.21 
C8orf21 chromosome 8 open reading frame 21 1.25 
CAMP cathelicidin antimicrobial peptide 1.99 
CARD15 "caspase recruitment domain family, member 15" -1.36 
CASP5 "caspase 5, apoptosis-related cysteine protease" 1.24 
CCL1 chemokine (C-C motif) ligand 1 1.20 
CCNG1 cyclin G1 -1.24 
CD3Z "CD3Z antigen, zeta polypeptide (TiT3 complex)" -1.21 
CD68 CD68 antigen -1.21 
CD74 
"CD74 antigen (invariant polypeptide of major histocompatibility 
complex, class II antigen-associated)" -1.22 
CD9 CD9 antigen (p24) -1.32 
CDC2L1 
"cell division cycle 2-like 1 (PITSLRE proteins),cell division cycle 2-like 
2 (PITSLRE proteins)" 1.39 
CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) 1.33 
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CDH15 "cadherin 15, M-cadherin (myotubule)" 1.23 
CDK5R1 "cyclin-dependent kinase 5, regulatory subunit 1 (p35)" 1.31 
CDK5RAP1 CDK5 regulatory subunit associated protein 1 -1.28 
CDKL5 cyclin-dependent kinase-like 5 1.31 
CEI CEI protein 1.35 
CEP1 centrosomal protein 1 -1.22 
Cep192 centrosomal protein 192 kDa -1.21 
CG018 hypothetical gene CG018 -1.21 
CGB8 
"chorionic gonadotropin, beta polypeptide 8,chorionic gonadotropin, beta 
polypeptide 5" 1.42 
CHGA chromogranin A (parathyroid secretory protein 1) 1.31 
CHMP1.5 CHMP1.5 protein -1.21 
CKLF chemokine-like factor 1.28 
CLDN11 claudin 11 (oligodendrocyte transmembrane protein) 1.22 
CLEC12A "C-type lectin domain family 12, member A" 1.60 
CLEC4G "C-type lectin superfamily 4, member G" 1.26 
CNFN cornifelin 1.21 
COG5 component of oligomericgolgi complex 5 -1.26 
CPA3 carboxypeptidase A3 (mast cell) -1.34 
CPNE3 copine III -1.20 
CREB5 cAMP responsive element binding protein 5 1.32 
CRHR1 corticotropin releasing hormone receptor 1 1.35 
CS citrate synthase -1.25 
CSTA cystatin A (stefin A) 1.32 
CTAG1A "cancer/testis antigen 1A,cancer/testis antigen 1B,cancer/testis antigen 2" 1.32 
CTSC cathepsin C -1.23 
CTSO cathepsin O -1.30 
CXXC5 CXXC finger 5 -1.22 
D4ST1 dermatan 4 sulfotransferase 1 -1.21 
DATF1 death associated transcription factor 1 -1.23 
DCN decorin 1.24 
DEFA3 
"defensin, alpha 1, myeloid-related sequence,defensin, alpha 3, 
neutrophil-specific" 1.86 
DERA 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) -1.21 
DKFZp434I099 hypothetical protein DKFZp434I099 1.22 
DMRTB1 "DMRT-like family B with proline-rich C-terminal, 1" 1.23 
DOC2A "double C2-like domains, alpha" 1.24 
DOCK10 dedicator of cytokinesis 10 -1.37 
DPAGT1 
dolichyl-phosphate (UDP-N-acetylglucosamine) N-
acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase) -1.22 
DRD2 dopamine receptor D2 1.26 
DYRK1B dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 1.25 
EDG6 "endothelial differentiation, G-protein-coupled receptor 6" 1.28 
EDG8 "endothelial differentiation, sphingolipid G-protein-coupled receptor, 8" 1.27 
EIF3S6 "eukaryotic translation initiation factor 3, subunit 6 48kDa" 1.28 
EIF4ENIF1 eukaryotic translation initiation factor 4E nuclear import factor 1 -1.21 
EIF4G2 "eukaryotic translation initiation factor 4 gamma, 2" -1.21 
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EIF5B eukaryotic translation initiation factor 5B -1.22 
ELAVL1 
"ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R)" -1.26 
ELF1 E74-like factor 1 (ets domain transcription factor) -1.36 
ELMO2 "engulfment and cell motility 2 (ced-12 homolog, C. elegans)" -1.21 
EME2 essential meiotic endonuclease 1 homolog 2 (S. pombe) 1.38 
ENTH enthoprotin -1.28 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 -1.21 
EVER2 epidermodysplasiaverruciformis 2 1.37 
F5 "coagulation factor V (proaccelerin, labile factor)" 1.23 
FAD158 factor for adipocyte differentiation 158 -1.22 
FAM33A "family with sequence similarity 33, member A" 1.30 
FBS1 fibrosin 1 1.21 
FBXL12 F-box and leucine-rich repeat protein 12 -1.22 
FBXL14 F-box and leucine-rich repeat protein 14 1.20 
FBXL18 F-box and leucine-rich repeat protein 18 1.36 
FBXO11 F-box protein 11 -1.26 
FER1L3 "fer-1-like 3, myoferlin (C. elegans)" -1.26 
FKBP14 "FK506 binding protein 14, 22 kDa" 1.26 
FKBP5 FK506 binding protein 5 -1.23 
FKSG2 apoptosis inhibitor 1.39 
FLI1 Friend leukemia virus integration 1 -1.24 
FLJ10925 hypothetical protein FLJ10925 1.41 
FLJ11127 hypothetical protein FLJ11127 -1.20 
FLJ12270 FLJ12270 protein 1.37 
FLJ13841 hypothetical protein FLJ13841 1.23 
FLJ14753 hypothetical protein FLJ14753 -1.26 
FLJ20160 FLJ20160 protein 1.30 
FLJ30277 hypothetical protein FLJ30277 1.35 
FLJ32115 hypothetical protein FLJ32115 -1.39 
FLJ32770 hypothetical protein FLJ32770 1.45 
FLJ36268 FLJ36268 protein 1.31 
FLJ37543 hypothetical protein FLJ37543 1.33 
FLJ41131 FLJ41131 protein 1.23 
FLJ43855 similar to sodium- and chloride-dependent creatine transporter 1.36 
FN5 FN5 protein 1.28 
FNTA "farnesyltransferase, CAAX box, alpha" -1.22 
FRAS1 Fraser syndrome 1 1.31 
FSCN1 
"fascin homolog 1, actin-bundling protein 
(Strongylocentrotuspurpuratus)" 1.22 
FUSIP1 FUS interacting protein (serine-arginine rich) 1 -1.20 
FUT5 "fucosyltransferase 5 (alpha (1,3) fucosyltransferase)" 1.25 
FXYD7 FXYD domain containing ion transport regulator 7 1.35 
GADD45G "growth arrest and DNA-damage-inducible, gamma" 1.25 
GATA2 GATA binding protein 2 -1.38 
GBGT1 "globoside alpha-1,3-N-acetylgalactosaminyltransferase 1" 1.49 
GBP4 guanylate binding protein 4 -1.34 
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GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) -1.30 
GFOD1 glucose-fructose oxidoreductase domain containing 1 -1.25 
GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase -1.20 
GOLGA1 "golgiautoantigen, golgin subfamily a, 1" -1.25 
GOT2 
"glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2)" -1.21 
GPR103 G protein-coupled receptor 103 1.26 
GPR135 G protein-coupled receptor 135 1.25 
GPR158 G protein-coupled receptor 158 1.32 
GPR172A G protein-coupled receptor 172A -1.22 
GPR25 G protein-coupled receptor 25 1.27 
GPR35 G protein-coupled receptor 35 1.46 
GPR44 G protein-coupled receptor 44 -1.31 
GPR45 G protein-coupled receptor 45 1.38 
GPR6 G protein-coupled receptor 6 1.25 
GPR8 G protein-coupled receptor 8 1.49 
GRP58 "glucose regulated protein, 58kDa" -1.20 
GTPBP3 GTP binding protein 3 (mitochondrial) -1.21 
GYPC glycophorin C (Gerbich blood group) 1.25 
GYPE glycophorin E 1.37 
HAMP hepcidin antimicrobial peptide 1.31 
HAVCR2 hepatitis A virus cellular receptor 2 -1.21 
HBZ "hemoglobin, zeta" 1.40 
HDC histidine decarboxylase -1.44 
HEBP1 heme binding protein 1 -1.21 
HGFAC HGF activator 1.33 
HIRIP3 HIRA interacting protein 3 -1.20 
HIST1H3I "histone 1, H3i" 1.31 
HIST3H3 "histone 3, H3" 1.29 
HLA-DMA "major histocompatibility complex, class II, DM alpha" -1.20 
HLA-F "major histocompatibility complex, class I, F" -1.29 
HMBS hydroxymethylbilane synthase 1.20 
HMGA1 high mobility group AT-hook 1 1.26 
HNRPH1 heterogeneous nuclear ribonucleoprotein H1 (H) -1.33 
HRH2 histamine receptor H2 1.27 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 1.20 
HSD-40 HSD-40 protein 1.24 
HSPA9B heat shock 70kDa protein 9B (mortalin-2) -1.27 
HSPB1 heat shock 27kDa protein 1 1.23 
HTR1D 5-hydroxytryptamine (serotonin) receptor 1D 1.25 
HUMPPA paraneoplastic antigen 1.58 
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha -1.23 
IDI1 isopentenyl-diphosphate delta isomerase -1.21 
IGFBP7 insulin-like growth factor binding protein 7 -1.23 
IGFL1 insulin growth factor-like family member 1 1.21 
IL20 interleukin 20 1.24 
IL27RA "interleukin 27 receptor, alpha" 1.47 
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IL28A "interleukin 28A (interferon, lambda 2)" 1.23 
IL2RB "interleukin 2 receptor, beta" -1.29 
ISYNA1 myo-inositol 1-phosphate synthase A1 1.28 
ITGA4 "integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)" -1.29 
ITPA inosinetriphosphatase (nucleoside triphosphate pyrophosphatase) -1.25 
JAK1 Janus kinase 1 (a protein tyrosine kinase) -1.25 
KAAG1 kidney associated antigen 1 1.34 
KCNF1 "potassium voltage-gated channel, subfamily F, member 1" 1.26 
KCNQ4 "potassium voltage-gated channel, KQT-like subfamily, member 4" 1.20 
KIAA0217 KIAA0217 -1.21 
KIAA0528 KIAA0528 gene product -1.22 
KIAA1185 KIAA1185 protein -1.20 
KIAA1441 KIAA1441 protein 1.29 
KIAA1446 brain-enriched guanylate kinase-associated protein 1.39 
KIAA1539 KIAA1539 1.41 
KIAA1875 hypothetical protein KIAA1875 1.42 
KIAA1904 KIAA1904 protein 1.35 
KIR2DL3 
"killer cell immunoglobulin-like receptor, two domains, long cytoplasmic 
tail, 3" 1.35 
KIRREL kin of IRRE like (Drosophila) 1.27 
KLHDC1 kelch domain containing 1 1.29 
KPNA2 "karyopherin alpha 2 (RAG cohort 1, importin alpha 1)" -1.24 
KRT16 keratin 16 (focal non-epidermolyticpalmoplantarkeratoderma) 1.35 
KRTAP12-3 keratin associated protein 12-3 1.38 
KRTCAP3 keratinocyte associated protein 3 1.24 
KRTHB3 "keratin, hair, basic, 3" 1.26 
LACTB "lactamase, beta" -1.20 
LAIR2 leukocyte-associated Ig-like receptor 2 -1.20 
LCMT2 leucine carboxyl methyltransferase 2 -1.27 
LCN2 lipocalin 2 (oncogene 24p3) 2.16 
LCN6 lipocalin 6 1.26 
LDLR low density lipoprotein receptor (familial hypercholesterolemia) -1.27 
LEPRE1 leucine proline-enriched proteoglycan (leprecan) 1 -1.20 
LGMN legumain -1.22 
LHB luteinizing hormone beta polypeptide 1.26 
LIF leukemia inhibitory factor (cholinergic differentiation factor) 1.26 
LIG1 "ligase I, DNA, ATP-dependent" -1.24 
LILRA1 
"leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 1" 1.22 
LIN7A lin-7 homolog A (C. elegans) 1.37 
LIPA "lipase A, lysosomal acid, cholesterol esterase (Wolman disease)" -1.27 
LIPF "lipase, gastric" 1.40 
LIR9 leukocyte Ig-like receptor 9 1.24 
LOC113655 hypothetical protein BC011982 1.29 
LOC134548 hypothetical protein LOC134548 1.21 
LOC149837 hypothetical protein LOC149837 1.21 
LOC220070 hypothetical protein BC004224 1.26 
 
105 
 
LOC221091 similar to hypothetical protein 1.29 
LOC283932 hypothetical protein LOC283932 1.26 
LOC374969 hypothetical protein LOC374969 1.31 
LOC55831 30 kDa protein 1.22 
LONP peroxisomallon protease -1.23 
LPIN2 lipin 2 -1.23 
LRRC10 leucine rich repeat containing 10 1.30 
LTF lactotransferrin 2.38 
LUC7L2 LUC7-like 2 (S. cerevisiae) -1.25 
MAP17 membrane-associated protein 17 1.32 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha 1.35 
MAP3K8 mitogen-activated protein kinase kinasekinase 8 -1.26 
MAT1A "methionine adenosyltransferase I, alpha" 1.29 
MC1R melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) 1.26 
MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) 1.22 
MEN1 multiple endocrine neoplasia I -1.24 
METTL3 methyltransferase like 3 -1.26 
MGC11335 hypothetical protein MGC11335 1.21 
MGC13057 hypothetical protein MGC13057 1.30 
MGC15476 thymus expressed gene 3-like 1.34 
MGC15619 hypothetical protein MGC15619 -1.27 
MGC16635 hypothetical protein BC009980 1.25 
MGC2574 hypothetical protein MGC2574 1.21 
MGC29816 hypothetical protein MGC29816 -1.20 
MGC3036 hypothetical protein MGC3036 1.44 
MGC5178 hypothetical protein MGC5178 1.47 
MGC61598 similar to ankyrin-repeat protein Nrarp 1.31 
MGC70857 similar to RIKEN cDNA C030006K11 gene 1.21 
MGC9712 hypothetical protein MGC9712 1.24 
MHC2TA MHC class II transactivator -1.28 
MINPP1 "multiple inositol polyphosphate histidine phosphatase, 1" -1.25 
MMP15 matrix metalloproteinase 15 (membrane-inserted) 1.24 
MMP28 matrix metalloproteinase 28 1.29 
MPN pancreasin 1.31 
MRAP melanocortin 2 receptor accessory protein 1.28 
MRGPRD "MAS-related GPR, member D" 1.33 
MRVI1 murine retrovirus integration site 1 homolog 2.18 
MSX2 mshhomeo box homolog 2 (Drosophila) 1.23 
MT1G metallothionein 1G 1.22 
MTSS1 metastasis suppressor 1 -1.24 
MYC v-mycmyelocytomatosis viral oncogene homolog (avian) -1.22 
MYCN 
"v-mycmyelocytomatosis viral related oncogene, neuroblastoma derived 
(avian)" 1.26 
MYL4 "myosin, light polypeptide 4, alkali; atrial, embryonic" 1.39 
NARG1L NMDA receptor regulated 1-like -1.22 
NCOR2 nuclear receptor co-repressor 2 1.37 
NDUFV3 "NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa" -1.25 
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NELL2 NEL-like 2 (chicken) -1.30 
NEUROG1 neurogenin 1 1.33 
NFAM1 NFAT activating protein with ITAM motif 1 1.33 
NFKBIA 
"nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha" -1.20 
NGB neuroglobin 1.26 
NKTR natural killer-tumor recognition sequence -1.22 
NOXA1 NADPH oxidase activator 1 -1.22 
NPAS1 neuronal PAS domain protein 1 1.27 
NR1I2 "nuclear receptor subfamily 1, group I, member 2" 1.26 
NUP50 nucleoporin 50kDa -1.25 
OR10H1 "olfactory receptor, family 10, subfamily H, member 1" 1.27 
OR1D4 "olfactory receptor, family 1, subfamily D, member 4" 1.40 
OR4D1 "olfactory receptor, family 4, subfamily D, member 1" 1.21 
OR4M1 "olfactory receptor, family 4, subfamily M, member 1" 1.38 
OR51G1 "olfactory receptor, family 51, subfamily G, member 1" 1.30 
OR52E6 "olfactory receptor, family 52, subfamily E, member 6" 1.25 
OR52N4 "olfactory receptor, family 52, subfamily N, member 4" 1.60 
OR56B4 "olfactory receptor, family 56, subfamily B, member 4" 1.24 
OR6B3 "olfactory receptor, family 6, subfamily B, member 3" 1.48 
OR6N1 "olfactory receptor, family 6, subfamily N, member 1" 1.29 
ORF1-FL49 putative nuclear protein ORF1-FL49 1.32 
ORM1 "orosomucoid 1,orosomucoid 2" 2.22 
OTOS otospiralin 1.26 
OVOL1 ovo-like 1(Drosophila) 1.30 
P53AIP1 p53-regulated apoptosis-inducing protein 1 1.42 
PAOX polyamine oxidase (exo-N4-amino) -1.25 
PAPD4 PAP associated domain containing 4 -1.22 
PBP prostatic binding protein 1.29 
PCDHA5 protocadherin alpha 5 1.21 
PCNT1 pericentrin 1 -1.20 
PCYT2 "phosphate cytidylyltransferase 2, ethanolamine" 1.56 
PDE7A phosphodiesterase 7A -1.31 
PDZK1 PDZ domain containing 1 1.25 
PGLYRP1 peptidoglycan recognition protein 1 1.42 
PHKG1 "phosphorylase kinase, gamma 1 (muscle)" 1.24 
PIAS2 "protein inhibitor of activated STAT, 2" -1.22 
PIGV "phosphatidylinositol glycan, class V" -1.21 
PKD1 polycystic kidney disease 1 (autosomal dominant) -1.24 
PKMYT1 "protein kinase, membrane associated tyrosine/threonine 1" 1.21 
PLAGL1 pleiomorphic adenoma gene-like 1 -1.20 
PLCB3 "phospholipase C, beta 3 (phosphatidylinositol-specific)" 1.33 
PLEKHA9 
"pleckstrin homology domain containing, family A (phosphoinositide 
binding specific) member 9" 1.21 
PLEKHH1 
"pleckstrin homology domain containing, family H (with MyTH4 
domain) member 1" 1.30 
PLXNA1 plexin A1 1.33 
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PPFIA1 
"protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 1" -1.25 
PPP1R12C "protein phosphatase 1, regulatory (inhibitor) subunit 12C" -1.22 
PQLC2 PQ loop repeat containing 2 1.21 
PRKCG "protein kinase C, gamma" 1.37 
PRKCH "protein kinase C, eta" -1.21 
PRLH prolactin releasing hormone 1.33 
PRNP 
"prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-
Scheinker syndrome, fatal familial insomnia)" -1.27 
PRPS2 phosphoribosyl pyrophosphate synthetase 2 -1.20 
PSD4 pleckstrin and Sec7 domain containing 4 1.20 
PSMB10 "proteasome (prosome, macropain) subunit, beta type, 10" -1.20 
PSMC3 "proteasome (prosome, macropain) 26S subunit, ATPase, 3" -1.25 
PSME2 "proteasome (prosome, macropain) activator subunit 2 (PA28 beta)" -1.21 
PSPH phosphoserine phosphatase 1.24 
PSTPIP2 proline-serine-threonine phosphatase interacting protein 2 -1.22 
PTDSS1 phosphatidylserine synthase 1 -1.25 
PTK2B PTK2B protein tyrosine kinase 2 beta 1.44 
PTMS parathymosin 1.25 
PUSL1 pseudouridylate synthase-like 1 1.34 
RAB1B "RAB1B, member RAS oncogene family" 1.32 
RAB3-GAP150 "rab3 GTPase-activating protein, non-catalytic subunit (150kD)" -1.20 
RASSF4 Ras association (RalGDS/AF-6) domain family 4 -1.22 
RBBP4 retinoblastoma binding protein 4 -1.25 
RBM15 RNA binding motif protein 15 1.31 
RBM16 RNA binding motif protein 16 -1.20 
RBM19 RNA binding motif protein 19 1.26 
RINT-1 Rad50-interacting protein 1 -1.20 
RNASET2 ribonuclease T2 -1.21 
ROBO4 "roundabout homolog 4, magic roundabout (Drosophila)" 1.35 
ROD1 ROD1 regulator of differentiation 1 (S. pombe) 1.23 
RHOA Ras homolog gene family, member A -1.22 
RPA3 "replication protein A3, 14kDa" 1.20 
RPL21 ribosomal protein L21 1.26 
RPS6 ribosomal protein S6 1.22 
RRN3 RRN3 RNA polymerase I transcription factor homolog (yeast) -1.21 
RTP2 receptor transporting protein 2 1.26 
S100A12 S100 calcium binding protein A12 (calgranulin C) 1.61 
S100A8 S100 calcium binding protein A8 (calgranulin A) 1.47 
SACM1L SAC1 suppressor of actin mutations 1-like (yeast) -1.25 
SCGB1A1 "secretoglobin, family 1A, member 1 (uteroglobin)" 1.37 
SCO1 SCO cytochrome oxidase deficient homolog 1 (yeast) 1.22 
SDFR1 stromal cell derived factor receptor 1 -1.20 
SDS serine dehydratase 1.21 
SEH1L SEH1-like (S. cerevisiae) -1.21 
SERF1A 
"small EDRK-rich factor 1B (centromeric),small EDRK-rich factor 1A 
(telomeric)" -1.20 
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SFRS1 
"splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing 
factor)" -1.22 
SFRS2 "splicing factor, arginine/serine-rich 2" -1.25 
SHANK1 SH3 and multiple ankyrin repeat domains 1 1.31 
SIRT6 
sirtuin (silent mating type information regulation 2 homolog) 6 (S. 
cerevisiae) 1.36 
SLC1A6 
"solute carrier family 1 (high affinity aspartate/glutamate transporter), 
member 6" 1.21 
SLC22A18 "solute carrier family 22 (organic cation transporter), member 18" 1.21 
SLC2A3 "solute carrier family 2 (facilitated glucose transporter), member 3" 1.31 
SLC31A1 "solute carrier family 31 (copper transporters), member 1" -1.26 
SLC35A5 "solute carrier family 35, member A5" -1.21 
SLC35E2 "solute carrier family 35, member E2" -1.21 
SLC41A1 "solute carrier family 41, member 1" 1.26 
SLC7A6 
"solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 6" -1.27 
SMAD4 "SMAD, mothers against DPP homolog 4 (Drosophila)" -1.24 
SMARCA2 
"SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2" -1.22 
SMBP SM-11044 binding protein -1.24 
SMCR8 "Smith-Magenis syndrome chromosome region, candidate 8" 1.45 
SMN1 
"survival of motor neuron 1, telomeric,survival of motor neuron 2, 
centromeric" -1.22 
SMNDC1 survival motor neuron domain containing 1 -1.23 
SMS spermine synthase -1.20 
SOCS3 suppressor of cytokine signaling 3 1.29 
SP3 Sp3 transcription factor -1.26 
SP6 Sp6 transcription factor 1.35 
SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 1.51 
SRRM2 serine/arginine repetitive matrix 2 1.32 
ST8SIA4 "ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4" -1.23 
STAT1 "signal transducer and activator of transcription 1, 91kDa" -1.27 
STK39 "serine threonine kinase 39 (STE20/SPS1 homolog, yeast)" -1.20 
STX1A syntaxin 1A (brain) 1.27 
STXBP3 syntaxin binding protein 3 -1.22 
SUMF1 sulfatase modifying factor 1 -1.22 
SUSD2 sushi domain containing 2 1.42 
SYK spleen tyrosine kinase -1.21 
SYPL synaptophysin-like protein -1.20 
TACC1 "transforming, acidic coiled-coil containing protein 1" -1.25 
TAP1 "transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)" -1.23 
TCP1 t-complex 1 -1.22 
TEKT2 tektin 2 (testicular) 1.39 
TESK2 testis-specific kinase 2 -1.24 
TFCP2L1 transcription factor CP2-like 1 1.24 
TFG TRK-fused gene -1.23 
TGFB1I4 transforming growth factor beta 1 induced transcript 4 -1.25 
THEG Theg homolog (mouse) 1.33 
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TITF1 thyroid transcription factor 1 1.21 
TIZ TRAF6-inhibitory zinc finger protein 1.21 
TK1 "thymidine kinase 1, soluble" 1.32 
TLR9 toll-like receptor 9 1.44 
TM4SF11 transmembrane 4 superfamily member 11 (plasmolipin) 1.38 
TM4SF9 transmembrane 4 superfamily member 9 1.30 
TMEM38A transmembrane protein 38A 1.26 
TNFAIP2 "tumor necrosis factor, alpha-induced protein 2" -1.21 
TNNI2 "troponin I, skeletal, fast" 1.29 
TOR3A "torsin family 3, member A" -1.27 
TP53I5 tumor protein p53 inducible protein 5 1.24 
TPM3 tropomyosin 3 -1.22 
TPP2 tripeptidyl peptidase II -1.26 
TRAF4 TNF receptor-associated factor 4 -1.21 
TRIM22 tripartite motif-containing 22 -1.30 
TRIM4 tripartite motif-containing 4 -1.24 
TRIM50A tripartite motif-containing 50A 1.35 
TSN translin -1.21 
TTBK1 tau tubulin kinase 1 1.35 
TTYH3 tweety homolog 3 (Drosophila) -1.26 
TUB tubby homolog (mouse) 1.21 
TXK TXK tyrosine kinase -1.36 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 1.29 
UBXD1 UBX domain containing 1 1.28 
UCKL1 uridine-cytidine kinase 1-like 1 -1.22 
UCN urocortin 1.27 
UCP2 "uncoupling protein 2 (mitochondrial, proton carrier)" -1.21 
UGT2A1 "UDP glycosyltransferase 2 family, polypeptide A1" 1.41 
ULK2 unc-51-like kinase 2 (C. elegans) 1.31 
UNQ5783 DTFT5783 -1.21 
UPK2 uroplakin 2 1.28 
UPK3B uroplakin 3B 1.31 
UROC1 urocanase domain containing 1 1.22 
UROS uroporphyrinogen III synthase (congenital erythropoietic porphyria) -1.22 
USP49 ubiquitin specific protease 49 -1.21 
USP52 ubiquitin specific protease 52 -1.20 
USP54 ubiquitin specific protease 54 1.25 
UTX "ubiquitously transcribed tetratricopeptide repeat, X chromosome" -1.21 
UVRAG UV radiation resistance associated gene -1.22 
VDP vesicle docking protein p115 -1.26 
VPS13C vacuolar protein sorting 13C (yeast) -1.24 
VPS4B vacuolar protein sorting 4B (yeast) -1.25 
WDFY2 WD repeat and FYVE domain containing 2 -1.21 
WDR1 WD repeat domain 1 1.24 
WDR37 WD repeat domain 37 -1.26 
XLKD1 extracellular link domain containing 1 1.44 
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XPO4 exportin 4 1.28 
ZC3HDC7 zinc finger CCCH type domain containing 7 -1.23 
ZCCHC14 "zinc finger, CCHC domain containing 14" -1.22 
ZF HCF-binding transcription factor Zhangfei -1.22 
ZFP36L2 "zinc finger protein 36, C3H type-like 2" -1.37 
ZMAT2 "zinc finger, matrin type 2" 1.27 
ZNF3 zinc finger protein 3 (A8-51) 1.32 
ZNF488 zinc finger protein 488 1.32 
ZNF579 zinc finger protein 579 1.33 
ZNFN1A1 "zinc finger protein, subfamily 1A, 1 (Ikaros)" -1.41 
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4.3.2 Molecular and functional analysis of the significant genes obtained through the 
comparison of gene expression profiles of Healthy donors and breast cancer patients 
Understanding the biological meaning of the results obtained through microarray or 
RNA-Seq can be difficult. The conventional way to achieve this is to classify the genes based on 
their function and their cellular location. Gene ontology is used to annotate genes with respect to 
their function. The Gene ontology project is an initiative which evolved out of the need to 
consolidate the descriptions of each gene and its products across different species for consistence 
to enable functional interpretation of experimental data. The Gene Ontology analysis was 
performed using a tool called Gene Ontology for Functional Analysis (GOFFA) developed by 
the USA Food and Drug Administration (FDA) Department. This tool is further explained in 
Section2.4.3.2.Other methods  to analyse microarray data include the KEGG pathway  and 
protein-protein interaction cluster analyses using databases such as Biomolecular Interaction 
Network Database (BIND), Biological General Repository for Interaction Datasets (BioGRID)  
and others ( discussed in Section2.4.3). 
4.3.2.1 Gene ontology-Biological Processes 
Gene ontology analysis was performed with the 506 significant probes obtained through 
the comparison of gene expression profiles between WBCs of breast cancer patients and healthy 
donors, with a particular purpose to highlight the changes in immune functions of WBCs in 
breast cancer patients. GOFFA was used to perform ontology as described in Section2.4.3.1. The 
software organises gene ontology into three main categories: Molecular function, Biological 
processes and Cellular components. Figure 4.3A shows the results for the gene ontology 
classification based on the biological function. The number of genes changed are related to 
metabolic processes (40%) followed by biological regulation (36%) and response to stimulus 
(30%). 
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A 
 
B 
Figure 4.3 Gene Ontology of significantly different genes between the PBCs of Healthy 
donors and Breast cancer Patients from GSE16443 dataset: Genes identified to be 
differentially present in the WBCs of breast cancer patient and healthy donors Gene Ontology 
was performed using GOFFA and based on biological processes (n=506). A) Ontology was done 
based on Biological processes and genes were grouped under different categories. B) Sub 
classification of immune system related genes (n=54). 
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4.3.2.2 Analysis of genes associated with immune system processes 
The number of significant genes which were related to immune system processes (GO: 
0002376) are 54 genes (10%). The genes related to the immune system were further sub 
classified based on different immune system functions (Figure 4.3B). The hierarchical clustering 
was performed using the Multiexperiment viewer on the significant probes which correspond to 
the immune system processes which shown in Figure 4.4. The clustering showed four distinct 
groups of genes in which the patterns of expression were same within the different cohorts of 
samples. The first and second group has genes which are under expressed in the breast cancer 
patient cohort. The genes in the last two groups are overexpressed in the breast cancer patient 
cohort. The category having most number of genes within the immune system process is the 
regulation of immune system (40%) followed by the innate immune response (27%). Table 4.2 
gives the list of all the genes which are related to the immune system.  
The categories involved in the immune system processes are given in Table 4.3 along 
with the significant genes involved. It can be observed that most of the genes have functions 
corresponding to the innate immune system processes such as leukocyte activation, leukocyte 
migration, antigen presentation etc. This might be due to the fact that leukocytes constitute a 
major fraction (~75%) of the WBCs. The genes involved in innate immune response which were 
down-regulated were HLA-DMA, JAK1, STAT1, LCN2, TAP1, HLA-F, PGLYRP1 and up-
regulated genes were C2, UBA52, GCH1, S100A12, TLR9, SOCS3 and NFKBIA. The down-
regulated genes in the innate immune response are mostly involved in antigen recognition, 
processing and presentation. The upregulated genes are involved in inflammatory responses. All 
the genes involved in lymphocyte activation were also involved with leukocyte activation (Table 
4.3). Only three genes ANXA3, STXBP3 and ZNF3 were unique to leukocyte activation. All the 
genes involved in leukocyte activation were down regulated with the exception of ANXA3, 
NFAM1 and ZNF3.Annexin A3 (ANXA3) is a calcium dependent phospholipid binding protein 
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which inhibits phospholipase A2. Phospholipase A2 releases arachidonic acid causes 
inflammation through the prostaglandin and leukotriene pathway(Hofmann et al., 2000). 
SCGB1A1 (Secretoglobin Family 1A, Member 1) encodes a small disulfide linked dimeric 
protein also called as Uteroglobin has also been implicated to inhibit phospholipase A2 activity 
(Peri et al., 1993). Zinc finger protein 3 (ZNF3) is DNA binding transcription factor which 
involved in cell differentiation and proliferation. Syntaxin binding protein (STXBP3) binds to 
STX2 and STX4 which are involved in targeting and fusion of intracellular transport vesicles. 
NFAT Activating Protein with ITAM Motif 1 (NFAM1) encodes for a type 1 membrane receptor 
which regulates B cell development and signalling (Ohtsuka and Arase, 2004). Table 4.3 shows 
the list of genes which are involved in the inflammatory response and only APOL3 and LIPA 
were downregulated which suggests that the inflammatory response is induced in the breast 
cancer patients. Only Lipase A (LIPA) and Apolipoprotein L3 (APOL3) were down regulated. 
LIPA catalyses the hydrolysis of cholesteryl esters and triglycerides in the lysosome and APOL3 
affects the movements of lipids and facilitates their attachment to the organelles. Among the 506 
significant genes the genes involved in T-cell receptor signalling (ELF1, NKBIA, PRNP, HLA-
DMA and SYK) were down regulated in the breast cancer patient category. 
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Figure 4.4 Hierarchical clustering of significant genes related to the immune system 
obtained through the comparison of expression profiles between the WBCs of Healthy 
Donors and Breast Cancer Patients: Hierarchical Clustering was done using GOFFA. Red 
indicates that the gene is relatively overexpressed in breast cancer patient samples and green the 
vice versa. Four distinct clusters were observed among the samples. 
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Table 4.2 List of differentially expressed genes involved in the immune response obtained 
from the comparison between breast cancer patients and healthy donors: Significant genes 
were identified by analysing GSE16443 dataset and gene ontology was done to identify immune 
system related genes using GOFFA. Red colour indicates overexpressed genes and green colour 
indicates under expressed genes in the breast cancer patient cohort. 
Gene 
Symbol Gene Name 
Up/Down 
regulated 
Gene 
Symbol Gene Name 
Up/Down 
regulated 
ACE 
angiotensin I 
converting enzyme 
(peptidyl-dipeptidase 
A) 1   LILRA1 
leukocyte 
immunoglobulin-like 
receptor   
ADSS 
adenylosuccinate 
synthase   LTF lactotransferrin   
ANXA3 annexin A3   MAP3K8 
mitogen-activated 
protein kinase 8   
AP1M2 
adaptor-related 
protein complex 1, 
mu 2 subunit   MEN1 
multiple endocrine 
neoplasia I   
BNIP3L 
BCL2/adenovirus 
E1B 19kDa 
interacting protein 3-
like   NFAM1 
NFAT activating 
protein with ITAM 
motif 1   
C2 
complement 
component 2   NFKBIA 
nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 
inhibitor, alpha   
CCL1 
chemokine (C-C 
motif) ligand 1   ORM1 orosomucoid 1   
CD74 CD74 antigen    PGLYRP1 
peptidoglycan 
recognition protein 1   
CKLF chemokine-like factor   PRNP prion protein (p27-30)    
CRHR1 
corticotropin 
releasing hormone 
receptor 1   PSMB10 
proteasome subunit, 
beta type, 10   
CTSC cathepsin C   RBM15 
RNA binding motif 
protein 15   
ELF1 E74-like factor 1   RNASET2 ribonuclease T2   
GCH1 
GTP cyclohydrolase 
1 (dopa-responsive 
dystonia)   S100A12 
S100 calcium binding 
protein A12   
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GPR44 
G protein-coupled 
receptor 44   SCGB1A1 
secretoglobin, family 
1A, member 1   
HAMP 
hepcidin 
antimicrobial peptide   SLC7A6 
solute carrier family 7 
member 6   
HBZ hemoglobin, zeta   SOCS3 
suppressor of cytokine 
signaling 3   
HLA-
DMA 
major 
histocompatibility 
complex, class II, 
DM alpha   SP3 
Sp3 transcription 
factor   
HLA-F 
major 
histocompatibility 
complex, class I, F   STAT1 
signal transducer and 
activator of 
transcription 1   
HRH2 
histamine receptor 
H2   STXBP3 
syntaxin binding 
protein 3   
IL27RA 
interleukin 27 
receptor, alpha   SUSD2 
sushi domain 
containing 2   
ITGA4 integrin, alpha 4    SYK spleen tyrosine kinase   
JAK1 Janus kinase 1    TAP1 
transporter 1, ATP-
binding cassette, sub-
family B (MDR/TAP)   
KAAG1 
kidney associated 
antigen 1   TLR9 toll-like receptor 9   
KIR2DL3 
killer cell 
immunoglobulin-like 
receptor, two 
domains, long 
cytoplasmic tail, 3   TRIM22 
tripartite motif-
containing 22   
LCN2 lipocalin 2   TTBK1 tau tubulin kinase 1   
LIF 
leukemia inhibitory 
factor    UBA52 
ubiquitin A-52 residue 
ribosomal protein 
fusion product 1   
LIG1 
ligase I, DNA, ATP-
dependent   ZNF3 
zinc finger protein 3 
(A8-51)   
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Table 4.3 Ontology of the differentially expressed genes involved in immune system 
processes: The expression profiles of WBCs of breast cancer patients and healthy donors were 
compared and the differentially expressed genes were obtained. Gene ontology was performed 
using GOFFA. The genes involved in various immune system processes (GO: 0002376) were 
identified which are given below. 
Description Genes involved P 
value 
Innate Immune response C2,GCH1,HLA-DMA,HLA-F,JAK1,LCN2,NFKBIA, 
PGLYRP1,S100A12,SOCS3,STAT1,TAP1,TLR9,UBA52 
0.010 
Lymphocyte Activation CD74,HLA-DMA,ITGA4,MAP3K8,NFAM1, 
PRNP,SCGB1A1,SP3,SYK 
0.019 
Activation of Immune response C2,ELF1,HLA-DMA,NFAM1,NFKBIA, 
PRNP,SYK,TLR9,UBA52 
0.034 
Antigen processing and presentation CD74,HLA-DMA,HLA-F,TAP1 0.005 
Immune effector process ACE,ANXA3,AP1M2,BNIP3L,C2,CD74, 
HLA-DMA,STXBP3,SYK,TAP1 
0.022 
Immune system development CD74,HLA-DMA,ITGA4,MAP3K8, 
NFAM1,PRNP,SCGB1A1,SP3,SYK 
0.000
5 
Leukocyte activation ANXA3,CD74,HLA-DMA,ITGA4,MAP3K8,NFAM1, 
PRNP,SCGB1A1,SP3,STXBP3,SYK,ZNF3 
0.006 
Leukocyte Migration 
 
CD74,CKLF,ITGA4,SLC7A6,SYK 0.012
5 
Regulation of Immune system 
processes 
AP1M2,C2,CD74,ELF1,HLA-DMA,HLA-F,ITGA4, 
JAK1,KIR2DL3,LIF,LILRA1,MAP3K8,NFAM1,NFKBIA, 
ORM1,PRNP,RBM15,SCGB1A1,SOCS3,STAT1,SYK, 
TAP1,TLR9,UBA52 
0.001
2 
Adaptive immune response C2,CD74,HLA-DMA, TAP1 0.048 
Positive regulation of immune 
system 
C2,CD74,ELF1,HLA-DMA,MAP3K8, 
NFAM1,NFKBIA,PRNP,SYK,TAP1,TLR9,UBA52 
0.008 
Negative of immune system CD74,ELF1,PRNP,SCGB1A1,TAP1,TLR9 0.067 
Inflammatory response APOL3,ACE,LIPA,IL20,UCN,NFAM1,APOE, 
SCGB1A1,TLP9,S100A8,S100A12,ORM1 
0.045 
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4.3.2.3 Analysis of genes associated with apoptosis 
 Gene ontology was done on the 506 significant genes using GOFFA. Genes involved in 
cell death were identified. Figure 4.3 shows that only 8% (n=40) of the 506 genes that changed 
in the WBCs of breast cancer are involved in cell death. Hierarchical clustering was done on 
these genes which shown in Figure 4.5A.It was observed that 22 genes involved in the cell death 
were down regulated in breast cancer patients and 19 genes were up regulated. Thus a conclusion 
on the effect of tumour on the WBCs cell death could not be achieved. So the genes involved in 
induction of apoptosis were identified and the genes involved were GCH1, STAT1,TAP1, 
SMNDC1, ARHGEF9, ARHGEF3, PLAGL1, BNIP3L, UBA52 and APOE which has been shown 
in Table 4.3. It was observed except for BNIP3L, UBA52 and APOE all the other genes involved 
in the induction of apoptosis were down regulated which suggests that the WBCs were not 
driven towards apoptosis. The genes which were involved in cell growth are also given Table 
4.3. It was observed that all the genes involved in positive regulation of cell growth were 
overexpressed and genes involved in negative regulation of cell growth were under-expressed 
(except for ADRB1 and CAMP). This supports the observation that the WBCs are not driven 
towards cell death but towards cell proliferation. 
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4.3.2.4 Analysis of genes involved with cell migration 
 Cell adhesion and cell migration are very important for WBC function to detect antigens 
in different tissues and organs. WBC movement to the site of infection is very important for 
initiation and regulation of both the innate and adaptive immune response. WBC cell migration 
has been discussed in Chapter 1 (see Section 1.4).Gene ontology analysis was performed on the 
significant genes differentially expressed in the breast cancer patient cohort and genes involved 
in cell migration were obtained using GOFFA. Figure 4.5 B shows the hierarchical clustering of 
genes involved in cell migration and there were two groups of genes: Upregulated 
(ACE,ANXA3,APOE,CDK5R1,CDKL5,CKLF,DRD2,FSCN1,PTK2B,ROBO4) and 
downregulated genes (CD74, ITGA4, ELMO2,SLCA6, SYK) in breast cancer category. Table 
4.5shows the functions of the genes involved in cell migration and also the effect on cell 
migration. All the genes which have negative effect on cell migration were overexpressed. The 
genes involved in leukocyte migration specifically are ITGA4, CKLF, CD74, SLCA6 and SYK 
(Table 4.3). Except for CKLF all the genes are downregulated. This suggests that cell migration 
is negatively affected in the WBCs of breast cancer.  
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A 
 
B 
Figure 4.5 Hierarchical clustering of significant genes involved in cell death and cell 
migration: The genes which were significantly changed in the WBCs of breast cancer were 
identified through Student’s T-Test. Gene ontology was done and genes involved in Cell Death 
(A) and Cell migration (B) were identified. Hierarchical Clustering was done using GOFFA. Red 
indicates that the gene is relatively overexpressed and green the vice versa in the breast cancer 
cohort. 
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Table 4.4 Ontology of the genes involved in cell death and cell growth obtained by 
comparison expression profiles in the WBCs of breast cancer patients and healthy donors: 
The genes which changed significantly in WBCs of breast cancer patients were identified 
through T-Test and gene ontology was done using GOFFA. Genes involved in Cell death (GO: 
0008219) and growth (GO: 0016049) were identified. 
Biological 
Process 
Genes involved 
P value 
Cell Death GCH1,IL2RB,STAT1,PRNP,PSMC3,MEN1,CCNG1, 
SMAD4,TAP1,SMNDC1,LGMN,FNTA,CD74,ARHGEF9, 
EIF4G2,PSME2,TRAF4,ELMO2,ARHGEF3,PLAGL1,PSMB10, 
NFKBIA,BTC,RPS6,MSX2,HSPB1,CASP5,ACE,GADD45G, 
UCN,SOCS3,BNIP3L,UBA52,CDK5R1,CRHR1,APOE, 
PRKCG,FKSG2,PTK2B,LCN2 
0.006 
Positive 
regulation of 
apoptosis 
ACE,APOE,ARHGEF3,ARHGEF9,BNIP3L,CDK5R1,GCH1, 
MEN1,MSX2,PLAGL1,RPS6,SMNDC1,STAT1,TAP1,UBA52 
0.002 
Negative 
regulation of 
apoptosis 
APOE,BNIP3L,BTC,CCNG1,CD74,HSPB1,IL2RB,LGMN, 
MSX2,NFKBIA,PRNP,PTK2B,SOCS3,UBA52 
0.022 
Induction of 
apoptosis 
GCH1,STAT1,TAP1,SMNDC1,ARHGEF9,ARHGEF3, 
PLAGL1,BNIP3L,UBA52,APOE 
0.0056 
Cell growth ADRB1,APOE,CAMP,CDKL5,DRD2,IGFBP7,LGMN, 
MEN1,NELL2,PRLH,PTK2B,SMAD4,SMARCA2,SOCS3, 
TFCP2L1,UCN,ULK2 
0.044 
Negative 
regulation of 
cell growth 
ADRB1,CAMP,LGMN,MEN1,SMAD4,SMARCA2,ULK2 
0.032 
Positive 
regulation of 
cell growth 
CDKL5,DRD2,PTK2B,TFCP2L1,UCN 
0.047 
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Table 4.5 Ontology of significant genes in WBCs of breast cancer patients relating to Cell 
migration: Gene ontology was done using GOFFA on differentially regulated genes in the 
WBCs of breast cancer patients obtained by comparison with healthy donors. Genes involved in 
Cell migration process (GO: 0016477) were identified. 
Gene 
Symbol 
Gene name Function 
Fold 
Change 
Effect on 
migration 
ACE 
angiotensin I converting 
enzyme  
Involved in blood vessel constriction + Decreases 
ANXA3 annexin A3 Inhibits phospholipase A + Decreases 
APOE apolipoprotein E 
Transports vitamins and lipids into 
the lymph system 
+ Decreases 
DRD2 dopamine receptor D2 receptor for dopamine + Decreases 
ROBO4 
roundabout homolog 4, magic 
roundabout (Drosophila) 
Receptor for Slit proteins involved in 
angiogenesis.  
+ Decreases 
CD74 CD74 antigen  
Involved in antigen recognition and 
interacts with Macrophage inhibitory 
factor 
- Increases 
CKLF chemokine-like factor 
Acts as chemoattractant for 
neutrophils and lymphocytes 
+ Increases 
ELMO2 engulfment and cell motility 2  
Involved in actin cytoskeletal 
rerrangement 
- Increases 
FSCN1 
fascin homolog 1, actin-
bundling protein  
Increases Actin organisation in 
filipodia 
+ Increases 
ITGA4 integrin, alpha 4  
Involved in adhesion and 
transendothelial migration 
- Increases 
PTK2B 
PTK2B protein tyrosine 
kinase 2 beta 
Regulates reorganization of the actin 
cytoskeleton, cell migration and 
adhesion 
+ Increases 
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4.3.2.5 Pathway enrichment analysis of genes differentially expressed in the WBCs of 
breast cancer patients 
   Pathway analysis is another approach to interpret the biological meaning 
of a microarray dataset. This approach can be used to observe subtle and consistent changes in 
the pathways using functional annotations. Pathway analysis was performed on the 506 
significant genes using GenMAPP software as described in Section 2.4.3.3. The pathway 
database used was KEGG (Kyoto Encyclopedia of Genes and Genomes). The top ten pathways 
obtained by using GenMAPP are shown in Table 4.6 along with the altered genes. The pathways 
relevant to immune system processes in the table are antigen processing, Jak-STAT signaling 
pathways and leukocyte transendothelial migration which are shown in Figure 4.6, Figure 4.7 
and Figure 4.8 respectively.  
   It was observed that all the genes (HLA-DMA,LGMN,PSME2,HLA-
F,CD74,TAP1) which changed in the antigen processing and presentation pathway was 
downregulated except for ARHGDIG (Brp57) and Killer Cell Immunoglobulin-Like Receptor 
(KIR2DL3).KIR2DL3 is receptor found on natural killer cells which inhibits their activity. Thus 
the data suggests that antigen presentation is negatively affected in the WBCs of breast cancer 
patients. All the genes in the Jak-STAT signaling pathway were also downregulated except for 
Suppressor of cytokine signaling 3 (SOCS3), Interleukin 20 (IL20) and Leukemia inhibitory 
factor (LIF). SOCS3 binds to tyrosine kinase receptors such as LIF, IL12, GCSF etc instead of 
STAT4 to inhibit cytokine based signaling and it also inhibits JAK2 kinase (Sasaki et al., 1999; 
Yamamotoa et al., 2003). But interleukin 20 (IL20) and leukemia inhibitory factor (LIF) 
belonging to the IL6 family are Upregulated. The receptor for both IL20 and LIF which is 
Interleukin receptor Interleukin-2 receptor (IL2RB) subunit beta is downregulated. Thus it can be 
concluded that the Jak-STAT pathway is also downregulated in the WBCs of breast cancer 
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patients. Antigen presentation is regulated through the Jak-STAT pathway by activation of IL2 
and IFN-γ receptors (Schroder et al., 2004). The leukocyte transendothelial migration pathway 
had five genes changing: Integrin alpha 4 (ITGA4), Tyrosine protein kinase (TXK) were 
downregulated and Protein Kinase C Gamma (PRKCG), Protein Tyrosine Kinase 2 Beta 
(PTK2B), Claudin 11 (CLDN11) were upregulated. All the genes changed in the pathway favours 
cell migration. It can be observed in Figure 4.8 that the effect of cancer on the leukocyte 
transendothelial migration in WBCs is inconclusive. But the expression data can be combined 
with protein data to obtain a better understanding of this pathway. 
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Table 4.6 Top 10 Pathways obtained by comparison of gene expression profiles of healthy 
donors and breast cancer patients:   List of pathways and genes involved in immune response 
to tumour obtained by high throughput proteomics by comparison of WBCs from healthy donor 
and breast cancer patients. 
Kegg Pathway 
No of 
Genes 
Genes involved 
P value 
Metabolic 
pathways 
37 
MAT1A,FUT5,AK2,UROC1,GNE,B3GAT3,DPAGT1, 
ISYNA1,PLCB3,GBGT1,IDI1,AMY2B,GOT2,ALPL,CS, 
NDUFV3,PCYT2,ALDH18A1,ACAD8,PIGV,SMS, 
TK1,LIPF,UROS,UGT2A1,ITPA,UCKL1,IDH3A,ADSS, 
SDS,PRPS2,GCH1,AANAT,HMBS,PTDSS1,PSPH,HDC 
2.49e10 
Neuroactive 
ligand-receptor 
interaction 
10 
ADRA2C,CRHR1,DRD2,MC1R,LHB,ADRB1, 
ADRA2B,HRH2,HTR1D,GPR35 
0.0014 
Pathways in 
cancer 
10 
PRKCG,JAK1,TPM3,MYC,NFKBIA,STAT1, 
PIAS2,TFG,TRAF4,SMAD4 
0.005 
Jak-STAT 
signaling 
pathway 
9 
LIF,JAK1,MYC,STAT1,PIAS2,IL20,IL28A,I 
L2RB,SOCS3 
0.0002 
Lysosome 8 
CD68,AP1M2,CTSC,CTSO,AP3M2,SUMF1, 
LGMN,LIPA 
0.0002 
Antigen 
processing and 
presentation 
8 
HLA-DMA,LGMN,PSME2,HLA-F,KIR2DL3, 
 
CD74,TAP1,ARHGDIG 
0.0002 
Hepatitis C 7 JAK1,NFKBIA,LDLR,STAT1,SOCS3,PIAS2,CLDN11 0.0014 
Osteoclast 
differentiation 
6 JAK1,SYK,NFKBIA,LILRA1,STAT1,SOCS3 
0.007 
Leishmaniasis 5 HLA-DMA,JAK1,ITGA4,NFKBIA,STAT1 0.0044 
Leukocyte 
transendothelial 
migration 
5 PTK2B,PRKCG,ITGA4,TXK,CLDN11 
0.019 
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Figure 4.6 Effect of breast tumour on the Antigen presentation pathway in WBCs: Pathway 
analysis was done using the differentially expressed genes in the WBCs of breast cancer patients. 
The antigen processing and presentation pathway was significantly changed. GenMAPP was 
used to draw maps and the pathway database used was KEGG. 
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Figure 4.7 Effect of breast tumour on the JAK-STAT pathway in WBCs: Pathway analysis 
was done using the differentially expressed genes in the WBCs of breast cancer patients. The 
JAK-STAT pathway was significantly changed. GenMAPP was used to draw maps and the 
pathway database used was KEGG. 
 
 
 
 
 
129 
 
 
Figure 4.8 Effect of breast tumour on the Leukocyte transendothelial migration in WBCs: 
Pathway analysis was done using the differentially expressed genes in the WBCs of breast cancer 
patients. Leukocyte transendothelial migration pathway was significantly changed. GenMAPP 
was used to draw maps and the pathway database used was KEGG. Genes colored in red were 
upregulated and green were downregulated in the WBCs of breast cancer patients. 
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4.3.2.6 Construction of gene regulatory network models using the differentially expressed 
genes in the WBCs of breast cancer patients    
   Gene interaction network construction was done using Osprey software. 
Osprey is a tool for graphical visualisation of complex biological interaction networks using the 
gene ontology annotated dataset maintained by Biological General Repository for Interaction 
Datasets (BIOGRID). This has been explained further in Section2.4.3.4. The list of significant 
genes differentially expressed in the WBCs (Table 4.1) was used to generate the interaction 
network (Figure 4.9). Hub genes are those genes which are highly connected to other genes and 
when altered leads to drastic phenotypic changes in the cell which could be lethal. The hub genes 
which were identified in Figure 4.9 were MCM7, SMAD4, SYK, STX1A, PTK2B, JAK1, RBBP4, 
LUC7L2, STAT1, NFKIBA and NCOR2. All the genes except for MCM7, PTK2B and STX1A 
were downregulated in the breast cancer patient cohort. A gene regulatory network was also 
created using the genes involved in immune response (Figure 4.10) using the list in Table 4.2. 
The hub gene nodes in the immune system gene network were JAK1, STAT1, SOCS3, MAP3K8 
and NFKBIA. The ontology terms enriched among these hub genes were cell proliferation 
(MCM7, NFKBIA, PTK2B, RBBP4, SMAD4, STAT and SYK), regulation of immune system 
process (JAK1, MAP3K8, NFKBIA, SOCS3, STAT1andSYK) and regulation of localisation 
(NFKBIA, PTK2B, SMAD4, STX1A and SYK). The genes involved in major pathways are JAK1, 
STAT1 (Jak-STAT pathway), and NFKIBA (NFκB pathway). Jak-STAT pathway is involved in 
various immune responses such as antigen presentation, interferon-γ signalling and interleukin 
signalling (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) (Shuai and Liu, 2003). NFκB pathway also is 
very important in activating several immune system pathways such as chemokine signalling, 
inflammatory processes etc (Richmond, 2002). 
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 Figure 4.9 Identification Hub gene nodes changed in the WBCs of breast cancer patient 
cohort: Differentially expressed genes in the WBCs of breast cancer patients were used to 
construct gene regulatory networks. Network was constructed using Osprey 
(http://biodata.mshri.on.ca/osprey/servlet/Index). The lines between gene nodes represent 
interactions and the genes with most interactions (hub genes) are arranged on the outer layer of 
the network. 
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Figure 4.10 Identification Hub gene nodes related to immune response changed in the 
WBCs of breast cancer patient cohort: Differentially expressed genes involved in the immune 
response in the WBCs of breast cancer patients were used to construct gene regulatory networks. 
Network was constructed using Osprey (http://biodata.mshri.on.ca/osprey/servlet/Index). The 
lines between gene nodes represent interactions and the hub genes with their own network are 
arranged independent of each other. 
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4.4 Discussion 
 The microarray and more recent RNA-Seq technologies, used to generate gene 
expression profiles in different tissues and biological fluids have been very useful to understand 
the molecular mechanisms of diseases allowing identification of potential biomarkers for cancer 
and other conditions, although such studies are also very challenging.  The WBCs represent a 
valuable resource for such studies. Indeed, the potential WBC biomarkers have been obtained by 
using these technologies for several types of cancers including pancreatic (Baine et al., 2011), 
colorectal (Xu et al., 2013b), renal (Twine et al., 2003) and lung cancers (Rotunno et al., 2011). 
These studies have also shown that the expression profiles in the WBC in cancer patients is 
altered compared with healthy donors.  However, it has been generally accepted by the scientific 
community that  in order to further evaluate the data obtained in these experiments, additional 
analyses of the RNA ( e.g. by RT-qPCR) and proteins ( e.g. by immunostaining, western blot, 
ELISA)are required.  
The challenge of analysing the dataset of the breast cancer WBC (GSE16443) has been 
that WBCs are a mixture of different types of cells. Also each sample was taken from different 
individuals at varying stages of disease progression. This may be the cause for the variability of 
individual gene levels in the same cohort of healthy donors or breast cancer patients. Such 
variations were also reported in the peripheral blood mononuclear cells of patients with advanced 
renal cell carcinoma (Twine et al. 2003). It will be interesting to identify whether this high level 
of variability could be correlated with any clinical categories of diagnosis or response to 
treatment.  
 In this chapter the analysis was done on the gene expression data of the WBCs of breast 
cancer patients. The gene expression profiles of breast cancer patients were compared with 
healthy donors using Students T-Test to give 506 significantly expressed genes with a “p”- value 
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cutoff of <0.05 and fold change of ±1.2 (Table4.1). Compared to the analysis done by Aarøe et 
al., 2010 there were 49 genes which overlapped with the analysis done in this chapter. Four 
genes which had a fold change of more than +2 in breast cancer patients. They were Lipocalin2 
(LCN2), Lactotransferrin (LTF), Orosomucoid (ORM1) and murine retrovirus integration site 1 
homolog (MRVI1). LCN2, also known as neutrophil gelatinase-associated lipocalin, is involved 
in innate immunity and its function is to sequester iron that limits bacterial growth. LCN2 is used 
as a biomarker for kidney injury (Devarajan, 2010) and is also present at elevated levels in urine 
and tissue samples of breast cancer patients and increases tumour cell migration (Yang et al., 
2009). Lactotransferrin (LTF) is present in secreted fluids such as milk, tears, saliva and also 
present in neutrophil secondary granules. LTF also has iron binding properties LCN2 and binds 
to bacterial wall lipopolysaccharides. Both LTF and LCN2 have similar antimicrobial properties 
and also have anti-inflammatory properties (Adlerova et al., 2008; Shashidharamurthy et al., 
2013). 
Gene ontology analysis revealed that genes involved in inflammatory response were 
overexpressed in the WBCs of breast cancer patients. The altered genes which were common 
with lung cancer patient WBC study (Rotunno et al., 2011) were 
CD9,CPA3,DOCK10,HEBP1,NKTR,S100A12 and colorectal cancer WBC study (Xu et al., 
2013a) were DOCK10,FKBP5,EPB41L3,F5,CLEC12A. Functional analysis was done using gene 
ontology, pathway enrichment analysis and gene regulatory network construction. Gene ontology 
analysis was directed at the immune system processes, cell death and cell migration. The number 
of genes which were involved in immune system processes was 52. Further gene ontology 
analysis revealed that genes positively regulating WBC activation, antigen recognition, 
processing and presentation were under-expressed in the breast cancer cohort. Some of the 
altered genes involved in the antigen presentation are also responsible for lymphocyte activation 
were down-regulated. But the genes involved in the inflammatory response were up-regulated. 
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These ontology results correlated with pathway analysis where the antigen processing and 
presentation pathway was down-regulated as was the JAK-STAT signaling pathway which 
positively regulates the antigen presentation pathway. The immune response ontology analysis 
and pathway analysis suggests that antigen presentation in the innate immune cells, leukocyte 
activation and lymphocyte activation are affected in the WBCs of breast cancer patients. 
Although the genes involved in inflammation were up-regulated. Chronic inflammation caused 
by diseases such as Crohn’s disease, schistosomiasis, Hepatitis C infection and Heliobacter 
pylori infection can cause cancer in the bowel, liver and stomach respectively (Coussens and 
Werb, 2002). It has also been reported that immunosupression after organ transplant increases 
the probability of developing a tumour between 5-6% (Penn and Starzl, 1973). 
Notably, the WBCs in breast cancer patients had properties associated with cell 
proliferation. Thus, the genes involved in induction of apoptosis were down-regulated and genes 
in positive regulation of cell growth were up-regulated. It was previously reported  that Fas 
ligand attracts inflammatory cells into the tumour microenvironment to induce apoptosis 
(O’connell et al., 1996; Whiteside, 2002), however the data in this study only represent 
peripheral blood WBCs not the WBCs infiltrating the tumour. 
It has been shown in several studies that leukocyte migration is inhibited in various 
carcinomas (Brandes and Goldenberg, 1976; Kadish et al., 1976; Lee et al., 1977). Analysis of 
differentially expressed genes involved in cell migration revealed that all the genes negatively 
affecting cell migration were overexpressed in the breast cancer patient cohort. The gene 
network analysis also demonstrated that the hub genes which changed were involved in cell 
proliferation and regulation of cell localisation or migration. The hub genes which were involved 
in major cell processes were JAK1, STAT1 and NFKBIA. NFKBIA codes for Nuclear Factor of 
Kappa Light Polypeptide Gene Enhancer in B-Cellsa member of the NFκB inhibitor family. 
NFκB has been implicated to play a central role in inflammation and cancer, and is required for 
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B-cell maturation and survival (Karin, 2006). TNFα, IL61, VEGF and IL6  have been known to 
be secreted in tumour microenvironments which also activate NFκB(De Visser et al., 2006). The 
gene expression analysis provided potential biomarker candidates which would be compared in 
tandem with the proteomics data from the previous chapter to provide a shortlisted list of 
biomarker candidates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
Chapter 5: Characterisation and Validation of novel Biomarkers for Breast 
Cancer from White Blood Cells 
 
5.1 Introduction 
 The understanding of molecular signatures of different types of cells has greatly 
increased over the past decade due to rapid technological advances. The clinical need in finding 
cancer biomarkers led to huge investments into this area. Since 1986 there has been over 5000 
projects funded by the US National institute of Health for biomarker discovery. Between 1990 
and 2008 the number of publications relating to biomarkers alone have exceeded 4000 (Ptolemy 
and Rifai, 2010). Approaches using technologies such as microarrays, highthroughput DNA 
sequencing, highthroughput proteomics and other modern methods have been useful in 
identifying potential biomarkers for different disease conditions. However, despite huge research 
efforts the number of biomarkers used in the clinic is very small. One of main problems is the 
failure of the biomarkers to pass the validation or clinical stages when the study is expanded to 
include larger sample numbers. This has been explained and discussed in detail in Chapter 1 
(Section 1.10).Another challenge in biomarker discovery is data reduction to shortlist candidates 
for the next step in the biomarker discovery pipeline. Different research groups have combined 
both the genomics and proteomics approaches to identify biomarkers with the results of the 
combined data better than just analysing the data from one approach (Chen et al., 2002; 
Nishizuka et al., 2003; Orntoft et al., 2001).Using both genomic and proteomic approaches will 
reduce the overwhelming volume of data to be considered for preliminary biomarker selection. 
However the integration of gene expression and protein data needs to be approached with caution 
as the experimental and data processing methods vary which might lead to increase in the 
probability of obtaining false positives. In this chapter the results from the microarray dataset 
(Chapter 4) and the proteomic analysis (Chapter3) have been combined to shortlist a panel of 
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biomarkers. Additionally data from another study conducted by Dr. Dawn Farrar from our 
laboratory was also included in the shortlisting process. The latter study is described in the 
following Section. 
5.2 Advanced breast cancer pilot study 
 The aim of this investigation (acronymed Abs) was to explore the changes in the WBCs 
in patients with advanced breast cancer (also referred to as metastatic breast cancer, or MBC) in 
response to chemotherapy and endocrine therapy, using the 2D-gel electrophoresis method. This 
was a collaborative study between the Department of Oncology at the Colchester Hospital 
University NHS Foundation trust and the University of Essex. Experiments for this study were 
conducted by Dr. Dawn Farrar (Senior Research Fellow) from Prof. Elena Klenova’s laboratory 
5.2.1 Background of the study 
 The advanced (recurrent) breast cancer is often associated with distant spread or 
metastasis of tumour cells from the primary tumour. The incidence of advanced breast cancer is 
between 5%-10% of total number of breast cancers diagnosed newly and the mortality rate in 
this group is 80% (Cardoso et al., 2012). The pathology of advanced metastatic breast cancer is 
discussed in detail in Chapter 1.2. Currently the assessment of response to therapy relies on both 
subjective and objective measures. Subjective assessments can be confounded by the side effects 
of the therapy and objective measurements are not usually indicative of response until a number 
of cycles of chemotherapy or several months of hormonal therapy have been given. Some 
patients do not have easily measurable disease and the response to treatment can only be 
assessed on purely subjective measures. The currently available circulating markers e.g. CEA 
and CA15-3 are not ideal in metastatic breast cancer as they are not routinely elevated and do not 
reliably show an early change with therapy.  
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The clinical response is categorised subjectively based on the concept above as complete 
response (CR), partial response (PR), stable disease (SD, progressive disease (PD) and non-
evaluable disease (NE). This type of classification of treatment response is based purely on 
disease progression which changes rapidly in patients because metastatic breast disease is very 
aggressive and breast cancer at molecular level is diverse. The discovery of a suitably sensitive 
blood biomarker could potentially replace and/or complement the assessment currently 
performed using imaging such as CT, Isotope bone scans and MRI. The focus of the 
investigation was on the identification of WBC–based biomarkers for monitoring of anti-cancer 
treatment based on simpler biochemical tests. Such biomarkers are required to be sensitive, 
specific and more reliable for prognosis of metastatic breast cancer to therapeutic treatment 
which can also complement the existing methods of investigation. The focus of the investigation 
was on the identification of WBC–based biomarkers for monitoring of anti-cancer treatment 
based on simpler biochemical tests. The study was conducted in collaboration between the 
Colchester General Hospital and the University of Essex. 
5.2.2 Patient recruitment and blood sample collection 
 Patients with MBC were recruited for the study before the treatment commenced, with 
the written consent obtained from the participants. Two types of treatment were as follows: 
Chemotherapy (6 cycles) and Endocrine therapy (3 cycles). Patients in the final stages of the 
disease with less than 3 months of life expectancy did not participate in the study.  The blood (10 
ml) was collected from the patients before the beginning of the treatment and before each 
treatment cycle. Patients were assessed by physicians before each cycle using radiological 
investigation techniques. Samples were collected at 6 weeks and 12 weeks after the beginning of 
treatment for endocrine therapy patients. The WBCs were fractionated from whole blood 
samples in the lab according to the protocol in Chapter2 (Section2.1) and the WBCs were split 
into different parts for various experiments. 2D-gel electrophoresis was performed on pre- and 
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post-treatment WBC samples according the protocol in Chapter 2 (Section 2.2.3). Protein spots 
of interest were identified through image analysis using Samespots and the protein identification 
was done by Mass spectrometry. 
5.2.3 Results for the Advanced breast cancer pilot study 
Thirty one patients were recruited for this study. Twenty patients had chemotherapy, two 
patients had both therapies and nine had endocrine therapy. The patients responses at the end of 
the treatment were varied; CR=1, PR=8, SD=4, PD=14 and NE=1. Three patients had died 
during or immediately after the course of treatment. The 2D gel electrophoresis was performed 
on the WBC samples and 64 protein spots were identified to be potential biomarker candidates 
for prognosis which showed correlation with treatment response and treatment type. Figure 5.1 
shows the 2D- gel image of the WBCs from patient Abs013 where the64 significant protein spots 
are shown. The protein spots were identified using mass spectrometry and 75 protein 
identifications were obtained. Table 5.1 gives the list of these proteins. 
5.3 Aims of the Chapter 
 In this Chapter genomic data from the GSE16443 dataset analysis (Chapter 4), proteomic 
data (both high throughput proteomics and 2D-PAGE) ( Chapter 3) and data from the advanced 
breast cancer study conducted by Dr. D Farrar have been combined to identify a panel of 
potential WBC biomarkers to be validated using the reverse transcriptase quantitative PCR (RT-
qPCR) method first. Based on the results from RT-qPCR promising candidates were chosen for 
further validation by western Blotting (WB). 
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Figure 5.1 Identification of novel Metastatic Breast Cancer biomarkers from WBCs: Blood 
samples were collected from MBC patients before treatment and over the course of treatment. 
2D- gel electrophoresis was carried out on each sample and gels were run in triplicates. Protein 
spots (n=64) which changed over the course of treatment and with types of metastasis were 
identified using Samespots software. Fold change in protein concentration was taken into 
consideration. Protein ids were obtained through mass spectrometry. (Experiments were 
performed by Dr D. Farrar). 
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Table 5.1 List of protein spot identifications obtained by comparing WBC protein 
expression profiles over the course of chemotherapy and endocrine therapy from 
Metastatic breast cancer (MBC) patients: Blood samples were collected from MBC patients 
before treatment and over the course of treatment. 2D- gel electrophoresis was done on each 
sample and gels were run in triplicates. Protein spots (n=64) which changed over the course of 
treatment and with types of metastasis were identified using Samespots software. Fold change in 
protein concentration was taken into consideration. Protein ids were obtained through mass 
spectrometry. 
Gene symbol Gene name Gene symbol Gene name 
ACTN1 Actinin, alpha 1 LDHB Lactate dehydrogenase B 
ADH5 Alcohol dehydrogenase 5  LTF Lactotransferrin 
ALDOA Aldolase A, fructose-
bisphosphate 
MMP8 Matrix metallopeptidase 8  
ALDOC Aldolase C, fructose-
bisphosphate 
MMP9 Matrix metallopeptidase 9  
ANXA11 Annexin A11 MPO Myeloperoxidase 
ANXA3 Annexin A3 MSN Moesin 
ANXA6 Annexin A6 MYH9 Myosin, heavy chain 9, non-
muscle 
ANXA7 Annexin A7 NONO Non-POU domain-containing 
octamer-binding protein 
 
ARHGDIB Rho GDP dissociation 
inhibitor (GDI) beta 
NCF4 Neutrophil cytosolic factor 4, 
40kDa 
ARPC2 Actin related protein 2/3 
complex, subunit 2, 34kDa 
P4HB Procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), beta 
polypeptide 
BASP1 Brain abundant, membrane 
attached signal protein 1 
PCNA Proliferating cell nuclear antigen 
CALR Calreticulin PDIA4 Protein disulfide isomerase 
family A, member 4 
CAPG Capping protein (actin 
filament), gelsolin-like 
PGAM1 Phosphoglyceratemutase 1 
(brain) 
CAPZA1 Capping protein (actin 
filament) muscle Z-line, alpha 
PGK1 Phosphoglycerate kinase 1 
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1 
CAT Catalase PGLYRP1 Peptidoglycan recognition 
protein 1 
CHIT1 Chitinase 1 (chitotriosidase) PKM2 Pyruvate kinase, muscle 
CLC Charcot-Leyden crystal 
protein 
PNP Purine nucleoside phosphorylase 
CORO1A Coronin, actin binding 
protein, 1A 
PPP1CA Protein phosphatase 1, catalytic 
subunit, alpha isoform 
CPNE3 Copine III PPP2CA Protein phosphatase 2 (formerly 
2A), catalytic subunit, alpha 
isoform 
CTSG Cathepsin G PRKCSH Protein kinase C substrate 80K-
H 
DEF6 Differentially expressed in 
FDCP 6 homolog (mouse) 
PRTN3 Proteinase 3  
DSP Desmoplakin PTPRC Protein tyrosine phosphatase, 
receptor type, C 
FLNA Filamin A, alpha (actin 
binding protein 280) 
PYGL Phosphorylase, glycogen 
G6PD Glucose-6-phosphate 
dehydrogenase 
RAN RAN, member RAS oncogene 
family 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
RPIA Ribose 5-phosphate isomerase A 
(ribose 5-phosphate epimerase) 
GNAI3 Guanine nucleotide binding 
protein (G protein), alpha 
inhibiting activity polypeptide 
3 
RPS3A Ribosomal protein S3A 
GNB2L1 Guanine nucleotide binding 
protein (G protein), beta 
polypeptide 2-like 1 
S100A8 S100 calcium binding protein A8 
HBB Hemoglobin, beta SERPINA1 Serpin peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 1 
HNRNPA1 Heterogeneous nuclear 
ribonucleoprotein A1 
SERPINA3 Serpin peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 3 
HNRNPA2B
1 
Heterogeneous nuclear 
ribonucleoprotein A2/B1 
SERPINB1 Serpin peptidase inhibitor, clade 
B (ovalbumin), member 1 
HSP90AA1 Heat shock protein 90kDa 
alpha (cytosolic), class A 
member 1 
SERPINB10 Serpin peptidase inhibitor, clade 
B (ovalbumin), member 10 
HSPA1A Heat shock 70kDa protein 1A SERPINB6 Serpin peptidase inhibitor, clade 
B (ovalbumin), member 6 
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HSPA8 Heat shock 70kDa protein 8 TALDO1 Transaldolase 1 
ITGAM Integrin, alpha M  TKT Transketolase 
ITGB2 Integrin, beta 2  TPM3 Tropomyosin 3 
LCN2 Lipocalin 2 (oncogene 24p3) VCP Valosin-containing protein 
LDHA Lactase dehydrogenase A WDR1 WD repeat domain 1 
XRCC6 X-ray repair complementing 
defective repair in Chinese 
hamster cells 6  
YWHAE Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, epsilon polypeptide 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
5.4 Results 
5.4.1 Selection process of new WBC candidate biomarkers for further characterisation 
and validation 
5.4.1.1 Comparing genomic and proteomic data to identify common overlaps 
 The short listing of biomarkers involved comparing the data from both genomics and 
proteomics approaches. Significant genes or proteins had been obtained by comparing expression 
profiles of the WBCs of breast cancer patients and healthy donors, using appropriate fold change 
and p-value cut-offs. The next step was to compare the list of these significant genes to find 
common overlaps. The data from the metastatic breast cancer study was also was also used to 
identify common overlaps. Figure 5.2 shows the comparison of the three datasets and the number 
of overlapping molecules between each of the datasets. The list from the highthroughput protein 
analysis and 2D-gel electrophoresis analysis of primary breast cancer patients were combined to 
give the primary breast cancer proteomic dataset. It was surprising to observe that there were 
only four overlaps between the microarray dataset and proteomics dataset of primary breast 
cancer patients. Seventeen proteins overlapped between the proteomic datasets of primary breast 
cancer and metastatic breast cancer. Eleven overlaps were found between primary breast cancer 
microarray dataset and the metastatic breast cancer dataset. There were no common proteins 
between all the three datasets. The table in Figure 5.2 gives the list of those genes which have 
overlapped in more than one dataset. 
5.4.1.2 Short listing of candidates for validation using RT-qPCR 
 The common overlaps were identified by comparing the list of genes or proteins between 
different datasets. The next step in short listing involved several criteria such as: normal presence 
in WBC, correlation with clinical response/data, relative levels to healthy donor, function in 
immune response and association with cancer through literature search. Genes or proteins which 
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were involved in purely metabolic processes were excluded. Genes with immune system 
functions were given priority while shortlisting. Fifteen genes which appeared in more than one 
dataset were chosen for validation on these criteria for validation by RT-qPCR.  For example, 
ALOX5, OSTF1 and FGL2 were chosen based on their WBC expression profiles of breast 
cancer patients from the highthroughput proteomics dataset. FGL2 was not present in the healthy 
donor cohort but present in the breast cancer cohort. ALOX5 and OSTF1 were chosen because of 
their fold change of +1.6 in the breast cancer cohort. The list of the proteins is given in Table 5.2 
along with the details of their presence in different types of datasets.The presence in metastatic 
breast cancer cohort is denoted by ‘X’ and the fold change is not included since the initial 
analysis did not include comparison with healthy donors. 
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A 
Category Overlapping candidate biomarkers 
Between Primary Breast 
cancer Genomics and 
Proteomics data ( 4 
candidates) 
CAMP,CSTA,ITGA4,RHOA 
Between Primary Breast 
cancer  and Metastatic 
Breast cancer proteomics 
data (17 candidates) 
ACTN1,ARPC2,CAPG,CAPZA1,CHIT1,CORO1A,GNAI3,HNRNPA1,IT
GAM,MSN,NCF4,PGAM1,PYGL,SERPINB1,SERPINB6,TKT,YWHAE 
Between Primary Breast 
cancer Genomics data and 
Metastatic Breast cancer 
proteomics data (11 
candidates) 
ANXA3,BASP1,CALR,CPNE3,LCN2,LTF,NONO,PGLYRP1,S100A8,TP
M3,WDR1 
B 
Figure 5.2 Overlapping data between genomic and proteomic approaches presented as 
Venn diagram. Data was obtained by comparing the WBC profiles of breast cancer patientsand 
healthy donors using microarray expression dataset (GSE16443) and proteomic dataset 
(highthroughput protein profiling and 2D-gel electrophoresis. This was compared with the 2D-
gel electrophoresis analysis results for metastatic breast cancer patient WBC to find overlapping 
proteins to be shortlisted for characterisation and validation. 
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Table 5.2 Short listed candidates chosen for validation by RT-qPCR: Genes common from 
different datasets comparing healthy donors, primary breast cancer patients and metastatic breast 
cancer patients were obtained. The overlapping genes were further shortlisted based on several 
criteria; normal presence in WBC, correlation with clinical response/data, relative levels to 
healthy donor, function in immune response and association with cancer through literature search 
to give a 15 panel gene list to be validated using RT-qPCR. Red coloured cells indicate 
overexpression; green indicates underexpression; pink overexpression only in low grade breast 
cancer.The presence in metastatic breast cancer cohort is denoted by ‘X’ and the fold change is 
not included since the initial analysis did not include comparison with healthy donors 
 
Candidates Primary 
Breast cancer-
2D-gel 
electrophoresis  
Primary 
Breast 
cancer- 
High 
throughput 
proteomics  
Primary 
Breast cancer 
-Microarray 
(GSE16443) 
Metastatic 
Breast cancer-
2D-gel 
electrophoresis 
No of 
categories 
of the 
overlap 
SERPINB1 +1.3 +1.46  X 3 
CALR   +1.4 X 2 
YWHAE  +1.46  X 2 
CPNE3   +1.2 X 2 
ANXA3   +1.97 X 2 
ANXA1 +1.3 +1.49   2 
LTF   +2.37 X 2 
NONO   +1.21 X 2 
ITGA4  -3.4 -1.28  2 
WDR1   -1.23 X 2 
RHOA  +1.4 +1.5  2 
LCN2   +2.16 X 2 
ALOX5  +1.6   1 
FGL2  +   1 
OSTF1  +1.23   1 
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5.4.1.3 Description of genes selected for validation using RT-qPCR 
5.4.1.3.1 SerpinB1 (SERPINB1) 
 SerpinB1 is also known as neutrophil elastase inhibitor. The protein encoded belongs to a 
class of protease inhibitors. SerpinB1 inhibits neutrophil serine protease, elastase, cathepsin G 
and proteinase-3 (Farley et al., 2012). It also is involved in neutrophil extravasation and 
formation neutrophil extracellular traps SerpinB1 is associated with cancer as both tumour 
suppressor and promoter (Chou et al., 2012; Cui et al., 2014; Tseng et al., 2009). 
5.4.1.3.2 Calreticulin (CALR) 
 Calreticulin is a chaperone protein which binds to calcium and is involved in several 
functions of the immune system such as Major histocompatibility complex folding and assembly, 
phagocytosis (Raghavan et al., 2013). Calreticulin is also implicated in breast cancer 
aggressiveness and metastasis (Lee et al., 2012; Lwin et al., 2010). It is also proposed that 
Calreticulin is serum biomarker for lung cancer and bladder cancer (Kageyama et al., 2004; Liu 
et al., 2012a). 
5.4.1.3.3 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
epsilon (YWHAE) 
 YWHAE belongs to the family of 14-3-3 proteins which are involved in various 
biological processes such as cell signalling, cell cycle, apoptosis and regulation of transcription 
(Tzivion et al., 2001). Reduced YWHAE expression is shown to contribute to the epithelial to 
mesenchymal transition of hepatocellular and gastric cancer cells (Leal et al., 2012; Liu et al., 
2013). Increased expression has also been reported in breast cancer and lung cancer (Li et al., 
2006; Qi et al., 2005). 
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5.4.1.3.4 Copine 3 (CPNE3) 
 Copine3 is a ubiquitously expressed protein but its function is unknown. It belongs to a 
family of phospholipid binding protein. Copine 3 is upregulated in tumour cells and interacts 
with ErbB2 to promote tumour cell migration (Cowland and Carter, 2003; Heinrich et al., 2010). 
5.4.1.3.5 Annexin A1 and Annexin A3 
 Annexins are also called lipocortins and belong to family of calcium dependent 
phospholipid binding proteins located on the cytosolic face of the plasma membrane. ANXA1 
and ANXA3 both inhibit phospholipase A2 which causes inflammation (Walther et al., 
2000).Reduced ANXA1 expression is linked to invasiveness of breast cancer, gastric cancer and 
neck cancer (Pedrero et al., 2004; Yom et al., 2011; Yu et al., 2008a). ANXA3 also correlates to 
tumour progression in thyroid cancer and hepatocellular carcinoma (Jung et al., 2010; Pan et al., 
2013). 
5.4.1.3.6 Lactoferrin (LTF) 
 Lactoferrin is secreted protein that is found in various bodily fluids such as milk, saliva, 
tears and nasal secretions. LTF is an iron-binding protein antibacterial, anti-carcinogenic and 
antioxidant effects. LTF is expressed in three different isoforms and first was isolated form 
neutrophils (Levay and Viljoen, 1995). LTF has been shown to inhibit cancer growth and 
metastasis (Bezault et al., 1994; Damiens and Yazidi, 1999). 
5.4.1.3.7 Non-POU Domain Containing, Octamer-Binding (NONO) 
 NONO is a RNA-binding protein which plays various roles in cellular processes 
including transcriptional regulation and RNA splicing (Amelio et al., 2007). NONO is implicated 
in progression of malignant melanoma (Schiffner et al., 2011). 
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5.4.1.3.8 Integrin Alpha 4 (ITGA4) 
 ITGA4 is also known as CD49d belongs to the family integrin alpha chain proteins which 
are involved in cell adhesion and migration.Integrin receptors are critical for cell attachment to 
the extracellular matrix (ECM) and this is mediated through integrin-fibronectin interaction 
(Barczyk et al., 2010). Integrins are also involved in transendothelial migration of leukocytes 
which is very important for the functioning of the innate immune system (Williams and 
Solomkin, 1999).  
5.4.1.3.9 WD Repeat domain 1 (WDR1) 
 WDR1 protein contains nine WD domains that are involved on protein-protein 
interactions. The function of WDR1 is unclear but it may help actin cytoskeletal rearrangement 
and cell migration. This protein has been reported to be overexpressed in ovarian cancer 
(Haslene-Hox et al., 2013). 
5.4.1.3.10 The Ras Homolog Family Member A (RHOA) 
RHOA is a small GTPase protein which regulates the formation of actin fibers linking 
which connects the receptors on the plasma membrane. RHOA overexpression has been linked 
to tumour progression/invasion in breast cancer, prostate cancer and testicular cancer (Hodge et 
al., 2003; Kamai et al., 2004; Pillé et al., 2005). 
5.4.1.3.11 Lipocalin 2 (LCN2) 
LCN2 protein is associated with multiple cellular processes such as apoptosis, innate 
immunity etc. Its molecular function is sequestering iron siderophores which limits bacterial 
growth. LCN2 overexpression was found to be associated with aggressive breast tumors (Yang 
et al., 2009) and linked to breast cancer patient response to neoadjuvant chemotherapy 
(Wenners et al., 2012). 
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5.4.1.3.12 Arachidonate 5 Lipoxygenase (ALOX5) 
 ALOX5 plays a role in synthesis of leukotrienes from arachidonic acid. Leukotrienes are 
important mediators of inflammation. ALOX5 has been linked to promoting prostate cancer and 
breast cancer cell survival (Ghosh, 2003; Hu et al., 2011). 
5.4.1.3.13 Fibrinogen-like 2 (FGL2)  
 The function of FGL2 is unknown but it may play a role physiologic lymphocyte function 
at mucosal sites.FGL2 has been implicated playing a role in conversion of prothrombin to 
thrombin. It has shown to be overexpressed in colon, breast, lung, gastric, oesophageal and 
cervicalcancers (Liu et al., 2012b). 
5.4.1.3.14  Osteoclast Stimulating Factor (OSTF1) 
 OSTF1 is produced by osteoclasts and indirectly induces osteoclast formation and bone 
resorption. Breast cancers commonly cause bone metastasis and this process is dependent on 
osteoclast-mediated bone resorption (Thomas et al., 1999). 
5.4.2 Optimisation of RNA extraction and quality control to study gene expression from 
WBCs 
5.4.2.1 Background  
 Relative quantification of RNA is a popular method to study the gene expression changes 
to cells in response to biological stimuli. To obtain high quality results for this analysis it is 
important to (i) obtain high quality RNA and (ii) identify a suitable reference gene to normalise 
the expression of the target gene. Purification of RNA from white blood cells (fresh or 
cryopreserved) can be very challenging. The RNA yield is often very low when extracting due to 
the presence of residual red blood cells in the WBC mixture, the RNA quality is poor because of 
the salts carried over from RNAlater and purity is not satisfactory due to contaminating genomic 
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DNA. Furthermore, RNA degrades rapidly by exogenous and endogenous RNA nucleases, 
storage in cryostate over the time and also exposure to heat. These changes in RNA integrity can 
lead to falsely altered gene expression patterns. 
5.4.2.2 Optimisation of RNA extraction from WBCs 
In order to obtain RNA samples of sufficient quality from WBCs to be used for RT-qPCR the 
procedure of RNA purification needed to be optimised as the initial experiments resulted in the 
WBCs RNA of poor quality and low amounts.  The conventional phenol extraction protocol was 
modified to suit WBCs to extract RNA of satisfactory quality and purity (see Section 2.3.1). The 
total RNA yield was low when 5x10
6
 cells were originally used and stored in RNAlater. The 
WBCs numbers were therefore increased up to 1x10
7
 cells for preservation in RNAlater at -80
0
C. 
The purity of RNA which was extracted was assessed by the use of Nanodrop UV/vis 
spectrophotometer (see Section 2.3.3). A ratio of absorbance at 260, 230and 280 nm 
(A260:A280 and A260:A230) greater than 1.8 is usually considered as an acceptable indicator of 
RNA purity (Glasel, 1995). It was essential that the chloroform step was to be repeated twice for 
the 260/280 values to be higher than 1.8. The RNA had to be washed at least twice with 70% 
ethanol for the 260/230 values to be higher than 1.8. 
Treatment of RNA with DNase is recommended to eliminate DNA contamination after 
RNA extraction in tissues and cell lines (Becker et al., 2010).In our experiments, RNA was 
treated with DNase (see Section 2.3.2) to eliminate DNA contamination. After DNase treatment, 
RNA was evaluated for their integrity using Agilent 2100 bioanalyzer and the results are 
presented in Figure 5.3. The bioanalyzer analysis does not show the presence of DNA 
contaminations. The electropherogram peaks in Figure 5.3 indicate the RNA marker, 5sRNA, 
18sRNA and 28sRNA in the order of appearance from left to right respectively. A value of 
above1.5 for the ratio between 28sRNA and 18sRNA is generally viewed as acceptable for RNA 
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integrity. The gel image also shows if there is degradation in RNA samples. Examples of both 
good quality RNA and poor quality RNA are shown in Figure 5.3. It can be observed from the 
gel image and the electropherogram that RNA obtained from sample Brca1501 had degraded 
while RNA from sample HD3 is not. The final product was then converted to cDNA using RNA 
reverse transcriptase using the protocol described in Section 2.3.5. The absence of contamination 
with genomic DNA was confirmed in RNA preparations treated with DNAse and also in cDNA 
samples by PCR using β-actin primers (Forward primer- CTGGGACGACATGGAGAAA and 
reverse primer- GGGATAGCACAGCCTGGATA). The actin primers were designed across 
different exons so that they can both amplify cDNA and genomic DNA. After quality control the 
cDNA was used to gene expression studies to validate WBC biomarkers using RT-qPCR. 
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Figure 5.3 Quality control of Total RNA extracted from WBCs using Agilent 2100 
Bioanalyzer: Total RNA was extracted by a modified phenol-chloroform protocol as described 
in Section 2.3.1. Electropherograms for two samples (HD3 and Brca1501) have been shown with 
the gel images on the right. The samples were treated for DNA contamination with DNase and 
Agilent 2100 bioanalyzer was used to assess RNA integrity. Samples with 28s:18s ratio lower 
than 1.5 were not selected for further analysis. 
 
 
 
156 
 
5.4.3 Selection of suitable reference gene for RT-qPCR reactions from cDNAs 
 The selection of reference gene to normalise the expression of a target gene across 
different samples from different conditions is important to obtain and interpret the biological 
meaning of the data. In this study we are analysing for the difference in gene expression of 
candidate biomarkers in the WBCs of breast cancer patients. The samples are obtained from 
different participants at different stages of the disease (Healthy donor and breast cancer) and 
breast cancer is a heterogeneous disease at the molecular and cellular level. Also, the WBCs are 
a mixture of different types of cells at varying proportions among participants. Therefore, it is 
important to identify a reference gene which can be applied for specific conditions and the 
varying nature of samples. Although several reference genes have previously been suggested for 
the whole blood (Dheda et al., 2004) and neutrophils (Ledderose et al., 2011), it was important to 
test a panel of the candidate reference genes in our experimental settings. 
The reference gene should meet several criteria: have a constant level of expression 
across different samples, have stable expression across different disease conditions and have a 
low Ct range across the samples. To achieve this aim equal amount (500ng) of RNA was taken 
and converted to cDNA. Expression of six reference genes (HuPO- human acidic ribosomal 
protein; CycloB- cyclophylinB; B2M- β2-microglobulin; HPRT- hypoxanthine phosphori-
bosyltransferase; 18sRNA- 18S ribosomal RNA; RPL32- ribosomal protein 32; TBP- Tata box 
Binding Protein) were evaluated to find the reference gene with the lowest variance among the 
samples. The primers used for each reference gene are given in Table 2.2 in Chapter 2. The 
cDNA from six WBC samples (Breast cancer-4, Healthy Donor-2) were used for the analysis. 
Quantitative PCR was performed using the cDNAs and the mean Cq values were obtained and 
the Box plots were constructed using SPSS (Figure 5.4). It was observed that RPL32 was the 
best, with high consistency and low variance among the samples.TBP showed low variation but 
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the Cq values were high. B2M and HuP0 had the highest variability. RPL32 was chosen as the 
housekeeping gene to normalise the expression of the target genes to be validated. 
 
 
 
 
 
 
 
 
 
 
158 
 
 
Figure 5.4 The RT-qPCR cycle threshold values in RNA fromWBC samples: Expression 
levels of genes are shown as medians (lines), 25th percentile to the 75th percentile (boxes), and 
ranges (whiskers) for 6 human WBC samples (4 breast cancer patients and 2 healthy donors). 
HuPO, human acidic ribosomal protein; CycloB, cyclophylinB; B2M, β2-microglobulin; HPRT, 
hypoxanthine phosphoribosyltransferase; 18sRNA, 18S ribosomal RNA; RPL32, ribosomal 
protein 32; TBP, Tata box Binding Protein. 
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5.4.4 Validation of a panel of 15 biomarkers using RT-qPCR in the WBCs of breast 
cancer patients 
For experiments described in this section RNA was extracted by a modified protocol as 
described in Section 5.4.2. DNase treatment was done and the integrity of RNA was assessed 
using the Agilent 2100 bioanalyzer. The RNA was then converted to cDNA (refer to Section 
2.3.5). This cDNA was used to validate the biomarker candidates obtained by the selection 
process described in Section 5.4.1. The primers for the candidate genes were designed to span 
different exons. The details about the primers and the cycling conditions uses are given in Table 
2.3. The RT-qPCR was conducted as explained in Section 2.3.7 using RPL32 as the reference 
gene. Three technical repeats were performed for the experiment. In the initial series of 
experiments, the WBC samples from ten breast cancer patients (Panel 1) and five healthy donors 
were used (the patient details are given in Table 5.3).The qPCR was performed and the data was 
analysed using the Biorad CFX manager software. The software calculated the Cq values and 
normalised the expression values with respect to RPL32. These expression values for each 
sample were taken and box plots were constructed using SPSS. The Mann-Whitney U test was 
performed between the healthy donors and breast cancer patients with a p value cut-off of 0.05 to 
find significant differences in gene expression. RT-qPCR of the 15 different genes revealed that 
the differences in expression of three genes, ITGA4, CPNE3 and LCN2 were significant (P 
value<0.05) between the WBCs of breast cancer patients and healthy donors. The respective fold 
changes were -1.03,-1.6 and -3.28 in breast cancer patients. The box plots of the expression 
values are given in Figure 5.5 along with the P values obtained from the T-test.WDR1 had a p 
value of 0.053 which is very close to the cut-off and had a fold change of -1.4. All the other 
genes tested had higher p values. The genes which passed the threshold were tested again with an 
extended panel of primary breast cancer patients and metastatic breast cancer patients. This is 
explained in the following Section. 
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Table 5.3 Clinical data for breast cancer patient samples used for validation by RT-qPCR: T size- Tumour size, T Grade- Tumour grade, T 
stage- Tumour stage, DCIS- Ductal Carcinoma in situ, IDC- Invasive Ductal Carcinoma, LCIS- Lobular carcinoma in situ and ILC- Invasive 
Lobular Carcinoma. Nodes indicate if the tumour had spread to the lymph nodes. 
 
Study No AGE T SIZE T 
STAGE 
T GRADE NODES DIAGNOSIS 
Panel 1       
1535 67 20 II 1 NEG IDC 
1477 46 8 I 1 NEG IDC,DCIS(LOW 
GRADE) 
1560 82 20 II 3 NEG IDC 
1532 73 10 II 3 NEG IDC+DCIS 
1492 47 >50 III 1 POS LCIS+ILC 
1556 46 25 NA High NA DCIS 
1512 74 23 II 2 POS ILC+LCIS 
1561 41 25 II 2 POS ILC+DCIS 
1438 53 9 NA Intermediate ND DCIS 
1490 81 40 II 2 NA IDC+ILC+DCIS+LCIS 
Panel 2       
1276 64 10 II 1 POS Tubulo-lobular+DCIS 
1499 67 15 I 1 NEG IDC+DCIS+Tubulo-
lobular 
1432 63 20 II 2 POS IDC+DCIS 
1500 65 23 II 2 POS IDC+DCIS 
1553 36 20 II 2 POS IDC+DCIS 
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1558 85 15 II 2 POS IDC 
1516 46 14 III 3 NEG IDC+DCIS 
1528 84 20 II 3 NEG IDC+DCIS 
1494 66 25 II 3 NEG IDC+DCIS 
1554 65 30&3 II  3 NEG IDC+DCIS 
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Figure 5.5 Validation of the 15-gene signature in WBCs of breast cancer patients using RT-
qPCR: RT-qPCR was performed on the cDNA obtained from the WBCs of breast cancer 
patients (n=10) and healthy donors (n=5). RPL32 was used as the housekeeping gene to 
normalise the target genes and the expression values were used to construct a box plot using 
SPSS. Mann-Whitney U test was performed to identify the significance of the expression values 
between both groups to identify gene targets which have p value<0.05. Expression levels of 
genes are shown with medians and their quartile ranges. HD-Healthy Donor, Brca-Primary breast 
cancer. *pvalue<0.05 
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5.4.4.1 Validation of ITGA4, CPNE3 and LCN2 using an extended panel of primary and 
metastatic breast cancer patients 
 The WBC expression profiles of ITGA4, CPNE3 and LCN2 showed a significant 
difference between the healthy donors and primary breast cancer patients when tested using RT-
qPCR. These three genes were therefore chosen for validation using an extended panel which 
included ten more participants (Panel 2, Table 5.3). The RNA samples from 7 pre-treatment 
metastatic breast cancer patients were also included in this panel. The rationale behind including 
metastatic samples was that it may provide biomarkers to diagnose or predict distant organ 
tumour metastasis. After the samples were analysed by RT-qPCR, the data were compiled 
together by normalising different runs using the expression values of a common sample used in 
both RT-qPCR runs and scatter plots were generated in SPSS. The different groups were then 
compared for significance by performing a Kruskal-Wallis test and a confidence interval of 95% 
(p value<0.05) was considered. 
 Figures 5.6, Figure 5.7 and Figure 5.8 show the box plots of the normalised expression 
data of ITGA4, CPNE3 and LCN2 respectively (see Figure legends for details). It was observed 
that ITGA4 expression was significantly less in the WBCs of primary breast cancer (average fold 
change= -1.54) and metastatic breast cancer patients (average fold change= -2.21) when 
compared to the healthy donor cohort. CPNE3 expression was significantly higher (fold change= 
+2.37) in the metastatic breast cancer cohort when compared to both healthy donor and primary 
breast cancer cohorts. LCN2 expression was less in the primary breast cancer patients (fold 
change= -1.35) and significantly higher (fold change= +3.13) in the metastatic breast cancer 
patients. 
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Figure 5.6 RNA expression profiles of Integrin Alpha 4 (ITGA4) in the WBCs of Healthy 
donors and Breast cancer patients: RT-qPCR was performed using RNA obtained from the 
WBCs of healthy donors, primary breast cancer patients and metastatic breast cancer patients to 
detect the expression of ITGA4. RPL32 was used as the reference gene in all experiments. The 
data was normalised using the expression value of sample HD3 which was used in all 
experiments. Kruskal-Wallis test was performed to test for significance between the different 
sample cohorts used. Expression levels of genes are shown with medians and their quartile 
ranges. HD-Healthy Donor, Brca-Primary breast cancer, ABS- Advanced breast cancer.. 
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Figure 5.7 RNA expression profiles of Copine3 (CPNE3) in the WBCs of Healthy donors 
and Breast cancer patients: RT-qPCR was performed using RNA obtained from the WBCs of 
healthy donors, primary breast cancer patients and metastatic breast cancer patients to detect the 
expression of CPNE3.RPL32 was used as the reference gene in all experiments. The data was 
normalised using the expression value of sample HD3 which was used in all experiments. 
Kruskal-Wallis test was performed to test for significance between the different sample cohorts 
used. Expression levels of genes are shown with medians and their quartile ranges. HD-Healthy 
Donor, Brca-Primary breast cancer, ABS- Advanced breast cancer. 
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Figure 5.8 RNA expression profiles of Lipocalin2 (LCN2) in the WBCs of Healthy donors 
and Breast cancer patients: RT-qPCR was performed using RNA obtained from the WBCs of 
healthy donors, primary breast cancer patients and metastatic breast cancer patients to detect the 
expression of LCN2. RPL32 was used as the reference gene in all experiments. The data was 
normalised using the expression value of sample HD3 which was used in all experiments. 
Kruskal-Wallis test was performed to test for significance between the different sample cohorts 
used. Expression levels of genes are shown with medians and their quartile ranges. HD-Healthy 
Donor, Brca-Primary breast cancer, ABS- Advanced breast cancer.  
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5.4.4.2 Validation of SERPINB1using RT-qPCR in an extended panelof primary and 
metastatic breast cancer patients 
 Leukocyte elastase inhibitor (SERPINB1) was found to be upregulated in the WBCs of 
breast cancer patients in this study by both highthroughput proteomics (Fold change= +1.46) and 
2D gel electrophoresis (Fold change= +1.46).  SERPINB1 was also found to be positively 
correlated with mortality and disease progression in the experiments using the WBCs of 
metastatic breast cancer patients.  These combined results are presented in Figure 5.9. 
Although the RNA levels of SERPINB1 were measured using RT-qPCR in the WBCs of 
primary breast cancer patients and results were not significant when compared to the levels in the 
healthy donors (Section 5.4.4), it was possible that SERPINB1 may be linked to metastatic breast 
cancer and not primary breast cancer. We therefore assessed SERPINB1 mRNA levels using the 
extended panel with metastatic patients. The results presented in Figure 5.10 demonstrate 
significantly higher levels of SERPINB1 mRNA (Fold Change= +3.4) in the WBCs of metastatic 
breast cancer patients when compared to both healthy donors and primary breast cancer patients. 
The difference was not significant between primary breast cancer cohort and the healthy donors. 
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A  
B  
C  
Figure 5.9 Levels of SERPINB1 in WBCs of Breast cancer patients: protein spots identified 
as SERPINB1 in primary breast cancer patients by (A) 2D-gel electrophoresis,(B) 
Highthroughput proteomics and in (C) metastatic breast cancer patients by 2D-gel 
electrophoresis. PD- Progressive Disease, SD- Stable Disease, HD-Healthy donor, Brca- Breast 
cancer. The error bars indicate the standard deviation. 
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Figure 5.10 RNA expression profiles of SerpinB1 in the WBCs of Healthy donors and 
Breast cancer patients: RT-qPCR was performed using RNA obtained from the WBCs of 
healthy donors, primary breast cancer patients and metastatic breast cancer patients to detect the 
expression of SERPINB1. RPL32 was used as the reference gene in all experiments. The data 
was normalised using the expression value of sample HD3 which was used in all experiments. 
Kruskal-Wallis test was performed to test for significance between the different sample cohorts 
used. Expression levels of genes are shown with medians and their quartile ranges. HD-Healthy 
Donor, Brca-Primary breast cancer, ABS- Advanced breast cancer.  
 
171 
 
5.4.5 Validation of biomarkers at protein level using western blotting 
 The fifteen shortlisted candidates obtained by combining the data from different 
approaches were validated using RT-qPCR. Four genes ITGA4, CPNE3, LCN2 and SERPINB1, 
passed the significance test and showed considerable difference between the healthy donor and 
primary breast cancer and/or metastatic breast cancer cohorts. Out of these candidates CPNE3, 
LCN2 and SERPINB1 were chosen for further validation at protein level using western blotting. 
ITGA4 was not chosen because the difference in Cq values and the normalised expression ratios 
between healthy donors and breast cancer patients were low. Antibodies for Copine3 (cat no: 
ab97919), SerpinB1 (cat no: ab47731), and Lipocalin2 (cat no: ab63929) were purchased from 
Abcam. All antibodies were rabbit polyclonal antibodies and, according to Abcam specifications, 
were suitable for western blotting. The secondary antibody used was anti-rabbit horseradish 
peroxidase (HRP) conjugated from Abcam (cat no: ab99697). The antibody for loading control 
(β-Actin) was the anti β-Actin antibody from Sigma (cat no: A1978). Western blotting was 
carried out as described in Chapter 2 (Section 2.2.1) and the antibody signal was visualized. The 
samples were normalised with each other by normalising the target signal with the actin signal. 
5.4.5.1 Evaluation of Copine 3 protein expression in breast cancer patients 
 Breast cancer patients’ samples (Primary and Metastatic) were compared with healthy 
donors using western blotting. Samples from nine healthy donors, 22 primary breast cancer and 
twelve metastatic breast cancer patients were used for this analysis. The membrane was probed 
with the anti-Copine 3 (CPNE3) antibody; the results of western blotting are shown in Figure 
5.11. The positive control was the lysate from 293T cell and the negative control was the lysate 
from NB4 cell. A band around 60kDa was observed in the WBC samples and the positive 
control. The intensity values were obtained using Image J as described in Section 2.2.1.4; the 
CPNE3 values were normalised to β-Actin for each sample. The values between different 
western blotting analyses were normalised with each other using the expression values of 
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common samples in different westerns assays. The combined results from different westerns are 
represented as a box plot in Figure 5.12 and Kruskal-Wallis was performed using SPSS to 
confirm significance in difference between different sample cohorts. It was found that CPNE3 
expression in WBCs was highly variable and there were no significant differences between the 
healthy donor and primary breast cancer and metastatic cancer cohorts. The expression data did 
not show any correlation between any clinical data and we therefore concluded that Copine 3 
was not likely to be a suitable biomarker for diagnosis and prognosis for breast cancer. 
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Figure 5.11 Protein expression of CPNE3 in WBCs of breast cancer patients using western 
blotting: western blot analysis showing expression of CPNE3 in the WBCs of healthy donors, 
primary breast cancer patients and metastatic breast cancer patients. Lysates from breast cancer 
cell line 293T was used as a positive control and actin as loading control. The proteins were 
resolved by SDS - PAGE, blotted and probed with CPNE3 IgG (rabbit) antibody and 
visualized.(Br - Breast cancer, HD - Healthy donor, Abs- advanced breast cancer study, ACTB- 
beta-actin). 
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Figure 5.12 Scatter plot of Protein expression of Copine3 (CPNE3) in WBCs of breast 
cancer patients: western blotting was performed using the lysates obtained from the WBCs of 
healthy donors, primary breast cancer patients and metastatic breast cancer patients to detect the 
expression of CPNE3. Β-Actin was used as the loading control. Kruskal-Wallis test was 
performed to test for significance between the different sample cohorts used. Expression levels 
of genes are shown with medians and their quartile ranges. HD-Healthy Donor, Brca-Primary 
breast cancer, ABS- Advanced breast cancer. 
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5.4.5.2 Analysis of SERPINB1protein levels in breast cancer patients 
 SERPINB1 protein expression was evaluated by western blotting in the breast cancer 
cohorts and compared with healthy donors. A band of approximately 43kDa was observed. The 
SERPINB1 signal was normalised using the β-Actin using Image J. Expression values between 
westerns were compared by normalising the expression values from the common sample used in 
each experiment (usually a sample from a healthy donor). Figure 5.13 represents a typical 
western showing expression of SERPINB1. It can be clearly observed that expression in 
metastatic patients is much higher than in healthy donors and primary breast cancer patients. 
Figure 5.14 shows the combined data in scatter plots. The fold change in primary breast cancer 
was +3.9 and metastatic breast cancer was +7 when compared to healthy donor cohort. Around 
47% of primary breast cancer patients had higher levels of SERPINB1 when compared to 
median of healthy donors. Also 90% of metastatic breast cancer patients had higher SERPINB1 
levels when compared to primary breast cancer patients. The p values were low (<0.05) between 
the different cohorts. Since SERPINB1 levels were higher in metastatic breast cancer patients, 
SERPINB1 expression was correlated in primary breast cancer patients with the node status. 
Figure 5.15 shows the expression of SERPINB1 between the node positive and node negative 
breast cancer cohorts. The p value was not significant but the median of node positive samples 
was higher than node negative samples. 
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Figure 5.13 Protein expression of SerpinB1 in WBCs of breast cancer patients using 
western blotting: western Blot analysis showing expression of SERPINB1 in the WBCs of 
healthy donors, primary breast cancer patients and metastatic breast cancer patients. β-Actin was 
used as loading control. The proteins were resolved by SDS - PAGE, blotted and probed with 
SERPINB1 IgG (rabbit) antibody and visualized. (Br - Breast cancer, HD - Healthy donor, Abs - 
advanced breast cancer study, ACTB- β Actin, M-protein marker). 
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Figure 5.14 Scatter plot of Protein expression of SerpinB1 in WBCs of breast cancer 
patients: western blotting was performed using the lysates obtained from the WBCs of healthy 
donors, primary breast cancer patients and metastatic breast cancer patients to detect the 
expression of SERPINB1. Β-Actin was used as the loading control. Kruskal-Wallis test was 
performed to test for significance between the different sample cohorts used. Expression levels 
of genes are shown with medians and their quartile ranges. HD-Healthy Donor, Brca-Primary 
breast cancer, ABS- Advanced breast cancer. 
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 Figure 5.15 Scatter plot of Protein expression of SerpinB1 in WBCs of breast cancer 
patients according to node status: western blotting was performed using the lysates obtained 
from the WBCs of healthy donors and primary breast cancer patients to detect the expression of 
SERPINB1. Β-Actin was used as the loading control. Kruskal-Wallis test was performed to test 
for significance between the different sample cohorts used. Expression levels of genes are shown 
with medians and their quartile ranges. HD-Healthy Donor, NN-Node Negative primary breast 
cancer, NP-Node Positive primary breast cancer. 
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5.4.5.3 Evaluation of SerpinB1 protein expression in metastatic breast cancer patients as a 
marker of prognosis 
Since SERPINB1 was present in the metastatic breast cancer dataset its levels were tested 
in WBCs of metastatic breast cancer patients before and after treatment to assess whether it may 
be a marker of treatment efficacy and prognosis. Figure 5.16A shows the levels of SERPINB1 in 
such paired metastatic breast cancer WBC samples; five paired samples from patients who 
underwent chemotherapy and four samples from patients who underwent endocrine therapy 
patients were used. Out the nine patient samples tested, in two samples SERPINB1 levels 
decreased after treatment (Abs065 and Abs048) and in all other samples increased. The patient 
data for the samples used in these experiments are presented in Figure 5.16,including the 
information regarding the type of metastasis and survival in months. The overall tendency was 
for increased levels of SERPINB1 to correlate with diminished response to therapy and poorer 
survival. For example, in the case of participant Abs048, complete response for the treatment 
was observed, the participant was alive after 18 months and the SERPINB1 levels decreased 
after treatment. In participants Abs054 and Abs061 the amount of SERPINB1 was about two-
fold higher after treatment; these patients survived for only two and four months, respectively. 
However, the pattern of changes in SERPINB1 levels in participant Abs059 cannot be explained 
by this hypothesis. Unfortunately, due to time restraints, it was not possible to perform these 
experiments using a large panel of samples, which in addition to the first and the last samples 
would include intermediate time points. These experiments are currently being carried out in our 
laboratory.  
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5.4.5.4 Evaluation of Lipocalin 2 protein expression in breast cancer patients 
 The Lipocalin 2 (LCN2) protein was another promising WBC biomarker and it was 
selected for further validation by western blotting (Figure 5.17 shows these results). The 
predicted size for LCN2 is 23 kDa; there was no signal from the anti-LCN2 antibody in this 
range. The LCN2 protein was previously reported to be present in MCF7 cells (Yang et al., 
2009). Therefore the MCF7 cell lysate was included in this experiment as a positive control; 
however no band was detected in this sample. The presence of sufficient amount of protein in all 
specimens was confirmed be re-probing the membrane with the anti -Actin antibody. We 
concluded that the anti-LCN2 antibody tested was not suitable for western blotting experiments; 
these assays will need to be repeated with another antibody.  
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A 
Sample 
ID 
SERPINB1 Fold 
Change after 
Treatment 
Treatment Type Metastasis type Prognosis 
Survival in months 
(as on 31-05-2012) 
Abs048 -1.10078 Endocrine Lung CR Alive 
Abs050 1.421607 Chemotherapy Liver, Lung, Bone SD 10 
Abs054 3.328652 Chemotherapy Liver, Bone SD 4 
Abs057 1.384492 Chemotherapy Liver, Lung, Bone, Brain PD 8 
Abs059 1.565282 Endocrine Lung SD Alive 
Abs061 2.062586 Chemotherapy Lymph nodes PR 2 
Abs063 1.427723 Endocrine Bone PR 7 
Abs065 -1.2011 Chemotherapy Liver, Lung, Bone, Brain PR 6 
Abs067 1.068564 Endocrine Liver, Bone, Skin SD 10 
 
B 
 Figure 5.16 Expression of SERPINB1 in metastatic breast cancer patient samples from 
before treatment and after treatment: (A) The WBC samples from metastatic breast cancer 
patients who underwent two types of treatment (Chemotherapy and endocrine therapy) were 
used. SERPINB1 levels were assessed by western blotting. Samples were loaded analysed in 
pairs (before and after treatment). The images obtained by western blotting was analysed by 
Image J and SERPINB1 levels were normalised against β-Actin values. (B) Patient information 
and levels of SERPINB1 for samples used in the experiments shown in panel A. The fold change 
of SERPINB1 after treatment is also given along with disease survival. SD= Stable Disease, PD = 
Progressive Disease, CR = Complete Response, PR = Partial Response. 
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Figure 5.17 Protein expression of Lipocalin 2 in WBCs of breast cancer patients using 
western blotting: Expression of LCN2 in the WBCs of healthy donors, primary breast cancer 
patients and metastatic breast cancer patients has been analysed; β-Actin was used as loading 
control. The proteins were resolved by SDS - PAGE, blotted and probed with the anti-LCN2 IgG 
(rabbit) antibody and visualized. Br - Breast cancer, HD - Healthy donor and ACTB- β Actin. 
 
 
 
 
 
 
 
 
183 
 
5.5 Discussion 
The aim of the work described in this chapter was to identify potential biomarkers using three 
different experimental datasets and then validate the selected candidates using RT-qPCR and 
western blotting.  
 In order to carry out RT-qPCR, RNA had to be extracted from WBCs and converted into 
cDNA. The WBCs were stored in RNAlater solution at -80
0
C so that RNA could be extracted at 
convenience. Extracting RNA from WBCs proved to be difficult as the yield and the quality of 
RNA (purity and integrity) were initially very poor. Indeed this has been noted by several groups 
using RNA form peripheral blood (Debey et al., 2004; Feezor et al., 2004; Wang et al., 2004). 
According to Minimum Information of Quantitative real-time PCR experiment (MIQE) 
guidelines the assessment of nucleic acid purity and integrity is essential (Bustin et al., 2009). 
According to the modified protocol for RNA extraction described in this chapter the second 
chloroform step and an additional ethanol wash was required to obtain pure RNA without protein 
or salt contamination. The yield of RNA from WBCs which were stored in RNAlater was very 
low (10 million cells were used to obtain only around ~200ng of RNA. Alternatively the RNA 
yield was observed to be higher when WBCs were freshly lysed after separation from whole 
blood using Trisure (300ng/10 million cells). This lysate prepared by using Trisure could only be 
stored at -80
0
C but only for a maximum of four weeks according to the manufacturer’s 
instruction. Due to large numbers of sample collection and delayed availability of clinical 
diagnosis data RNAlater was used and RNA extraction protocol was optimised to it. 
 DNA contaminations in RNA preparations can cause significant problems in gene 
expression analysis. The conventional phenol-chloroform method for RNA extraction does not 
completely eliminate DNA. There are no RNA extraction procedures available that completely 
avoid DNA contamination and also there are no techniques available to detect DNA in RNA 
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preparations other than PCR. In our study the RNA preparations had DNA contamination which 
was detected in cDNA preparations. RT-qPCR analysis and cDNA preparations are expensive, 
therefore DNase treatment is essential and ensured that RNA was DNA-free. 
The selection of a suitable reference gene in RT-qPCR reactions is important as it 
determines the significance of the results. In this study it was observed that reference genes like 
β-actin, human acidic ribosomal protein and β2-microglobulinproduced false results when the 
target genes were normalised with the reference genes, especially if the change in target gene 
levels were low. RPL32showed minimum transcription range across the tested samples and was 
chosen as a reference gene. A recent study (Xu et al. 2013) used several reference genes to 
validate candidate genes from the WBCs of colorectal cancer patients. Although this approach it 
is very labor- and time-consuming, it ultimately improves the outcomes of the RT-qPCR 
reactions. 
The shortlisting of candidates from the three different datasets proved to be very 
challenging as the datasets were very large and involved significant amount of computing. The 
main criteria for the shortlisting process were (1) presence of the same candidate in more than 
one dataset, (2) biological function in WBC (in particular, in immune response) and (3) 
association with cancer. An initial panel of 15 biomarkers was chosen using the above criteria to 
be validated by RT-qPCR in the first instance. Table 5.4 shows the list of candidates chosen to 
be validated by RT-qPCR and the results in the form of fold change. Only YWHAE, ANXA3 and 
ALOX5 were overexpressed in the breast cancer cohort. All the other genes tested were 
overexpressed in the primary breast cancer cohort. It was observed that out of the 12 genes 
which were overexpressed in the high throughput data (both genomic and proteomic) only 
CPNE3, ANXA3 and ALOX5 followed the same trend in RT-qPCR analysis. ITGA4 and WDR1 
showed consistent negative change in breast cancer patients in RT-qPCR analysis and the 
microarray data. This result is consistent with other groups where only 25-30% of genes 
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correlate at both RNA and protein levels (Lundberg et al., 2010; Tian et al., 2004; Vogel et al., 
2010).ITGA4, CPNE3 and LCN2 showed significant difference (T-test p value<0.05) in the 
primary breast cancer cohort. Although SERPINB1 did not show significance at RNA levels in 
primary breast cancer patients it was chosen for further validation based on the information 
obtained from proteomics and also the RNA expression in metastatic breast cancer patients. 
All four genes (ITGA4, CPNE3, LCN2 and SERPINB1) showed significant difference at 
the RNA expression levels in the metastatic breast patient cohort (Section 5.4.4.1 and 5.4.4.2). 
Only ITGA4 had negative expression in both breast cancer and metastatic breast cancer cohort. 
Others showed significantly higher expression levels in metastatic breast cancer patients. 
Of note, it has been reported in the literature that protein levels do not always correlate 
with the levels of corresponding mRNA (Lundberg et al., 2010; Tian et al., 2004; Vogel et al., 
2010). Therefore, it is likely that the number of potential candidate biomarkers discovered in the 
course of this study is much higher.  The integration of genomics and proteomics provided 
stricter pre-requisitions and helped us to shortlist a manageable panel of candidates for 
validation. 
 
 
 
 
 
 
 
186 
 
Table 5.4 Candidate WBC biomarkers chosen for validation by RT-qPCR and the 
summary of RT-qPCR results: Genes common from different datasets comparing healthy 
donors, primary breast cancer patients and metastatic breast cancer patients were obtained. The 
overlapping genes were further shortlisted to give a 15 panel gene list to be validated using RT-
qPCR. Fold change refers to fold change in primary breast cancer cohort. Red coloured cells 
indicate overexpression; green indicates underexpression; pink overexpression only in low grade 
breast cancer. *T-test p value<0.05. The presence in metastatic breast cancer cohort is denoted 
by ‘X’ and the fold change is not included since the initial analysis did not include comparison 
with healthy donors. 
 
Candidates Primary 
Breast cancer-
2D-gel 
electrophoresis  
Primary 
Breast 
cancer- 
High 
throughput 
proteomics  
Primary 
Breast cancer 
-Microarray 
(GSE16443) 
Metastatic 
Breast cancer-
2D-gel 
electrophoresis 
Fold 
Change 
in RT-
qPCR 
SERPINB1 +1.3 +1.46  X -1.16 
CALR   +1.4 X -1.4 
YWHAE  +1.46  X +1.03 
CPNE3   +1.2 X 
-1.47* 
ANXA3   +1.97 X +1.98 
ANXA1 +1.3 +1.49   -1.02 
LTF   +2.37 X -1.60 
NONO   +1.21 X -1.08 
ITGA4  -3.4 -1.28  
-1.4* 
WDR1   -1.23 X -1.46 
RHOA  +1.4 +1.5  -1.39 
LCN2   +2.16 X 
-1.35* 
ALOX5  +1.6   +1.28 
FGL2  +   -1.23 
OSTF1  +1.23   -1.56 
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The results of RT-qPCR identified four candidates: ITGA4, LCN2 and CPNE3. The 
LCN2 and CPNE3 proteins were then validated at a protein level using western blotting. 
Additionally, SERPINB1 was added to this panel to be validated by western blotting. Although 
CPNE3 expression at RNA levels in both primary breast cancer and metastatic breast cancer 
cohorts were significantly different from the healthy donor cohort, western blotting revealed that 
CPNE3 expression was not significantly different in both breast cancer cohorts, with CPNE3 
expression hugely varying in the primary breast cancer cohort. If the panel was extended CPNE3 
could be correlated with the clinical data to observe if it could be used as prognosis marker.  
SERPINB1 levels were significantly higher (Fc=+7) in the metastatic breast cancer 
cohort and also in the primary breast cancer cohort (Fc=+3.5).  From these data it can be 
concluded that SERPINB1 represents a very attractive candidate to be used as a biomarker of 
metastatic breast cancer. There was also positive correlation of SERPINB1 protein levels to 
lymph node metastasis state in the primary breast cancer cohort, whereby participants who had 
lymph node metastasis had higher levels of SERPINB1.Therefore, higher SERPINB1 may be an 
indicator/predictor of metastasis and hence used as a prognostic biomarker. Further retrospective 
studies will be required to assess how levels of SERPINB1 correlate with the recurrence and 
survival. This was not possible with the samples collected for this study as the information was 
not available. 
The levels of SERPINB1 were also measured to observe if it could be used as a 
prognostic marker for treatment response and survival. The initial 2D gel electrophoresis study 
revealed that higher SERPINB1 levels could indicate poor prognosis. The analysis carried out in 
this study was not conclusive as the sample numbers were low. Regarding ITGA4 and LCN2 the 
RT-qPCR results look very promising and antibodies could be used to validate them at protein 
levels in the future. 
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There is still lack of standardised protocol for protein biomarker development pipeline 
while the validation protocols are well developed for the pharmaceutical industry for drug 
development (Buyse et al., 2010).Western blotting is an effective method to validate biomarker 
candidates initially but it is limited to the sample number which could be used at the same time. 
Although many protein analytical techniques are available for validation ELISA still dominates 
in a clinical setting. ELISA is a very effective technique to validate potential biomarkers in a 
clinical setting quantitatively and also a large number of samples could be used. Further 
validation of SERPINB1 by ELISA would be helpful to gain further data to continue on to the 
clinical phase in the biomarker development pipeline. 
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Chapter 6: General Discussion 
 
6.1  The challenging field of breast cancer biomarkers 
 Although the survival for female breast cancer has greatly improved in the recent years, 
breast cancer remains a very serious condition. Breast cancer is challenging to screen or diagnose, 
it is fast growing once it reaches critical mass and possesses high ability to metastasise to multiple 
sites in the body. It has been suggested that breast cancer metastasis occurs 5 years even before 
the primary tumour is clinically detected (Engel et al., 2003). The current major clinical diagnostic 
technique for breast cancer is the use of mammograms which detects abnormal lumps of tissue in 
the breast. Mammography has a high rate of false negatives (10-15%) where the tumour is present 
and is not detected (Heywang-Köbrunner et al., 2011); this may endanger patients’ lives. On the 
other hand, over-diagnosis may also take place in these screenings because the number of false 
positives in mammography is also high. In addition, mammograms do not provide information 
about the abnormal lump i.e. whether it is benign or malignant. As a result, for final diagnosis 
tissue biopsies may be required which puts patients under unnecessary anxiety and stress.  
This justifies the need for biomarkers for screening, diagnosis and prognosis of breast 
cancer. Currently there are six FDA approved biomarkers: three are tissue based (estrogen 
receptor, progesterone receptor and HER2/neu) and three plasma based (circulating tumour cells, 
CA 15-3 and CA 27-29), to monitor breast cancer disease progression and response to therapy 
(Füzéry et al., 2013). These biomarkers are not accurate in predicting response to treatment and 
also cannot be used for diagnosis or screening. With the rapid development of the “omics” 
technologies several groups have tried to identify breast cancer biomarkers in tissue and plasma 
(refer to Section 1.7, 1.8 and 1.9); however still no biomarkers have been discovered to screen or 
diagnose breast cancer. In this study we have hypothesized that breast tumour would interact with 
the immune system causing a systemic change in immune expression profile. This could be 
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exploited to find novel biomarkers for breast cancer and in this study we have explored 
biomarkers in a novel source, the white blood cells 9WBCs). We also applied these findings to 
elucidate the effects of the breast tumour on the immune system. 
6.2  Protein profiling expression analysis of WBCs from breast cancer patients 
 In this study we used several approaches for biomarker discovery. The High throughput 
proteomics using mass spectrometry is more efficient than genomics technologies because almost 
all of the clinical diagnostics techniques are antibody based assays targeting proteins. Moreover 
RNA levels do not always correspond to the translated protein levels in the cell. Drabovich et.al 
2014 has proposed an integrated protein biomarker discovery pipeline. This study has almost 
followed the steps in the proposed pipeline even though the group published the work just recently 
(Figure 1.3). However it has to be noted that none of the existing breast cancer biomarkers have 
been discovered using mass spectrometry based approaches. This may be due to the lengthy 
period of validation, clinical trials and the approval process following the protein biomarker 
discovery. It is therefore possible that the candidate biomarkers first discovered in the 2000s may 
obtain the FDA approval very soon if they satisfy all the criteria.  Regardless of the status with the 
biomarkers currently in the FDA pipeline, the search for breast cancer biomarkers continues. 
 The proteomic technologies used in this study were the high throughput profiling by 
OrbitrapVelos mass spectrometer and conventional 2D-PAGE. The high throughput proteomics 
approach resulted in the detection of around 2577 proteins in the membrane fraction of WBCs. 
This comparison illustrates the sensitivity of the mass spectrometry over the 2D-PAGE. The 
comparison between the protein profiles of healthy donors and breast cancer patients using high 
throughput proteomics gave 136 significant proteins while 2D-PAGE gave only 18 significant 
proteins. Performing 2D-PAGE was time consuming, costly and prone to experimental errors such 
as inter-gel variation, differences in staining intensities, low sensitivity to low abundant proteins,  
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poor inter-gel normalisation techniques and reduced resolution compared to mass spectrometry. 
The results from the both analyses showed that the genes which changed had less fold change 
range when compared to the data obtained from tumour tissues (from literature). The 
heterogeneity (variability) in the significant protein levels was also high due to the multiple cell 
type composition of WBCs and also the dynamic nature of the immune system. The heterogeneity 
of breast cancer subtypes might also be the cause for this. Three proteins appeared in both 
analyses; SERPINB1, JUP and ANXA1. SERPINB1 became an important candidate later in our 
biomarker pipeline. This will be discussed in the following sections. The data from the soluble 
fraction of the high throughput proteomics is still to be analysed. This will lead to discovery of 
more biomarkers. 
6.3  Gene expression analysis of WBCs in breast cancer patients 
 There is a vast amount of information in the microarray data produced and deposited so 
far. This includes the gene expression data for peripheral blood samples in breast cancer patients, 
although such data have been limited to only a few studies. In our investigation, we used these 
existing data to compare the expression profiles of blood samples from breast cancer patients and 
healthy donors. These data deposited in the GEO (id-GSE16443) (Aarøe et al., 2010) were from 
the gene expression analysis of RNA samples extracted from peripheral blood cells of 67 primary 
breast cancer patients and 54 healthy donors. The microarray method is fast and high throughput 
enabling to compare many genes simultaneously but it has several limitations. Experimental 
method drawbacks include frequent problems with quality/integrity of RNA, artefacts in the 
image after hybridisation, batch effects of hybridisation, difficulty in data reduction and lack of 
standard procedures for data collection/analysis. The high throughput RNA-sequencing (RNA-
Seq) has outdated the microarray technology and also overcame several limitations of microarray 
technology such as high background noise, poor detection of unknown transcripts and relative 
 
192 
 
quantification. Any future experiments related to WBC biomarker discovery are now likely to be 
performed using the RNA-Seq to avoid the limitations of microarrays.   
 The facts that for the gene expression studies the RNA samples were extracted from the 
whole blood (all blood cells plus serum) and also the heterogeneous nature of blood cells were 
important factors to consider in the data analysis performed in Chapter 4. This was reflected, for 
example, in the variation in expression levels of individual genes obtained after comparison 
between the individuals in breast cancer patient cohort and the individuals in the healthy donor 
cohort. Another notable phenomenon was that the majority of the genes obtained after comparison 
between the two cohorts was with fold change were less than ±2. The systemic changes in the 
blood would have been minimal because of the influence of tumour on immune cells, which is 
reason the fold change cut-off for genes was set at ±1.2. The comparison resulted in the 
identification of 506 differentially expressed genes in the breast cancer patient cohort. These data 
were combined with the proteomics data (Chapter 3) to shortlist biomarkers for further validation 
by RT-qPCR and Western blotting. Furthermore microRNAs are another promising source of 
biomarkers in blood. MicroRNAs like (miR-10b, miR-21, miR-125b, miR-145, miR-155 miR-191 
and miR-382) (George and Mittal, 2010; Mar-Aguilar et al., 2013) have shown promise and are 
currently in the development pipeline. 
6.4 Integrating data to understand the effect of breast tumours on the immune system 
 The relationship between tumours and the immune system is very complex and not fully 
understood. Tumours interact with the surrounding tissues and the immune system, and the 
changes in the cells of the immune system reflect such communications. The tumour, for example, 
manipulates the immune system to escape antigen recognition and also utilises the immune 
response for survival leading to metastasis (describe in Section 1.10. in more detail). In this study, 
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together with discovery of novel cancer biomarkers from WBCs, we used the data to investigate 
differences related to the immune system functions. 
 Functional analysis of both datasets (genomics and proteomics) showed overall consistent 
functional changes in the WBCs of breast cancer patients. The GO analysis of the gene expression 
data revealed that genes involved in WBC activation, antigen recognition, processing and 
presentation were downregulated in breast cancer patients.  These observations were 
complemented by the outcomes of the pathway analysis performed using KEGG database, 
showing that the JAK-STAT pathway downregulated. This analysis also revealed that some genes 
involved in the transendothelial migration, inflammatory response and cell proliferation were 
upregulated, but others down-regulated in the breast cancer cohort. The protein profiling data 
demonstrated that inflammatory response was upregulated in the breast cancer patients. The GO 
analysis also revealed that proteins involved in cell migration and cell survival were upregulated. 
The pathway analysis showed that leukocyte transendothelial migration pathway was upregulated.  
 The data obtained in these analyses suggest that systemic inflammatory response is 
increased in breast cancer patients. Breast cancer cells secrete various pro-inflammatory factors 
such as TNF-α, IL-8, IL-10, VEGF etc along with several chemokines which attract the immune 
cells to sites of inflammation. Interestingly, systemic inflammation markers such as neutrophil-
lymphocyte ratios, levels of platelets and platelet-lymphocyte ratios have been used as prognostic 
indicators of cancer outcome (Fox et al., 2013). In addition, elevated neutrophil counts, elevated 
platelet counts and low lymphocyte counts were predictors of low overall survival in renal 
carcinoma patients. This observation could play an important role in biomarker discovery process 
as several proteins are expressed at different levels in different cell types of the immune system. 
 The GO analysis specifically indicated that 30% of proteins which changed were involved 
in cellular localisation. In particular, proteins involved in cell migration were positively regulated 
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in the WBCs of breast cancer patients. This complements the fact that highly invasive tumours 
have increased immune cell (Dendritic cell, T-cell) infiltrations in breast tumour which correlates 
with poor prognosis (DeNardo et al., 2011; Leek et al., 1996; Ruffell et al., 2012). Some of the 
genes involved in WBC migration are also involved in tumour cell metastasis where a process 
similar to WBC migration occurs. The cell migration factors secreted by WBCs could be used by 
tumour cells to enhance cell adherence and invasion. It has been shown in several studies that 
leukocyte migration is inhibited in various carcinomas (Brandes and Goldenberg, 1976; Kadish et 
al., 1976; Lee et al., 1977). 
The observations regarding changes in the functions of the WBC could be validated using 
primary tumour tissue or cells and the WBC samples. Extracts from tumour tissues or cell culture 
media supernatants from breast cancer cell lines can be applied to WBC to induce changes in their 
functions related to cancer. These functions could be measured by appropriate assays such as 
migration, apoptosis, survival, reactive oxygen species measurement and other assays. 
Components of breast tumour tissue supernatants could be profiled using mass spectrometry to 
identify factors inducing WBC functions. This work is already progressing in our laboratory (data 
not shown) with the aims to identify factors inducing tumour specific molecules in WBCs. This 
study shows the importance of the effect of breast cancer on systemic WBC migration.   
6.5 Shortlisting and validation of breast cancer biomarker candidates 
 The shortlisting of candidates for validation had been very time consuming as the volumes 
of data generated by both genomic and proteomic approaches were very high.  The results from 
the third independent study performed using the WBCs of metastatic breast cancer patients were 
also used in the study ( see Section 5.2) to complement the shortlisting process. It was surprising 
to find that only 15 candidates overlapped between proteomics and genomics considering the 
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large number of significant genes obtained from gene expression analysis, while 21 candidates 
were common in both primary breast cancer and metastatic breast cancer proteomics datasets. 
 The first step of validation was to assess the RNA levels of 15 genes obtained from the 
shortlisting described above, in both primary breast cancer cohort and healthy donor cohort. RT-
qPCR revealed that out of the nine genes chosen for validation from the genomics dataset only 
three genes ANXA3, ITGA4 and WDR1 had the same trends in RNA expression as in the 
microarray data. Also only three genes CPNE3, LCN2 and ITGA4 passed the significance test in 
the RT-qPCR analyses. These genes were tested in an extended panel of primary breast cancer 
patients and metastatic breast cancer patients. ITGA4 levels were downregulated in both primary 
and metastatic breast cancer patients. Both CPNE3 and LCN2 showed similar RNA expression 
patterns, namely, downregulated in the WBCs of primary breast cancer patients and upregulated 
in metastatic breast cancer patients. SERPINB1did not pass the significance test in the primary 
breast cancer panel at mRNA levels, but it was significantly (by more than 3-fold) higher in the 
WBCs of metastatic patients. Two candidates, SERPINB1 and CPNE3, were validated at the 
protein levels to identify their potential use as breast cancer biomarkers. The levels of CPNE3 
were not significantly changed in the WBCs of primary breast cancer patients or metastatic breast 
cancer patients; the variance in the levels of CPNE3 was very high suggesting very low 
specificity. This disqualifies CPNE3 as a potential biomarker to be taken to the clinical stage. On 
the other hand, promising results were observed for SERPINB1. 
6.6 SERPINB1 as a potential biomarker for breast cancer progression and metastasis  
6.6.1 Biological functions of SERPINB1 
 SERPINB1 is the neutrophil elastase inhibitor, it was first characterised in neutrophils but 
it is present in most of the subsets of WBCs. SERPINB1 inhibits serine proteases elastase, 
cathepsin G and proteinase-3 (Farley et al., 2012). Neutrophil elastase is an inflammatory protein 
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which is involved in anti-microbial action and is released at sites of inflammation. Neutrophil 
elastase dissolves cellular junctions and aids in transmigration of WBCs across epithelial cells 
(Ginzberg et al., 2001). SERPINB1 also inhibits Granzyme H (Wang et al., 2013) which is used 
by natural killer cells to induce cell death in the  antigen presenting cells and tumour cells 
(Trapani and Smyth, 2002). SERPINB1 is involved in neutrophil extravasation and formation 
neutrophil extracellular traps to contain inflammation (Farley et al., 2012).The association of 
SERPINB1 with cancer is complex, thus BERPINB1 can be a tumour suppressor and promoter, 
at the same time, depending on the specific biology of the disease, microenvironment and other 
factors (Cui et al., 2014; Tseng et al., 2009). 
6.6.2 SERPINB1 as a prospective biomarker 
 SERPINB1 showed promising results when the protein levels in WBCs were measured by 
Western blotting. Thus, SERPINB1 levels were 3.5 times higher in 50% of the primary breast 
patient WBCs and 7 times higher in more than 90% of the metastatic breast cancer patient WBCs. 
Furthermore, SERPINB1 levels were higher in the WBCs in participants with node positive 
primary breast cancer than in node negative participants. If follow up clinical data could be 
collected for primary breast cancer patients to observe for recurrence and metastasis, SERPINB1 
could be correlated to those parameters to assess further its prognostic significance. Collectively 
the data suggests the possibility that SERPINB1 could be a marker of lymph node metastasis for 
primary breast cancer patients and a general metastatic breast cancer biomarker of prognosis. 
Metastatic breast cancer patients who initially had higher levels of SERPINB1 had poorer 
prognosis. More samples from metastatic breast cancer patients should be evaluated to identify 
changes in levels of SERPINB1 to validate it as a prognostic biomarker for disease progression 
and treatment response. These findings demonstrate that SERPINB1 could be taken to the next 
phase of biomarker development. It would be also important to design an ELISA based test for 
SERPINB1 because Western blotting will not be practical for clinical settings. The function of 
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SERPINB1 in the WBCs of breast cancer patients could point towards other biomarkers by 
searching for the factor that induces elevated SERPINB1 expression in WBCs of breast cancer 
patients. The expression of SERPINB1 could also be evaluated in the WBCs obtained from 
patients who have other types of cancer.  
6.7 Future work 
 Developing a clinical biomarker for diagnosis and screening is a time consuming process 
which is typically much longer than the period of a postgraduate research study. In this study we 
developed a pipeline for biomarker discovery and identified one prospective biomarker, 
SERPINB1, for prognosis of the disease and response to treatment. This investigation is 
continuing and Lyudmyla Pavlova, a current PhD student, who has taken over this project, 
confirmed the main findings described in this report using a larger panel of WBCs whereby the 
levels of Serpin-B1 were higher in the WBCs of patients with breast cancer than in healthy 
donors, the WBCs from lymph node positive participants had more SERPINB1 than from node 
negative and the highest  levels of Serpin-B1 were in the WBCs from the metastatic breast cancer 
cohort ( Figure 6.1). Another possible application for SERPINB1 is the biomarker of response to 
treatment. Recent experiments performed by Lyudmyla Pavlova in WBCs from the metastatic 
breast cancer cohort during chemotherapy and endocrine therapy treatment revealed the potential 
of SERPINB1 to predict the treatment efficacy and outcome (data not shown). SERPINB1 will 
also need to be evaluated in the WBCs of other cancer patients (e.g. prostate cancer and colorectal 
cancer patients- these materials are available in our laboratory and will be tested in due course). 
Development of the methods based on ELISA will be important; they will facilitate screening of 
larger numbers of samples and precisely establish the levels of SERPINB1 in WBCs, which in 
turn can be more accurately correlated with clinical parameters. Proteins ITGA4 and LCN2 are 
still to be validated at the protein levels as they showed promising results in RT-qPCR 
experiments. 
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Figure 6.1 Expression of SERPINB1 in the WBCs of breast cancer patients: SERPINB1 
protein levels were assessed in the WBCs by Western blotting and normalised to β-Actin levels. 
Data were produced by Lyudmyla Pavlova.  
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It has to be noted that only 15 candidates were chosen in the validation phase after a 
very stringent shortlisting process. More candidates for validation can still be obtained from our 
datasets. For example S100 family of proteins have been associated with the progression of 
breast cancer (Emberley et al., 2004). S100A8 and S100A12 appear in the microarray data 
analysed. S100A8 also appears in the metastatic breast cancer patient cohort. SERPINB6 was 
observed in the primary breast cancer and metastatic breast cancer proteomic datasets. The 
validation pipeline used in this study can be applied for validation using initially a small 
number of samples and then expanded with larger panel.  
 The value of this investigation will not only be relevant to the biomarker field but also for 
basic research, i.e. to elucidate the mechanisms of biological processes involved in the 
interaction between the tumour and immune system. The data generated for this study has given 
insight of how the immune system is altered in the breast cancer patients. The effect of breast 
tumour supernatant on immune cells have been previously studied (Eichbaum et al., 2011; 
Kusmartsev and Gabrilovich, 2006; Luboshits et al., 1999). Peripheral WBCs or cell lines can be 
treated with conditioned media after exposure with fresh tissues (normal and breast tumour) or 
selected regulatory molecules (chemokines, cytokines, growth factors).  The effects of these 
factors on WBCs biology in general, or expression of particular genes, including the candidate 
biomarkers identified in this study can be evaluated. Alternatively, immune cell functions such 
as antigen presentation (evaluation of innate and adaptive immune receptors), migration (cell 
migration assays), reactive oxygen species production etc can be tested to identify the systemic 
effect of tumour on the immune system. Purification of individual cell types from the whole 
WBCs population will help understand the function of these cells with the tumours. 
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6.8 General conclusions 
 The proposition that the tumour affects the WBCs in breast cancer patients resulting in 
the changes in the RNA and protein profiles provided the rationale for this study to discover 
novel breast cancer biomarkers. This aim was achieved and a panel of potential biomarkers has 
been generated. One biomarker in particular (SERPINB1) has shown promising results, but more 
samples will have to be analysed before it could be taken to the clinical phase of validation. 
Other shortlisted biomarkers found in this study (ITGA4 and LCN2) show promise but they need 
to be tested further. More additional candidate biomarkers can be selected from the initial list of 
biomarkers using this pipeline. The functional analysis of the data has also provided the insight 
into the immune response to cancer which now needs to be validated by laboratory based 
functional assays. 
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